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CHAPTER ONE 
INTRODUCTION AND OUTLINE 
INTRODUCTION AND OULINE 
Since their introduction into clinical practice almost 40 years ago, loop diuretics belong 
to the most widely prescribed drugs This class of drugs comprises ethaciynic acid, 
bumetamde, furosemide, and, not registered in The Netherlands, torasemide and pire-
tanide This thesis will focus on furosemide Furosemide has shown to be effective in 
oedematous states associated with cardiac, renal and hepatic disease In the past thirty 
years the pharmacokinetic and pharmacodynamic properties of furosemide have been 
extensively studied in healthy persons as well as in various disease states [1,2| 
In the treatment of chronic congestive heart failure the recommended daily dosage of 
fuiosemide is 20-200 mg [3j However, several studies have established the efficacy of 
daily dosages ranging from 250^1000 mg when recommended dosages fail to ι educe the 
excess of body fluid to the desired level in both renal failure and heart failure These 
supra-conventional dosages are often referred to as high dose fuiosemide 
In this thesis three aspects of the use of high dose furosemide are sudied 
Diuretic effects of high dose furosemide 
Although the continuous intravenous infusion of high dose furosemide has some theo­
retical advantages above other modes of administration (improved efficacy, less toxic 
side effects), studies comparing this mode of administration with intravenous bolus 
ìnjection(s) in patients with heart failure were contradictive [8,9| Moreover, in none of 
these reports the population consisted of patients with congestive heart failuie unre 
sponsive to conventional dosages of loop diuretics 
When chronic heart failure progresses some patients appear to become non-responsive 
even to the use of high dose fuiosemide, irrespective of the mode of administration 
Whether there are any effective treatment options for these patients is unclear The 
treatment with positive inotropic drugs, such as dobutamine, occasionally has been 
employed successfully to restore the diuretic response to loop diuretics Other studies 
suggest that patients with congestive heart failure may benefit from extracorporal tech-
niques like peritoneal dialysis or hemofiltration [10-18) However, in most of these stu 
dies the stage of heart failure is not well-defined or the extracorporal treatment modali-
ty was introduced before maximal conventional therapy, including high dose 
fuiosemide, was applied 
When conventional dosages of loop diuretics are combined with thiazide di ugs, this 
results m a vigorous natnuresis, even in patients with moderate renal failure [19-30] 
Whether the addition of a thiazide drug to high dose furosemide may cause a correction 
of the hydration status in patients with chronic decompensated heart failure (insuffi-
ciently responding to high dose furosemide) remains to be established 
After chronic administration of furosemide, its natriuretic effects attenuate due to sever-
al mechanisms [31-40] Animal studies have shown that coadministration of a thiazide 
preserves the natriuretic response to furosemide [41] In literature little evidence is avail 
able for the presence of this interaction m humans [34] 
In summary, the purpose of the studies described in this thesis, which focus on the 
diuretic aspects of high dose furosemide, was to answer the following questions 
• Is the use of high dose furosemide administeied as an intravenous continuous infusion effective 
and safe in patients with severe congestive heart failure unresponsive to conventional dosages of 
furosemide'' 
• Does the efficacy of high dose furosemide m patients with severe heart failure improve when 
furosemide is administered as a continuous intravenous infusion compared to an intravenous 
bolus іщеаюпі 
• Do patients with severe congestive heart failure and an inadequate response to high dose 
furosemide benefit from chronic intermittent hemodialysis and/or hemo/iltration7 
• is the addition of hydrochlorothiazide to high dose furosemide of any value for patients with severe 
congestive heart/aiiure and diuretic resistance to high dose furosemide? 
• Can the attenuation of the natriuretic response that occurs after chronic use of furosemide be pre­
vented by coadministration of hydrochlorothiazide7 
Vascular effects of high dose furosemide 
It is generally recognized that loop diuretics provide relief of symptoms in acute left ven­
tricular heart failure by its non-diuretic effects. Many studies have established that 9 
furosemide has vasoactive properties [42-49) The exact mechanisms involved in the 
vasoactivity of furosemide are unclear. Most studies so far failed to make a proper dis- я 
tinction between genuine direct vascular effects of furosemide versus effects on vascular с 
tone secondary to cardiovascular reflexes or regulatory mechanisms. The application of о 
techniques that can measure the effects of locally administered drugs on isolated vascu- ^ 
lar beds in vivo, enables us to answer the question whether furosemide acts directly on £" 
the vessel or induces indirect effects secondary to changes in intravascular volume and = 
blood pressure. ™ 
The questions in this thesis concerning the vascular effects of furosemide are 
• Does furosemide exert any direct vascular effect in humans7 
• If so, is it a vasodilator or a vasoconstrictor effect7 
• On which part of the vasculature (venous or arterial) does furosemide act? 
• If there is a direct vasoactive effect: is it mediated by prostaglandins or does NO, a potent 
vasodilator released by endothelial cells, play a role? 
Ototoxic side effects of high dose furosemide 
In the early 1970's it was shown that high dose furosemide was an effective mode of 
treatment in patients with renal insufficiency or heart failure unresponsive to conven-
tional dosages of loop diuretics. Soon after the introduction of high dose furosemide, 
ototoxicity was reported to be a major side effect of this therapy [50-54] Although in the 
majority of cases this ototoxicity was rapidly reversible, few reports described irre-
versible hearing loss, entirely attributable to the use furosemide [54-56). In the past two 
decades many studies in animals have been performed to elucidate the mechanisms 
involved in ototoxic side effects of loop diuretics, but many questions remain to be 
answered. It was shown that the ototoxic side effects were related to the furosemide 
endolymph concentration, which appeared to be linearly related to the serum 
furosemide concentration within a wide range [57,58]. To our knowledge no data are 
available that describe the relationship between the pharmacokinetics and the ototoxici-
ty of furosemide in humans. To clarify this relationship a study was performed aiming to 
answer the following questions: 
•is it possible to avoid ototoxicity by administration of high dose furosemide as a continuous intra 
venous infusion instead of an intravenous bolus injection7 
• If the serum furosemide concentration is the major determinant of the development of ototoxicity, 
is it possible to define a threshold furosemide concentration below which ototoxicity does not 
occur
7 
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CHAPTER TWO 
C O N T I N U O U S I N F U S I O N O F F U R O S E M I D E I N T H E 
TREATMENT OF PATIENTS WITH CONGESTIVE 
HEART FAILURE AND DIURETIC RESISTANCE 
Joseph J.M. van Meyel, Paul Smits, Tom P.). Dormans, Paul G.G. Gerlag, 
Frans G.M Rüssel and Frank W.J. Gribnau 
Journal of Internal Medicine 1994;235:329-334 
ABSTRACT 
Objectives: To assess the value of treatment with continuous intravenous infusion of 
furosemide in patients with refiactory congestive heart failure 
Design: Open uncontrolled dose response study 
Subjects: Patients with congestive heart failure (those with New York Heart Association 
(NYHA) class III and IVwith an assessed amount of oedema of more than 5 kg and diure-
tic resistance were included [n=10]) Diuretic resistance was defined as failure to lose 
weight and/or inappropriate urinary sodium excretion (50 mmol 24 h ') despite bed rest 
for a period of 2-3 days, salt and watei restriction, orally and intravenously administered 
furosemide in a dose of 250 mg day', digoxin, and when possible an ACE inhibitor 
Included patients were treated with continuous furosemide infusion at a delivery 
of 20 mg h over 24 h The infusion rate was gradually heightened up to a maximum 
dose of 160 mg h' 
Main outcome measures: Daily physical examination, history of side effects, determination 
of serum electrolytes and 24 h electrolyte excretion during treatment with furosemide 
Results: Weight loss (mean ±SD), 12 5 ±5 kg) and relief of symptoms was achieved in all 
patients Mean (±SD) 24 h sodium output rose from 19 ±16 mmol 24 h ' (n=10) on oral 
therapy with 250 mg congestive heart failure to 137 ±85 mmol 24 h ' (n=8) 
during 80 mg h and to 268 ±124 mmol 24 h (n=3) on the maximal dose of 160 mg h ' 
Conclusion: Continuous infusion of furosemide under careful monitoring of the patient 
is a safe, controllable and efficient treatment in patients with severe congestive heart 
failure and diuietic resistance 
INTRODUCTION 
Despite the important role of ACE inhibitors, diuretics remain the mainstay treatment for 
patients with congestive heart failure especially when fluid retention dominates [ 1 ] 
Conventional diuretic theiapy consists of a loop diuretic either as one or multiple oral 
doses or as an intravenous bolus dose [2] Most patients will respond with sufficient natn-
uresis, weight decrease and clinical improvement to this regimen However, some patients 
with severe congestive heart failure show diuretic resistance with an inadequate diuretic 
response as a consequence Diuretic resistance is a serious problem in these patients and 
seems to represent a final manifestation of congestive heart failure |3] When resistance to 
loop diuretics develops, combination theiapy with a diuretic that exerts its action in 
another part of the nephron tubule could be successful [3,4] However, it must be stressed 
that severe electrolyte disturbances can ensue when a combination of different diuretics is 15 
used Other therapeutic interventions, especially appropnate for patients with severe renal 
impairment, could be hemofiltiation or infusion with positive inotropic agents (eg § 
dopamine and dobutannne) [5,6] High bolus doses of a loop diuretic are successful, but i 
may be ototoxic [7,8] Also, continuous intravenous infusion of a loop diuretic -to make g 
optimal use of its diuietic properties has been advocated [4,9-11] From a theoretical point §, 
of view, continuous infusion of a loop diuretic may have two important advantages Firstly, 5 
the diuretic efficiency is optimal when there is a constant delivery rate of furosemide to о 
the proximal tubule and secondly, plasma furosemide levels remain relatively low making ¿f 
ototoxic side effects less piobable Up until now there are a few data regaiding the efficacy Ξ 
of continuous furosemide infusion therapy in patients with lefractory congestive heart S 
failure Therefoie, we conducted a study in patients with sevei e congestive heart failure ÏÏ 
and diuretic resistance, investigating the pharmacokinetic and pharmacodynamic deter- η 
minants of response during continuous furosemide infusion 5. 
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PATIENTS AND METHODS 
After approval of the protocol by the local ethical committee, we selected patients with 
severe congestive heart failure (NYHAIII-IV) of different origins with a proven diuretic resist­
ance and an assessed amount of oedema of moie than 5 kg Diuretic resistance was defined 
as a failure to lose weight and/οι inappropriate unnary sodium excretion (< 50 mmol 24 h') 
despite maximal conventional therapy ie bed rest for 2-3 days salt and water restriction, 
orally and intravenously administered furosemide in a dose of 250 mg day', digoxin, and 
when possible an ACE inhibitor The relevant patient characteristics aie shown in Table 1 
the mean age was 71 4 (range 57-84) years and the mean weight was 72 3 (range 43 7-88 2) kg 
The patients weie given a physical examination, complete blood count, electrocardio 
gram, echocardiogram and chest X lay and all gave their written informed consent prior 
to the study 
Continuous intravenous furosemide infusion treatment was started by an automatic 
syringe infusion pump (type STC 521, Terumo Corporation, Tokyo, Japan) with 480 mg 24 h 
(infusion rate 20 mg h ) Furosemide medication in the infusion pump was protected 
against light We heightened the furosemide infusion rate gradually when patients did 
not show weight loss or if there was no enhancement of diuresis ornatnuresis after 24 h 
The maximal furosemide infusion rate was 160 mg h (cumulative dose 3840 mg 24 h') 
During their stay in the hospital, the patients ieceived a diet containing 60 80 mmol 
sodium and 80-100 mmol potassium Total daily fluid intake was limited to 1500 ml 
Additional medication (e g digoxin, Captopril) was permitted and not changed during treat­
ment with continuous furosemide infusion Every day, all of the patients were physically 
examined by the same physician Continuous infusion was stopped when patients were 
clinically compensated At that time, oral furosemide administration was started at a 
dose of 250 mg In most cases, the dose required to contiol recurrent oedema had to be 
gradually increased (maximally up to 500 mg b i d ) during follow up 
Daily 24 h urine collection was carried out and the urine samples were carefully protect 
ed from light Aliquots of the urine samples were assayed immediately for sodium, potas­
sium, chloride, albumin and creatinine content and the rest of the samples were frozen 
for later analysis of furosemide concentration Venous blood samples were taken daily 
for determination of electiolytes, blood/uiea nitrates, creatinine and plasma furosemide 
concentration Also, venous blood samples weie taken on the day of admission and 1 day 
before the patient left the hospital for determination of urate bicarbonate, albumin, 
magnesium, aldosterone and renin The concentrations of furosemide in plasma and 
ui ine were detei mined by a recently developed HPLC assay, with a solid-phase exti action 
method [12] The plasma aldosteione and plasma renin concentrations were determined 
by radioimmunoassay [13,14] Routine blood chemistry was measured by auto-analyser 
Diuretic response was expressed as daily sodium excretion (mmol 24 h ) or as fractional 
sodium excretion (FENl), defined as 
FENa (%) = U v ' ' S g f l W0 
SeN„ TA, 
where UN l is the unnary sodium concenti ation (mmol 1 '), Sec r is the serum ci eatinme 
concentration (μιηοΐ l1), SeNa is the serum sodium concentration (mmol Γ) and UCr is the 
urinai y creatinine concentration (mmol 1') Each symbol in the dose-response curve rep­
resents the mean (SEM) FENl calculated from 24 h urine collections on the day after 
heightening of the furosemide dose, and the corresponding furosemide dose 
A two-dimensional echocaidiography was used to measure the left ventricular ejection 
fiaction Patients were daily interviewed about side effects Values were expressed as 
mean ±SD) unless indicated otherwise 
RESULTS 
The currently investigated patients were resistant to conventional diuretic treatment as 
demonstrated by the very low natnuresis (19 ±16 mmol 24 h' respectively 32 ±18 mmol 24 h ) 
despite therapy with 250 mg of furosemide orally ι espectively intiavenously As shown in Table 
1 the endogenous creatinine clearance was markedly reduced and the blood/urea nitrates 
creatinine (BUN/cr ) ratio was high in all patients These parameters including the low ejec­
tion fractions (Table 1) demonstrate the deteriorated hemodynamic state of these patients 
The mean (±SD) 24 h sodium output rose from 19 ±16 mmol 24 h (n=10) on oral therapy 
with250mgoffuiosemidetol37±85mmol 24 h (n=8) during 1920 mg 24 h and to 268 
±124 mmol 24 h (n=3) on the maximal administered dose of 3840 mg 24 h (infusion rate 
160 mg h1), whilst the mean daily potassium output rose from 50 ±21 mmol 24 h 1 to 78 ±41 
and 82 ±50 mmol 24 h ' respectively The mean duration of treatment was 13 ±5 days 
Table 2 Biochemical parameters of patients with congestive heoi t failure before (decompensated) 
and after (compensated) Ueatment with continuous furosemide infusion (n=10) 
BUN/cr 
Serum sodium (mmol 1') 
Serum potassium (mmol Γ) 
Serum albumin (g Γ) 
Serum urea (mmol 1 ') 
Serum bicarbonate (mmol 1 ') 
Serum urate (mmol 1') 
Serum magnesium (mmol 1 ') 
Renin(nmol T h ' ) 
Aldosterone (mmol Γ) 
Decompensated 
30 6 
134 
4 3 
31 
16 
30 6 
0 62 
0 88 
15 4 
15 
±3 5 
±2 1 
±0 2 
±2 5 
±17 
±2 4 
±0 04 
±0 04 
±5 4 
±0 6 
Compensated 
35 0 
138 
4 1 
32 
18 
32 3 
0 66 
0 98 
15 0 
15 
±4 2 
±01 
±0 2 
±2 3 
±21 
±2 4 
±0 06 
±0 06 
±4 8 
±0 5 
Values are mean ±SEM 
BUN/ci blood/uiea nitiates creatinine ratio 
Figure 1 shows the daily urinary volume and electrolyte excretions and some biochemi 
cal parameters of one representative patient (no 2) Increasing the furosemide dose also 
increased volume and electrolyte excretions However when patients had almost 
reached the compensated state the responsiveness of the kidney to furosemide dimin­
ished with a lower natnuresis as a consequence In all patients an improvement of the 
state of compensation and a weight reduction was realized Mean weight reduction was 
12 0 (range 6 3 19 1) kg Seium sodium concentiations gradually increased to noimal val­
ues and a mild easy to treat hypokalemia occurred in almost all patients especially in 
those with hyperaldosteronism Otherwise no serious side effects were observed 
Table 2 shows the biochemical parameters before and after continuous furosemide infu 
sion when patients were decompensated and again when patients were compensated A 
small insignificant increase in the BUN/cr ratio and a small decrease in the mean arteri­
al pressure (MAP) was observed (MAP ±SEM decompensated 82 ±3 5 mmHg compensa­
ted 78 ±3 4 mmHg) However, we did not find significant increases in the serum renin 
and in the aldosterone levels 
Plasma furosemide levels aveiaged 4 3 ± 2 8 (range 2 6 5 8) Mg ml ' at the lowest infusion 
rate (10 mg h ) and increased to 71 1 ±33 3 (range 26 6 136 4) mg ml at the highest infu­
sion rate (160 mg h ) In one patient (no 3) furosemide plasma levels were in the ototoxic 
presumed range (> 100 mg ml ) but even in this patient no adverse effects were noticed 
This was the patient with the lowest ECC, who was treated with the maximum 
furosemide infusion rate (160 mg h') As shown in the dose-response relation (Figure 2) 
the is a positive correlation (r = 0 958, ρ = 0 0004) between the furosemide dose and the 
fractional sodium excretion, indicating that higher furosemide doses induce greater 
natnuresis 
DISCUSSION 
Our study shows that continuous furosemide infusion is an applicable, effective and safe 
treatment in patients with severe congestive heart failure and diuretic resistance 
Diuretic resistance in patients with severe congestive heart failure is a multi-causal phe­
nomenon and seems to be determined by pharmacokinetic as well as pharmacodynamic 
changes Firstly, in these patients there is an altered absorption that could be surpassed 
by intravenous administration [15,16] Secondly, most patients with severe congestive 
heart failure have an impaired renal function which causes an accumulation of endoge­
nous organic acids and, as a result of competition, a reduced secretion of furosemide 
from the proximal renal tubule with a decreased diuretic effect as a consequence [4] As 
shown in our study, higher doses of furosemide enhance natnuresis by forcing sufficient 
amounts of furosemide into the urine 
Figure 1 Daily urine volume and electrolyte excretions during continuous administration of 
furosemide (480-3840 mg 24 h ') in one representative patient UNu= urinary sociium 
excretion, UK= urinary potassium excretion, Uwl= urinary volume, 
U
mal= urinary creatinine excretion, Smal= serum creatine concentration 
Uv, (mmol 24h ) 
D 
U, (mmol 24h ) 
UV0 | (ml 24h ) 
Body weight (kg| 
"**ТМРР*" 
ШР 
U ( r e i t (mmol 24h ) 
π 
luiosemide js4i> 
(mg 24h | 
(Mmol 1 ) 
о—о 
2 4 6 8 10 12 14 16 IS 20 
Thirdly, in patients with severe congestive heart failure there seems to be an increased 
sodium reabsorption from the proximal tubule as a result of kidney hypoperfusion. In 
addition, as shown in recent studies, diuretic could be a result of the kidney adaptation 
to chronic diuretic therapy, resulting in an increased NaCl reabsorption in nephron seg­
ments downstream from the site of action [11]. It seems that continuous furosemide 
infusion is a mode of administration that could inhibit this increased sodium reabsorp­
tion in the distal renal segment. Recently it was demonstrated in patients with renal fail­
ure, in healthy volunteers and in patients with congestive heart failure, that continuous 
furosemide infusion was much more efficacious than bolus administration [17-19]. 
Although we did not compare bolus administration with continuous infusion, it is obvi­
ous that continuous infusion of furosemide is effective. In addition, this treatment 
modality seems safe because the high and potentially toxic plasma concentrations seen 
after bolus administration would be avoided; moreover, high cumulative dosages could 
be administered. Toxic plasma furosemide levels were observed in one patient with the 
lowest ECC (13 ml. min ') who was treated with the maximum furosemide infusion rate 
(160 mg. h '). With respect to toxic furosemide concentrations, a daily cumulative dose of 
3840 mg (infusion rate 160 mg. h ') seems safe when the ECC is higher than 23 ml. min'. 
As reported in the literature, loss of hearing can occur when the furosemide infusion 
rate is higher than 240 mg. h ' [8]. 
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Figure 2. Dose-response relation to 
continuous administration 
of furosemide relating the 
furosemide dose (mg) to 
fractional sodium 
excretion (%). Each point 
represents the mean (±SEM) 
fractional sodium excretion, 
calculated from the 24 h 
urine collections of the 
patients after heightening 
of the dose 
480 960 1440 1920 2400 2880 3360 3840 
Furosemide dose (mg. 24h1) 
In all our patients this treatment was successful and well tolerated. As shown in the 
dose-response curve, it seems rational to give higher (cumulative) daily doses of 
furosemide than is generally advocated. It was not possible to fit the data according to a 
sigmoid Em-„ model because maximum values were not reached and consequently the 
full extent of the curve could not be defined [17]. An expected finding was that the 
responsiveness of the kidney to furosemide diminished when patients were almost com-
pensated. As mentioned by Vasko et al, this could occur when patients attained dry 
weight and were in a sodium-avid state [15]. In addition, at that time their sodium levels 
were almost in balance with their diet. 
During this treatment no biochemical or clinical signs of dehydration were observed. 
Consequently, as stated by Ananá et al, careful clinical assessment of patients is a reliable 
method for preventing diuretic-induced dehydration [20]. Serum sodium normalized in 
most patients, as demonstrated in an earlier study in patients with severe congestive 
heart failure [7]. However, it must be stressed that combination with thiazides can result 
in severe hyponatremia because they act in the cortex and do not interfere with concen-
trating ability [l,22].We conclude that continuous furosemide administration is a safe, 
controllable and effective symptomatic treatment for patients with severe congestive 
heart failure and diuretic resistance. When this strategy lacks effect, combination with 
diuretics that exert their effect in another part of the nephron, infusion with positive 
inotropic drugs or hemofiltration could be helpful. 
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CHAPTER THREE 
D I U R E T I C E F F I C A C Y O F H I G H D O S E F U R O S E M I D E 
IN SEVERE HEART FAILURE'. BOLUS INJECTION 
VERSUS CONTINUOUS INFUSION 
Tom P.J. Dormans, Joseph J.M. van Meyel, Paul G.G. Gerlag, 
Yuen Tan, Frans G.M. Rüssel and Paul Smits 
Journal of the American College of Cardiology 1996;28:376-82 
ABSTRACT 
Objectives The efficacy of high dose furosemide as a continuous infusion was compared 
with a bolus injection of equal dose in patients with seveie heart failure 
Background The delivery late of furosemide into the nephron has been proved to be a 
determinant of diuretic efficacy in healthy volunteers 
Methods: In a ïandomized crossovei study we compared the efficacy of a continuous 
infusion of high dose furosemide (mean daily dosage 690 mg, range 250 - 2000 mg) ver-
sus a single bolus injection of an equal dose in 20 patients with severe heart failure The 
patients received an equal dosage, either as a single intravenous bolus injection or as an 
24 8 h continuous infusion preceded by a loading dose (20% of total dosage) 
σ 
§ Results Mean (±SEM) daily urinary volume infusion 2860 ±240 ml, bolus 2260 ±150 ml, 
F p= 0 0005) and sodium excretion (infusion 210 ±40 mmol, bolus 150 ±20 mmol, p~ 0 0045) 
S were significantly higher after treatment with continuous infusion than with bolus înjec-
EL tion, despite significantly lower urinary furosemide excretion (infusion 310 ±60 mg 24 h', 
Ζ bolus 330 ±60 mg 24 h ', ρ = 0 0195) The maximal plasma furosemide concentration was sig-
^ mficantly higher after bolus injection than during continuous infusion (infusion 24 ±5 pg ml , 
S bolus95±20pg ml',p<00001) Short term completely reversible hearing loss was only 
s reported aftei bolus injection in 5 patients 
m 
=4 
ro 
5 Conclusions We conclude that in patients with severe heart failure, high dose furose-
° mide administered as a continuous infusion is more efficacious than bolus injection and 
<§. causes less ototoxic side effects 
a. 
о 
l/l 
Φ 
О 
П> 
Э 
Q. 
INTRODUCTION 
Loop diuretics are commonly required in the management of heart failure In most 
patients orally administered conventional dosages of furosemide mobilize oedema and 
maintain adequate hydration However, with progression of the disease state, diuretic 
resistance - a potentially life-threatening phenomenon - frequently occurs, resulting in 
fluid and sodium ietention To overcome this complication the oral dosage of the loop 
diuretic is often increased Theie are two reasons for this strategy, firstly, in the course of 
heart failure impairment of renal function often occuis |1] In renal insufficiency, higher 
dosages of furosemide are necessary to create effective concentrations in the intraluminal 
site of the ascending limb of Henle's loop, the site of action of loop diuretic drugs 
Secondly, in patients with heart failure highei concentrations of fiuosemide in the renal 
tubule are required to induce an adequate natnuietic lesponse, in other words in these 
patients the dose-response curve is shifted to the ι ïght and downward [2] In addition to the 
absolute amount of drug earned to the site of action, the time course of delivery to the site 
of action appears to be an important determinant of overall diuretic response [3,4] This 
means that, theoretically, diuretic treatment can be optimized by the admimstiation of 
furosemide as a continuous intravenous infusion This mode of administration provides a 
constant delivery rate of furosemide to the renal tubule Furthermore sodium retention 
during the drug-free intervals maybe avoided and the risk for ototoxic side effects is 
reduced [5,6| Only two controlled studies have compared the efficacy of a continuous 
intravenous infusion of a loop diuretic drug with intravenous bolus administration in 
patients with heai t failure [7,8], with conflicting results with respect to the supposed supe-
rior efficacy of continuous infusion However, on the basis of the previous arguments and 
the results of studies in healthy volunteers and patients with ïenal insufficiency, optimizing 
furosemide delivery to the renal tubule may have a beneficial effect Consequently, we 
hypothesized that high dose furosemide administered as a continuous intiavenous infu-
sion would be more efficacious and less toxic than an intravenous bolus of an equal dosage 
furosemide in patients with severe chronic heart failure 
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PATIENTS AND METHODS 
Subjects 
After approval by the local ethics committee, we included 20 patients (7 women, 13 men) 
with severe heart failure of differing etiologies (New York Heart Association functional 
class III or IV) and long-term use of orally administered high dose Furosemide (at least 
250 mg) Each patient provided written informed consent before the start of the study 
No patient was taking non-steroidal anti-inflammatory drugs or probenecid Patients 
with cardiomyopathy due to alcoholism were excluded 
At the time of the study, 9 patients were in a clinically compensated state without oede­
ma and 11 patients had decompensated heart failure with an estimated oedematous 
mass of at least 5 kg Mean (±SbM) body weight at the start of the study was 72 9 ±3 7 kg 
Mean pretreatment endogenous creatinine clearance was 45 ±4 ml mm The clinical 
characteristics of the study patients are shown in Table 1 
Study design 
The study was a randomized crossover study All patients were placed on a standard diet 
with a daily content of 80 mmol of sodium and 100 mmol of potassium and a fluid 
intake of 1500 ml Extra potassium was administered for hypokalemia ( <3 5 mmol 1 ') 
During the study patients did not drink any coffee, tea or alcohol The daily furosemide 
dosage was left unchanged throughout the study All other medication was continued as 
previously prescribed Patients underwent physical examination with emphasis on 
hydration status Standing and supine blood pressures and weight were determined 
daily An indwelling urinary catheter was inserted when patients could not void on 
request The patients remained in the hospital for the duration of the study 
During days 1 and 2 of the study, the patients received a single dose of orally adminis­
tered furosemide (Lasix, Hoechst) At that time, blood samples were obtained for baseline 
measurement of serum electrolytes, blood cell counts, serum albumin, plasma epineph­
rine and norepinephrine, plasma renin and plasma aldosterone Urine samples were col­
lected over 24 h for measurement of volume and concentrations of creatinine, sodium, 
potassium, chloride and furosemide 
Table 2 Mean values (±SEM) of biochemical variables m 20 patients with severe heart failure 
before and after intravenous treatment with high dose furosemide (daily dosage 690 ±560 mg) 
Day 2 Days 3-5 Day 6 
Serum sodium (mmol Γ) 
Serum potassium (mmol 1') 
Serum chlonde (mmol 1') 
Serum creatinine (мтоі 1') 
Serum urea (mmol 1') 
Serum albumin (g 1') 
Aldosterone (nmol 1') 
Renin (ng 1') 
Epinephrine (nmol 1') 
Norepinephrine (nmol Г) 
1 5 ± 0 2 
222 ±62 
0 4 ± 0 1 
3 5 ± 0 5 
B d m 
Infilami 
(t=0h| 
137±1 
4 2 ± 0 1 
95±1 
132 ± 8 
18±2 
3 6 ± 1 
After 
Infusion 
(t-24h) 
137 ±1 
4 3 ± 0 2 
94±2 
139 ±9" 
19±2 
3 7 ± 1 
Brfrae 
Bohis 
(^oh) 
138 ±1 
4 1 ± 0 1 
95±1 
134 ±8 
19±2 
36±1 
After 
Bolus 
(t=24h| 
138 ±1 
4 3 ± 0 1 
94±2 
139 ±8t 
19±2 
36±1 
1 8 ± 0 5 
336 ± 1 » 
0 3 ± 0 1 
2 8 ± 0 4 
'p<0 01, tp<0 05 versus befoie treatment (Student t test for paired data) t=hme 
On day 3, patients wei e randomized to receive fui osemide either as an intravenous bolus 
injection (injected within 5 minutes) or as a continuous intravenous infusion The con­
tinuous intravenous infusion started with a loading dose, consisting of 20% of the total 
dose and administered within 5 min as a bolus injection, followed by an 8 h continuous 
intravenous infusion at an infusion rate of 10% of the total dose per hour (model STC-521 
infusion pump, Terumo Coi ρ .Tokyo, Japan) Either of the administration modes was 
started at 8 AM, after initial bladder emptying Blood samples were taken from the ante-
cubital vein in the arm contralateral to the drug infusion at 0,15, 30, 45, 60, 90,120,150, 
180, 240, 360, 480 and 1440 mm after the start of the intravenous furosemide adminis­
tration for determination of plasma furosemide concentrations Urine was collected at 
30, 60,120, 180, 240, 360, 420, 480 and 1440 nun after the start of furosemide administra­
tion for measurements of volume, sodium, potassium, chloride, creatinine and 
furosemide Intravenous furosemide pieparations as well as all urine samples were pro­
tected against light to prevent photochemical degradation of furosemide Urine losses 
were not replaced isovolumetncally Day 4 was used as a washout period patients 
received oral furosemide medication and blood and urine sampling was identical to the 
first 2 days On day 5 the crossover mode of intravenous administration was given as 
described previously On the final day (day 6), urine was collected, and blood samples 
(including renin, aldosterone and catecholamines) weie taken for comparison with base 
line parameters 
Analytical methods 
Sodium and potassium concentrations were measured by П а т е photometry, chloride 
concentrations by using a semiautomatic colometnc titration method and creatinine 
concentrations according to the Jaffe ìeaction in an autoanalyzei Plasma and urine con-
centi ations of furosemide were measured by a rapid and sensitive high performance liquid 
chromatography assay, as described previously [9[ Plasma aldosterone was determined by 
radioimmunoassay [10| Plasma renin was measured by means of an lmmunoradiometric 
sandwich technique with the use of two monoclonal antibodies and without enzymatic 
step (ERIA Diagnostics Pasteur, Marnes La Coquette, Fiance) [11] Blood samples for meas-
urement of plasma catecholamines were collected in piechilled tubes on melting ice con-
taining glutathione (0 2 mol l')andEDTA(0 25mol 1') The tubes were centnfuged at 4°C 
and plasma was stored at -80°C, analyses of plasma samples and infúsate occurred with-
in 2 months from collection Plasma samples were analyzed for concentrations of cate-
cholamines by high performance liquid chromatography with fluorometnc detection 
after precolumn denvatization with the selective detection agent 1,2-diphenylethylenedi-
amine The laboratory procedure is a modification of a previously desci ibed method [12] 
Data analysis 
The plasma concentration data obtained after bolus injection were fitted to an open two-
compartment model by use of the PCNonlin computer progiam [13] The area under the 
curve (AUC) was calculated by direct integration, and the half-life of furosemide was 
obtained from the terminal elimination rate constant The AUC below the plasma con-
centration-time curve during continuous infusion was calculated by means of the trape-
zoid rule and extrapolation to infinity using the terminal elimination rate constant of 
the curve after bolus injection Systemic clearance was determined by dividing the 
furosemide dose by the AUC Renal cleaiance was calculated as the amount of excieted 
drug during 24 h divided by the AUC Nonrenal clearance was defined as the systemic 
clearance minus renal clearance Overall efficiency was calculated by dividing the excreted 
amount of sodium (mmol 24 h') by the excreted amount of furosemide (mg 24 h ) 
Statistical analysis 
Statistical analyses of unpaired and paired data were made using the Student t test and 
the Student t test for paired data, respectively A ρ value < 0 05 was considered signifi­
cant Data are expressed as mean value ±SEM 
R E S U L T S 
Biochemical measurements 
Mean values of the biochemical parameters including catecholamines, renin and aldos­
terone did not change significantly during the study, with the exception of serum creati­
nine, which showed a significant increase after both treatment modes (Table 2) As shown in 
Table 1, the endogenous creatinine clearance was reduced in the majority of the patients 
According to the natnuresis, 13 patients were not resistant to oral therapy (Table 3) 29 
Howevei, six of these patients had a clearly negative sodium balance (>20 mmol 24 h1)
 o 
and did not lose weight during this phase of the study, suggesting poor compliance with 3 
the dietary restrictions An influence of cotreatment with angiotensin-converting 5 
enzyme inhibitors on the diuretic response could not be observed The renin levels 5 
between captopnl-treated and non Captopril treated patients did not differ significantly §. 
ΙΛ 
О 
< 
m 
Table 3 Urinary volume electrolyte and fui osemide excretion (mean ±SEM) 8 and 24 h aftei с 
administration offurosemide as oral dosage (day 2), intravenous bolus injection g-
or continuous infusion in patients with heart failure 5 
U
v
(ml) 
U N a(mmol) 
U k (mmol) 
U
c l (mmol) 
Ufi,„„emide (mg) 
Recovery (%) 
Eff(mmol mg') 
Oral. 0-24 h 
2200 ±160 
130 ±30 
70 ±6 
130 ±20 
140 ±30 
21 ±2 
2 9 ±15 
Bolus 
0-8 h 
1350 ±90 
110 ±10 
30 ±5 
120 ±10 
290 ±50 
44 ±2 
0 7 ±0 2 
0-24 h 
2260 ±150 
150 ±20 
70 ±5 
150 ±20 
330 ±60 
50 ±2 
0 9 ±0 3 
Infusion 
0-8 h 
1700 ±120 
140 ±20 
40 ±4 
150 ±20 
220 ±40 
33 ±2 
11+03 
0-24 h 
2860 ±240 
210 ±40 
80 ±5 
220 ±35 
310 ±60 
44 ±2 
13 ±0 4 
Bolus versus Infusion 
(p value) 
0-8 h 0-24 h 
0 0002 
0 0010 
0 0006 
0 0006 
<0 0001 
<0 0001 
0 0005 
0 0005 
0 0045 
<0 0001 
0 0018 
0 0195 
0 0195 
0 0019 
Abbreviations Eff= efficiency, ¡J, - unnary volume, Us, = urinary sodium excretion, 
Uk = urinary potassium excretion, Un = urinary chloride excretion 
Statistical analyses were made using the Student t test for paired data 
Pharmacokinetic parameters 
Apart from the maximal plasma furosemide concentration, which was signifantly higher 
after intravenous bolus injection, the pharmacokinetic measurements were similar in 
the two treatment modes (Table 4) 
Table 4 Pharmacokinetic variables (mean +SEM) of furosemide after administration as bolus or 
continuous infusion in 20 patients with heart failure 
Bolus 
14 2 ±4 0 
64 ±8 
30 ±3 
34 ±4 
139 ±7 
330 ±60' 
Infusion 
13 1 ±4 1 
67 ±6 
31 ±3 
36 ±4 
310 ±60 
AUC(g ml' mm') 
Systemic clearance (ml mm') 
Renal Clearance (ml mm ') 
Nonrenal clearance (ml min ') 
Half life (min) 
Furosemide excretion (mg 24 h') 
Abbreviation AUC = area under the curve 
'p<0 05 statistical analyses were made using the Student t test for paired data 
The plasma furosemide concentration-time profiles of the two dose regimens of one rep­
resentative patient are shown in Figure 1 
The furosemide plasma concentrations were in the supposed ototoxic range (>100 pg ml1) 
in seven patients immediately after bolus injection and in one patient during continu­
ous infusion During continuous infusion, the plasma furosemide concentration 
remained at steady state throughout the infusion period, with a significantly lower max­
imal plasma concentration (bolus 95 ±20 mg ml1, infusion 24 ±5 mg т Г , р < 0 0001) 
However, the plasma furosemide concentration was determined first at 15 min, after the 
start of the administration This implies that immediately after injection of the bolus, 
the plasma furosemide concentration was even higher The urinary furosemide excre­
tion rate followed a similar pattern for both ways of administration (Figure 1) 
100 -,. Plasma furosemide concentration (pg ml
1) 
120 240 
Infusion 
Bolus 
360 480 
Time (mm) 
Furosemide excretion rate (gg mm1) 
Infusion 
Bolus 
120 240 360 480 
Time (mm) 
Figure 1 Furosemide plasma concenti ation (Top) ana w mai y furosemide excretion rate (bottom) 
for a lepiesentative study patient (patient 1) after 500 mg of furosemide as a bolus 
injection or continuous infusion (50 mg h ' during 8 h preceded by a loading 
dose of 100 mg) 
After bolus injection, most of the furosemide was excreted within 2 h, whereas dining 
continuous infusion, the urinary excretion late was constant 
Pharmacodynamic parameters 
Although a smaller amount of fuiosemide was excreted in the urine during both 8 and 
24 h with the use of continuous infusion, the urinary volume and natnuiesis during 
both 8 and 24 h were significantly larger (Table 3) The differences in natriuretic 
îesponse between the two intravenous modes of administration and the interindividual 
variability of these responses are shown in Figure 2 and 3 
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Figure 2 Cumulative urinary sodium excretion (mean ±SEM) 24 h aftei bolus injection 
(open squares) and continuous infusion (solid squares) ofhigh dose furosemide 
Separate analysis of data of patients with compensated (n=9) and decompensated (n=ll) 
heart failuie revealed similar results for these subgroups, except for the urinary 
furosemide excretion In the two dose regimens there appeared to be a significantly 
lower excretion only in patients with compensated heart failure after continuous infu­
sion The sequence of diug administration did not influence the natriuretic response in 
either of the two intravenous administration methods Compaied with oral therapy (day 2) 
bolus injection did not differ significantly with respect to volume and electrolyte excre­
tion However, unnary recovery of furosemide was significantly lower (oral 21 ±2%, bolus 
50 ±2 % p<0 0001), and thus efficiency higher When continuous infusion was compared 
with oral therapy, volume and electrolyte excretion was significantly higher after contin­
uous infusion, whereas unnary furosemide recovery was significantly lower after oral 
administration (oral 21 ±2 % infusion 44 ±2%, p<0 0001) 
Unnary sodium excretion (mmol 24h1) 
Figure 3 individuell values foi 
uunaiy sodium 
exnetion 24 h after 
continuous infusion 
and bolus 
injection of high dose 
furosemide in 20 
patients vvithseveie 
heart/ciilure 
Infusion Bolus 
A dose-response curve was created for each patient However, sigmoid-shaped curves as 
seen in healthy subjects, were not observed (data not shown] Moieover, a high lntenndi-
vidual variability was observed To gain insight into the potential development of acute 
diuietic toleiance during continuous infusion of furosemide we compared the efficiency 
(mmol excreted sodium divided by mg of excieted furosemide) during two time inter­
vals-30-60 mm and 420-480 mm The amount of drug excieted pei hour during each inter­
val did not differ significantly, nor did the amount of sodium Hence, the efficiency was 
equal in both periods indicating that acute diuretic toleiance did not occur during con­
tinuous infusion Because of the design of the study (a single bolus instead of multiple) we 
could not determine whether acute di ug tolerance was present after bolus injection 
Side effects 
Although five patients reported hearing loss or tinnitus,or both, shortly after bolus 33 
injection this appeared to be tiansient in all five and disappeared within 15 min 
No other side effects were observed or reponed during this study § 
с 
DISCUSSION § 
с
1 
General conclusions δ 
Oui results cleaily show that in patients with severe heait failure, continuous infusion < 
of high dose fuiosemide causes excretion of a higher volume of mine and electrolytes £ 
than an equal dose administered as an intravenous bolus, and the maximal plasma g-
furosemide concentration is significantly lower A crossover design in combination with 5 
a washout period was used to balance out any possible time 01 sequence trends · | 
Moreover, the phai macokinetic data obtained suppoi ted the outcome of the study g 
Comparison with previous studies 
Few data aie available on the usefulness of continuous infusion of furosemide in disease, 
paiticularly in heait failure In an animal study, Lee et al [14] compared diffeient dura­
tions of infusion of an equal dosage of furosemide The diuretic ìesponse incieased with 
incieasing infusion times In healthy volunteeis a controlled comparison of bolus injec-
tion with continuous infusion of a conventional dosage of furosemide showed a larger 
diuietic effect of the lattei mode of administiation [4] In chrome renal insufficiency 
continuous infusion of bumetanide was more effective and less toxic than intermittent 
bolus therapy [15] Several uncontrolled reports describing small series of patients with 
congestive heart failure demonstrate succesful application of continuous infusion of 
loop diuretic drugs [5,16 20] 
To our knowledge only two controlled studies on this subject have been performed in 
patients with heart failure [7,8] Copeland et al |8| did not find any significant pharmaco-
dynamic differences in a comparison of continuous intravenous infusion and an equal 
dose given as two sepaiate bolus injections m patients after cardiac surgeiy However, 
that study lacked a crossover design, use of a loading dose before the start of continuous 
infusion and adequate study period Lahav et al |7] compared intermittent administration 
of furosemide with a continuous infusion of an equal dose in patients with congestive 
heart failure In their study which lacked pharmacokinetic data, continuous infusion 
was shown to be the preferì ed method of administiation In both studies conventional 
dosages of furosemide were used 
In our study the dosage of furosemide was > 250 mg day' mall patients The lesults of the 
present study can not be geneiahzed to patients receiving furosemide in the conventional 
dose range Howevei, in the conventional dose range a continuous infusions is usually not 
necessary, because diuietic resistance can be overcome by simply increasing the dosage 
Interpretation of pharmacokinetic and pharmacodynamic data 
In the present study, we included those patients who would benefit most from the pre-
sumed advantages of continuous infusion of furosemide, that is, patients with heart fail 
uie and, often impairment of ienal function High dose fuiosemide is used in these 
patients because of diuretic resistance to conventional dosages Thus, they are in need of 
an optimal diuretic regime without toxic side effects The higher efficiency of continu-
ous infusion is demonstrated by the observation that a smaller amount of diug excreted 
into the urine produced a larger natriuretic effect (Table 3) Several mechanisms may 
elicit this superior response firstly the time course of delivery of furosemide into unne 
Because the amount of diug excreted into the urine is even smaller aftei continuous 
infusion, the time coin se of delivery is consequently an important factoi influencing 
the diuretic response The maximally efficient exaction rate of furosemide can be calcu-
34 lated and the slope factor of the dose-iesponse curve appeals to be an important deter-
minant in this calculation |3 4) In healthy volunteers the maximally efficient excretion 
| rate appeared to be 115 \jg mm [4] As inpatients with heart failure studied by Biatet eta!, 
f, the dose-iesponse curves of the patients in the piesent study were shifted to the right [2] 
Ê Moreovei, the sigmoid shape could not be recognized, making a calculation of the maxi-
ç mally efficient excretion late impossible For this reason and because of the larger 
Ζ lnterindividual variability, an optimal infusion rate of furosemide can not be predicted 
°- in these patients However it is obvious that during continuous infusion, the urinai y 
о furosemide excretion rate will be closer to the maximally efficient excretion rate ovei a 
i longei period 
m 
i? 
~ Another cause for the observed difference in response between the two modes of admin-
2, istration could be the development of a more pronounced acute drug tolerance after 
m bolus injection [211 Because of a greater diuresis during the period immediately after 
g- the injection, the intravascular volume might decrease even in a volume-overloaded 
^ patient, causing activation of sodium- and volume retaining mechanisms The net result 
3 may be a smaller diuretic efficacy despite adequate urinary furosemide concentrations 
3 Because we used only one bolus injection instead of multiple inteimittent injections, 
Φ the presence of acute tolei ance could not be venfied Acute diuietic tolerance during 
continuous infusion appealed to be absent 
Finally, after bolus injection the drug free interval during which counteracting sodium 
retaining mechanisms aie active, is longei Although catecholamine levels were 
increased at the start of the study they weie not increased further at the end of the 
study Activation of the ìenin angiotensin aldosterone axis was not observed (Table 2) 
However variables weie measured at the start and at the end of the study, so a tiansient 
activation could have been missed In chronic heai t failure long-term coadministration 
of angiotcnsin-conveiting enzyme inhibitors may enhance furosemide induced natnure-
sis, possibly owing to a change in the set point for ι enal sodium handling [22) In 9 out of 
20 patients in this study, angiotensin-converting enzyme inhibitors were withdiawn in 
an earliei phase, because of further deterioration of renal function oi symptomatic 
hypotension Comparison of the patients treated with and without angiotensin-conveit-
ìng enzyme inhibitors did not reveal any diffei enees in furosemide-induced natnuresis 
for any of the modes of administration, and the mean daily dosage of furosemide did not 
diffei significantly between the two groups 
Side effects 
An important advantage of the use of continuous infusion is a smaller risk of ototoxicity, 
because high peak plasma levels of furosemide are avoided [6] In the present study the 
measured maximal plasma concentration during continuous infusion was lower than 
after bolus injection in all patients However, even a continuous infusion of high dose 
furosemide may lead to concentrations in the supposed ototoxic range in patients with 
severe renal insufficiency, as illustrated by one of the study patients (patient 9, endoge-
nous creatinine cleaiance 15 ml min1 1 73 m -, furosemide dosage 2000 mg, maximal 
plasma concentration in the course of continuous infusion 119 pg ml ) According to 
our clinical experience an infusion rate of 160 mg h ' seems safe, when the endoge-
nous creatinine clearance is higher than 20 ml mm' 173m [5| 
Intravenous versus oral treatment 3 5 
We observed a highei uiinary recovery of furosemide after bolus injection than with 
continuous infusion Tins difference reached significance only in the compensated | 
group of patients The exact mechanism of this discrepancy is not clear and needs fur 1 
ther exploration Although the uiinary recovery of furosemide after oral therapy is 5 
much lower (Table 3), owing to a lower bioavailability than after bolus injection, its effi- Ë, 
cacy is equal This means that the efficiency is higher after oial therapy than after bolus 5 
injection, which is probably the result of a better time course of delivery Although effi- Ξ 
ciency was equal in oral therapy and continuous infusion, the continuous infusion of an ¡5 
equal dose is more efficacious than oial administration because of a higher urinary σ 
excietion late of furosemide with continuous infusion (Table 3) In patients with conges- = 
tive heart failure, absorption of furosemide after oral therapy is delayed which results in 3 
lower drug concentration at the site of action An increase of oral dosage is less attractive, ~ 
because the exact duiation of delay is unknown, making the response unpredictable For 3 
this reason patients with manifest decompensated heart failure should preferably be 
treated with intravenous therapy, until the hydration state is corrected 
Summary 
The value of continuous infusion of furosemide in patients with severe congestive heart 
failure can be summarized as follows a higher efficiency (than with bolus injection) and 
a higher, more predictable urinary excretion rate of drug (than after oral theiapy) results 
in an improved diuretic response combined with a reduced risk for ototoxicity 
Continuous infusion of furosemide should be consideied in patients with decompensated 
heart failuie whenever the diuretic response after oral therapy with high dose 
furosemide is insufficient, especially in those patients at risk foi furosemide-induced 
toxicity because of impaired renal function 
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CHAPTER FOUR 
C H R O N I C INTERMITTENT HEMOFILTRATION AND 
HEMODIALYSIS IN END STAGE CHRONIC HEART 
FAILURE WITH OEDEMA REFRACTORY TO HIGH 
DOSE FUROSEMIDE 
Tom P.J. Dormans, Rien M.C. Huige and Paul G.G. Gerlag 
Heart 1996:75:349-351 
ABSTRACT 
Objective: To assess the benefits and problems of chronic intermittent treatment with 
hemofiltration 01 hemodialysis or both in patients with severe chronic heart failure 
(New York Heart Association class III or Г ) and oedema refractory to pharmacological 
treatment 
Design and setting: A retrospective case-cohort study A general hospital in The 
Netherlands 
Patients: The results of chronic intermittent treatment with hemofiltration (n=10) and 
hemodialysis (n=2) were analyzed in patients with severe chronic heart failure, predomi­
nantly due to coronary heart disease and oedema refractory to a pharmacological 
regime including high dose furosemide 
Intervention: Patients had an average (±SD) of 25 ±38 treatments 
Results: There was improvement of NYHA class Г to III in seven patients However, this 
was not reflected m a decrease of hospital admission only two patients could be man­
aged as outpatients The median survival after start of the treatment was 24 days (vaiy-
îng from 0 to 393 days) In four patients the treatment was discontinued after discussion 
with the patient and family 
Conclusion: The use of chiome intermittent hemofiltration and hemodialysis is of limit-
ed value in end stage chiome heart failure with oedema, refractory to maximal conven-
tional treatment 
INTRODUCTION 
Chiome heart failure is a major health problem Ultimately many patients become unre 
sponsive to maximal conventional treatment and remain severely symptomatic Short 
term relief of symptoms may be obtained by removing fluid either by venesection, 
hemodialysis hemofiltration, or peritoneal dialysis [2,3,4,5,6,7] The use of these tech­
niques in the acute setting may be worthwhile and can result in the restoiation of 
diuretic responsiveness 
Chronic intermittent hemofiltration and continuous ambulatory peritoneal dialysis of 
patients with heart failure may improve survival [8,9,10,11| The wide lange in outcome in 
these studies reflects the differing definitions of maximal pharmacological treatment and 
the heterogeneity of the patients studied Often data are lacking about the maximal 
dosages of diuretics, the use of inotropic or preload reducing drugs, and the seventy of left 
ventnculai dysfunction at the start of chronic intermittent treatment We therefoie set 
out to detei mine whether hemofiltration and hemodialysis used in this way can improve 
the quality of life in patients with chronic heart failure unresponsive to maximum conven­
tional treatment, including high dosages furosemide (500 to 4000 mg daily dosage) 
METHODS 
Patient characteristics 
In this retrospective study we reviewed the data of 12 patients who were treated in our 
hospital between October 1979 and April 1991 The clinical charactenstics of the studied 
patients are shown in Table I The mean age of the studied patients was 68 years, the pre­
dominant cause of chronic heart failuie was coronary heart disease, and all but one were 
in New Yoi к Heart Association (NYHA) class Г Other complicating conditions were also 
commonly present other vascular diseases (n=7), diabetes mellitus (n=4), chronic obstruc­
tive pulmonary disease (n=l) and renal disease (n=4) All patients were severely sympto­
matic with marked peripheral oedema Left ventricular ejection fraction values, by cross 
sectional echocardiography, were 21-30% (n=2), 11-20% (n=3) and less than 10% (n=4) The 
resting supine systolic blood pressine ranged from 130 to 60 mm Hg (median 90 mm Hg) 
Table 1 Characteristics of the patients be/ore the start of the hemo/i/tration tieatments 
Patient 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
Sex 
M 
F 
M 
M 
M 
M 
M 
F 
M 
M 
M 
M 
Age 
(years) 
64 
75 
62 
77 
71 
76 
61 
71 
56 
72 
66 
64 
NYHA 
Г 
Г 
tv 
rv 
IV 
rv 
Ш 
rv 
rv 
rv 
rv 
rv 
Underlying 
Disease 
CHD 
CHD 
CM 
CHD 
CHD 
CHD 
CHD 
VAD 
CHD 
CHD 
CHD 
CHD 
Furosemide 
Dosage (mg) 
500 PO 
1000 PO 
1500 PO 
1000 PO 
2000 Г 
1500 PO 
2000 IV 
2000 PO 
1000 PO 
2000 PO 
4 0 0 0 r v 
3000 rv 
Other 
medicat ion 
Dig Vd 
Dig 
Dig Асе 
Dig Ace, Vd Do 
Dig, Ace 
Dig Ace Vd 
Dig Ace 
Dig Ace Do 
Ace 
Ace Do 
Ace Do 
Dig Ace Do 
Abbreviations Ace = angiotensin converting enzyme inhibitor, CHD = coronary heart disease, CM = 
cardiomyopathy, Dig = digitalis, Do = dopamm, F - female, IV = intravenously, M = male 
P0 = oraîiy, Pt = patient, VAD = valvular disease, Vd = vasodilator 
Previous treatment 
Treatment consisted of salt iestnction bed lest and drug treatment including diuretics 
ЛСЕ inhibitors digoxin and dopamine (Table 1) All patients showed diuretic ïesistance 
defined as a failure to lose weight or to develop a negative sodium balance despite bedrest 
a sodium intake restnction of 80 mmol per day and high dose furosemide (1790 ±960 mg) 
Furosemide was given orally in eight patients and by continuous intravenous infusion 
in four Doses of fuiosemide exceeding 250 mg per day were given foi at least 22 days 
(mean 236 ±209 days) befoie the start of hemofiltration or hemodialysis 
Laboratory data at the start 
Before hemofiltiation renal function was considerably decreased in all patients 
Endogenous creatinine clearance (ECC) ïanged fiom 8 to 26 ml min 173 m with a 
40 meanECCof 15 7 + ±6 4) ml min 173 m The mean urea concentration was 40 4 ±13 6 
mmol 1 ' (ranging from 20 3 to 68 0 mmol 1 ) The serum sodium concentration varied 
ς from 118 to 146 mmol 1 mean 132 ±71 mmol Γ Serum potassium before treatment 
R varied from 3 2 to 6 1 mmol I mean 4 5 ±1 0 mmol 1 The mean hemoglobulin concen-
S tration was 78 ±11 mmol 1 (range 6 0 to 9 9 mmol 1 ) 
R E S U L T S 
Hemodialysis and hemofiltiation 
The initial treatment consisted of hemofiltration (n=10) or hemodialysis (n=2) During 
the fust session a double lumen femoral vein cathetei was used as a vascular access in 
seven patients a subclavian double lumen catheter in one a Scnbner shunt in one and a 
Cimino-Brescia fistula m three 
The mean number of hemodialysis oi hemofiltration treatments per patient was 25 ±38 
(ranging from one to 113) The mean treatment interval was 5 7 ±9 1 days (Table 2) The 
maximum treatment interval was 33 days The mean weight reduction during the first 
treatment procedure was 4 0 ±1 7 kg (ranging from 1 2 to 6 2 kg) The total weight reduc 
tion (weight before first treatment minus weight before last treatment) was 8 4 +8 5 kg 
(Table 2) 
Complications, quality of life, survival 
Four patients reported no complaints during the treatment, one repoited nausea and 
loss of hearing as main complaints while three suffeied from angina pectoris unrespon 
sive to pharmacological treatment Four patients became confused or had a decreased 
level of consciousness Seven improved from NYHA class Г to class III while five showed 
no change In four patients the treatment was discontinued after discussion with the 
patient or his family Other causes of death were hypotension (thiee patients) respirato­
ry insufficiency (two patients) and sudden death probably caused by a fatal arrhytmia 
(three patients) 
Patients were admitted to hospital for 12 ±9 % of the time during treatment with high 
dose furosemide During the treatment with hemofiltration oi hemodialysis patients 
were in hospital for 80 ±35 4 % of the time Eight patients were in hospital continuously 
two weie managed as outpatients for the major part of their treatment while two were 
discharged for a short period (14 (of 24) and 23 (of 393) days respectively) 
Table 2 Clinica! data concerning the hemofütwtion treatment 
Patient 
1 
2 
3 
4 
5 
6 
7 
β 
9 
10 
11 
12 
Method 
HD 
НГ 
HF 
HF 
HF 
HF 
HD 
HF 
HF 
HF 
HF 
HF 
Mean 
treatment 
interval (days) 
2 3 
19 
33 0 
3 0 
120 
3 0 
3 5 
22 
17 
0 0 
2 2 
3 0 
Total 
weight 
reduction (kg) 
6 8 
15 1 
74 
97 
6 9 
18 7 
15 
16 
79 
1 2 
211 
172 
NYHA 
class during 
treatment 
III 
III 
III 
IV 
IV 
III 
II 
III 
III 
IV 
III 
IV 
Period Of 
treatment 
(days) 
233 
21 
165 
9 
24 
24 
393 
20 
22 
0 
76 
24 
Cause 
of 
death 
DT 
RI 
CS 
DT 
DT 
DT 
FA 
CS 
FA 
CS 
RI 
FA 
Abbreviations CS= cardiogenic shock, FA=fatal airhytmia, HD= hemodialysis, HF~ hemofiltiation 
Pt=paticnt, Rl= respirato? у insufficiency, DT-discontinuahon of treatment 
The median survival after the start of hemofiltration treatment was 24 days, varying 
from 0 to 393 days The median survival after the last tieatment was three days, varying 
from 0 to 23 days 
DISCUSSION 
High dose furosemide is an effective, safe and controllable means of treating patients 
with severe chronic heart failure refractory to the conventional dosages of furosemide 
[12], but resistance even to high dose furosemide may develop Our study shows that the 
use of hemofiltration and hemodialysis in patients with end stage chronic heart failure, 
who have become unresponsive to such pharmacological treatment is of little benefit for 
either length or quality of life 
Peritoneal dialysis and hemofiltration may be of value in the treatment of patients with 
acute heart failure unresponsive to high dosages of diuretics and inotropic drugs [2,3,4,5,6,7] 
However, the place of these nonpharmacologic approaches, used on a chronic intermittent 
basis in the treatment of refractory congestive heart failuie remains unclear although 
the idea that excess of body water can be removed on a regular basis by the use of peri­
toneal dialysis or hemofilti ation, analogous to the treatment of end stage renal failure, 
seems appealing 
In contrast to hemodialysis, adverse hemodynamic effects are limited in peritoneal dialy­
sis and hemofiltration, which makes these two techniques more suitable for the treat­
ment of refractory chronic heart failure [13] Despite its negative hemodynamic side 
effects, two patients in this study had to be treated with hemodialysis because of life 
threatening uremia Renal function was seriously impaired initially in all patients, at 
least in part because of heart failure, and declined further during treatment with 
hemofiltration in the majority 
In some of the studies describing the use of hemofiltration or peritoneal dialysis in 
chronic heart failure, an improvement in both hemodynamics and responsiveness to 
diuretics after the first session was observed, making further treatment of this kind 
unnecessary [2, 4, 5, 6, 7,10]. This can not be completely explained by the influence of 
massive oedema on the pharmacokinetics and pharmacodynamics of high dose 
furosemide [14]. In our study only one patient could be treated at intervals of greater 
than 10 days over a long period. 
Life was substantially prolonged in only four patients and the median survival after the 
start of hemofiltration was short. Moreover, most patients were in hospital throughout 
the period of hemodialysis. Any improvement in NYHA class was limited. The slight bene­
fit combined with the high cost, make it questionable whether patients with end stage 
chronic heart failure refractory to high dose furosemide should be offered chronic 
hemofiltration. The addition of a thiazide diuretic, acting on the distal tubule, is effec­
tive, even in patients with a markedly impaired renal function [15). Treatment with a 
combination of diuretics acting on different segments of the nephron may be an alterna­
tive to chronic intermittent hemofiltration. In our view treatment with hemofiltration 
or hemodialysis in patients with chronic heart failure should only be considered when a 
remedial cause of heart failure is suspected or as a bridge to heart transplantation 
[10,121. 
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CHAPTER FIVE 
C O M B I N A T I O N O F H I G H - D O S E F U R O S E M I D E A N D 
HYDROCHLOROTHIAZIDE IN THE TREATMENT OF 
REFRACTORY CONGESTIVE HEART FAILURE 
Tom P.J. Dormans and Paul G.G. Gerlag 
Eur Heart J 1996;17:1867-1874 
ABSTRACT 
Objective: We studied the synergism between high dose furosemide and hydrochloro 
thiazide in patients with severe congestive heart failure and impaiied renal function 
showing diuretic resistance to daily dosages fuiosemide of at least 250 mg 
Design and setting: An open study A general hospital in The Netherlands 
Methods: In 20 patients with severe congestive heart failure (stage ІІІ-Г according to the 
New York Heart Association) with an oedematous mass of more than 5 kg and a proven 
diuretic resistance to high dose furosemide, hydrochlorothiazide (25-100 mg daily) was 
added to the medication for 3-12 days, leaving the other medication unchanged After 
correction of the hydration state, hydiochloiothiazide was withdrawn Vai ìables included 
body weight, serum electrolytes, renal function and natnuresis 
Results: Addition of hydrochlorothiazide resulted in a mean (±SD) body weight reduction 
of 6 7 ±3 3 kg per patient Mean daily urine volume increased from 1899 ±958 ml to 3065 
±925 ml (p < 0 001) Fractional sodium excretion increased significantly from 3 5 ±3 2 % to 
11 5 ±9 0 % (p < 0 001 ) The most important side effect of this combination therapy 
appeared to be hypokalemia Mean endogenous creatinine clearance decreased (not signifi-
cantly) from 32 7 ±22 5 ml mm ' 1 73 m - to 27 6 ±22 5 ml min ' 1 73 m 
Conclusions: Addition of hydrochlorothiazide to high dose furosemide is a powerful 
diuretic tool, even in patients with an importantly reduced renal function Because of its 
potentially dangerous side effects (hypokalemia), it should be used in a carefully con 
trolled setting 
INTRODUCTION 
In the majority of patients with congestive heart failure no causal treatment for the 
undeilying disease is available, thus only symptomatic therapy remains The basis of the 
management of decompensated patients consists of restriction of both physical activity 
and sodium intake together with pharmocological therapy In the management of 
patients with advanced chronic heart failure, pharmacological treatment comprises 
angiotensin converting enzyme inhibitors, vasodilators, digitalis and diuretics [1] 
Diuretics, most frequently the potent loop diuretics, are universally used once fluid 
retention occurs 
The usually recommended doses of loop diuretics will lead to clinical improvement in 
the majority of the patients, but in some this fails to reduce oedema In patients with 45 
refractory congestive heart failure glomerular filtration rate is often significantly 
reduced to a level of about 30 ml min due to both prerenal (low cardiac output, renal £ 
vasoconstriction due to sympathetic excitation) and renal (arteriosclerosis) factors [2| s 
In these cases, conventional doses of loop diuietic appear to be too low to create an ade- Ί 
quate concentration of loop diuretic in the renal tubule, resulting in an insufficient ¿s 
diuretic response In these patients, administration of high dose furosemide (250 to 4000 э 
mg per day) - supplied either orally or as a moie effective continuous intravenous infu­
sion- has been shown to be effective and safe [2,3] However, in a few patients with severe 
congestive heart failure even chronic therapy with high dose furosemide fails to reduce 
the volume of the extracellular compartment to the desired level and again diuretic 
resistance ensues A combination of diuretics acting on different segments of the 
nephron may then be a possible approach to master diuretic resistance 
The synergism between loop diuretiLS and thiazides have been described in several stud­
ies (4-13] However, in all studies concerning the synergism of diuretics, loop diuretic 
doses were relatively low (ι e oral furosemide dosages lower than 500 mg day') and in 
most of these studies renal function was fair While thiazides used as monotherapy are 
thought to be no longer effective when the glomerular filtration rate falls below approxi­
mately 25 to 30 ml min' [14,15], there are nevertheless limited data showing that addi­
tion of a thiazide to a loop diuretic increases natriuresis in patients with advanced renal 
failure 110,16] We studied the effects of the addition of hydrochlorothiazide to high dose 
furosemide in patients with severe congestive heart failure who showed an impaired 
natriuretic ìesponse to high dose furosemide (250^000 mg), or who were already recei-
ving the drug in combination with a diuretic acting on the collecting ducts 
Table 1 Characteristics of study patients and diuretic regimes 
Patient 
no 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
Sex 
M/F 
M 
M 
M 
M 
M 
M 
M 
F 
M 
M 
M 
M 
M 
F 
F 
F 
M 
M 
F 
F 
Age 
(years) 
61 
71 
58 
64 
73 
66 
69 
70 
86 
78 
83 
86 
51 
80 
81 
83 
78 
30 
79 
69 
Cause of 
illness 
CM 
CAD 
CAD 
CAD 
CAD + VD 
CAD 
CAD 
VD 
CAD 
CAD 
CAD 
CAD 
CM 
CAD 
CAD 
CAD 
VD 
CM 
VD 
CAD 
Furosemide 
Dosage 
(mg day1) 
2000 PO 
2000 PO 
2000 PO 
4 0 0 0 I V 
2000 PO 
500 PO 
2000 PO 
500 PO 
4 0 0 0 I V 
1000IV 
500 PO 
500 PO 
500 PO 
2000IV 
1000 PO 
2000IV 
2000 Г 
3000IV 
250 PO 
500 PO 
Other 
Diuretics 
(mg day') 
TRIAM 50 
SPIRO 50/AMILO 10 
AMILO 10 
AMILO 5/TRIAM 50 
SPIRO 100 
AMILO 10 
TRIAM 50 
TRIAM 50 
TRIAM 50 
AMILO 5 
SPIRO 100 
TRIAM 50 
TRIAM 50 
AMILO 10 
AMILO 5 
HCTZ 
Dosage 
(mg day') 
100 
100 
50 
50/100 
100 
25/50/100 
50 
50 
100 
25 
25 
25 
25 
50 
25 
25 
25 
25 
25 
25 
Period of 
Combination 
(days) 
8 
4 
3 
3/7 
4 
6/3/3 
3 
5 
3 
4 
4 
5 
7 
15 
5 
6 
9 
15 
5 
10 
Abbreviations CM= cardiomyopathy, CAD= coronary artery disease, HCTZ= hydrochlorothiazide, 
VD- valvular disease, P0= supplied orally, IV= supplied intravenously, TRIAM= triamterene, 
AMILO amilonde, SPIR0= spironolactone 
PATIENTS AND METHODS 
After approval of the protocol by the local ethics committee, we selected 20 inpatients 
(six female, 14 male) with severe congestive heart failure (stage III (n=5) or Г (n=15) 
according to the New York Heart Association classification) who gave their informed con­
sent for the study, which was performed between December 1989 and October 1994 All 
patients had an estimated oedematous mass of at least 5 kg and diuretic resistance 
Diuretic resistance was defined as a failure to lose weight and/or create a negative sodi­
um balance despite bedrest, salt and fluid intake restricted, a diuretic regime of high 
dose furosemide (250 to 4000 mg daily dosage), administered orally or by continuous 
intravenous infusion, either or not in combination with potassium sparing diuretics 
(triamterene, amilonde and/or spironolactone) All studied patients had been using 
high dose furosemide for at least two weeks before the start of the study 
Differences in diuretic legimes between the patients occurred because they were referred 
for treatment by various departments During the study 12 patients used angiotensin con-
verting enzyme inhibitors, in four patients enalapnl was withdrawn soon after its intro-
duction because of progressive renal impairment, while in two othei patients enalapnl 
caused symptomatic hypotension In two others we could retrospectively find no reason 
for withdrawal of angiotensin converting enzyme inhibition Ten patients used digoxin 
while none used dobutamin and/or low-dose dopamin 
The relevant patient characteristics are presented in Table 1 Mean age was 70 8 years 
(range 30 to 86 years) and the mean body weight at the start of the study was 73 7 kg (55 2 
to 96 8 kg) The underlying cause of heart failure was coronary artery disease (n=13), 
valvulai disease (n=3), cardiomyopathy (n-3) and a combination of coronary artery disease 
and valvulai disease (n=l) The left ventricle ejection fiaction, estimated by cross sectional 
echocaidiography, was less than 25% in all patients 
During the entire study the daily dietary sodium intake was limited to 80 mmol and the 
fluid intake to 1500 ml Physical examination including measurement of body weight, 
supine and standing blood piessures, pulse rate, central venous piessuie (determined by 
visual inspection of the neck veins [17]) and assessment of oedematous mass was per-
formed daily Patients weic daily interviewed for recognition of side effects The total 
daily output of urine was collected for creatinine, sodium, potassium chloride and pio-
tein measurements Daily blood samples were taken to determine serum sodium, potas-
sium, chloride, bicarbonate albumin, uric acid, creatinine and urea 
Monitoring was started at least 2 days days before administration and was continued 
until 2 days after withdrawal of hydrochlorothiazide Hydrochlorothiazide, either 50 oi 
100 mg (cieatinine clearance >25 ml mm ' 1 73 m 100 mg hydrochlorothiazide, creati-
nine cleaiance <25 ml mm' 173 m 50 mg hydiochlorothiazide), was added, leaving 
dosages of other medication (other diuretics included) unchanged Because three of the 
patients treated this way, showed signs of dehydration several days after withdrawal of 
hydrochlorothiazide, we decided to lower the starting dose to 25 mg hydrochloroth-
iazide in an attempt to avoid accumulation of hydrochlorothiazide In two patients the 
dosage of hydrochloiothiazide was increased during the study, because the at first cho-
sen dose appeared to be ineffective Potassium supplements were given when serum 
potassium was lower than 3 5 mmol 1' 
Patients were treated with combination of high dose furosemide and hydrochlorothiazide 
dining a period varying from 3 to 12 days When the hydration status of a patient was 
judged appropriate hydrochlorothiazide was stopped In two patients the 
hydiochloiothiazide medication was discontinued despite insufficient weight loss 
Because there was an important increase in natnuresis, we concluded that in these two 
patients weight loss was not achieved due to poor compliance with the dietary restric-
tions 
Results aie expressed as mean ±SD The Wilcoxon test was performed when the parame-
ters before and after combined treatment with high dose furosemide and hydrochloro-
thiazide were compaied 
48 
Figure 1. Treatment results in a 71 year old man with chronic heart failure (CHF) caused by coro-
nary artery disease (CAD, patient 2) 
'The lowest panel shows the diuretic therapy: to 2 gram Furosemide (F) per day adminis-
tered orally as the basic regimen, 100 mg hydrochlorothiazide (HCT) was added on 4 con-
secutive days. The fixed dose of spironolactone (50 mg) and amiloride (10 mg) is not 
shown.The upper panel shows the daily urine volume (UV), the natriuresis (US) and the 
course of the serum sodium (SS) and the serum potassium (SP), respectively, 'ITie dotted 
horizontal line represents the daily dietary sodium intake. Note that the lowest serum 
potassium value was 2.2 mmol. I ' which increased after the potassium chloride intake was 
raised to 160 mmol per day, in addition to the potassium sparíng diuretics. The upper 
middle panel shows the effects of the treatment on the bodyweight (SW) and (he central 
venous pressure (CVP). The lower middle panel shows the daily creatinine excretion (UCr), 
the course of the serum creatinine (SCr) and urea (SU) levels, and endogenous creatinine 
clearance (FCC). 
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RESULTS 
In the period preceding the combination therapy when only high dose furosemide was 
administered natnuresis was low in most patients indicating that sodium retaining 
mechanisms were activated However four patients showed a natnuresis of more than 
125 mmol day without weight reduction (range 137 188 mmol 24 h ) which can be 
explained by poor compliance with the dietary restriction The low natnuresis in the 
other patients (53 ±32 mmol 24 h' ranging from 7 to 100 mmol 24 h ) confirms the 
diuretic resistance to high dose furosemide A typical example of the effect of the combi­
nation therapy is shown in Figure 1 The average weight reduction during the five days 
preceding the addition of hydrochlorothiazide was 0 6 ±1 2 kg(n=17) in thiee patients 
hydrochlorothiazide was added already 2 days after admission to the hospital because 
of the seventy of the symptoms Patients were tieated with combination of high dose 49 
furosemide and hydrochloiothiazide d u n n g a penod vaiyingftom 3 to 12days During 
this treatment period body weight ι eduction vaned fiom 2 2 to 14 0 kg (6 7 ±3 3 kg) After s, 
withdrawal of hydrochlorothiazide the longest pei ìod of weight stabilization was in S" 
excess of 2 weeks in 16 patients Dunng the use of combined diuretic theiapy mean frac Ί 
tional sodium excretion incieased fiom 3 5 ±3 2 % to 11 5 ±9 0 "Á (p < 0 001) (Table 2) After 1 
stopping the administration of hydrochloiothiazide fractional sodium excretion э 
returned to the previous low level However in three patients using either 100 mg or 50 
mg hydrochlorothiazide the increased natnuresis lingered on resulting in dehydration 
more than 2 days after stopping the combination therapy 
All patients in this study had a reduced renal function Improvement of the hydiation 
state of these patients induced a (not significant) reduction in endogenous creatinine 
clearance (32 7 ±22 5 ml mm 1 73 m (range 4 4 to 110 7 ml min 1 73 m ) prioi to com 
bination therapy vs 276 ±22 5 ml mm 1 73 m (lange 8 9 to 100 8 ml nun 1 73 m 
after) In six patients correction of the hydiation state iesulted in an improvement of the 
endogenous creatinine cleaiance 
Hypokalemia was an impoitant side effect of the simultaneous administration of high dose 
furosemide and hydiochlorothiazide the elevated potassium excietion (65 ±33 mmol 24h ' 
prior veisus 115 ±55 during combined administiation) resulted in hypokalemia in 15 
patients (serum potassium lowei than 3 5 mmol 1 ) which could only be corrected by 
enlarging the potassium intake The lowest mean sei um potassium measured during the 
combination theiapy was 3 3 ±0 5 mmol 1 (ranging from 2 2 to 4 2 mmol 1 ) It should be 
noted that befoie hydrochlorothiazide was added to the medication most of the 
patients already used potassium sparing diuretics (see Table 1) which failed to pi event 
the development of serious hypokalemia On average the patients weie mildly hypona-
tremic (mean serum sodium 136 ±5 mmol 1 (reference value 138 to 144 mmol Г) which 
(not significantly) aggravated during the combination theiapy (134 ±8 mmol Г) 
Although serum uric acid concentration incieased (not significantly) during the com 
bined use of high dose furosemide and hydiochloiothiazide (0 67 ±0 26 mmol Г prior 
versus 0 79 ±0 27 mmol 1 ' post p<0 01) none of the patients developed attacks of gouty 
arthritis No side effects inpaiticulai hearing loss or tinnitus were recorded 
No hypotensive episodes weie observed during therapy 
Eight patients wei e ι ealloca ted from NYHA class Г іо III as a result of the treatment and one 
of five class III patients improved from class III to class II Fourteen patients were fit enough to 
be discharged from hospital Fifteen patients died with a mean survival of 122 ±129 days 
(ranging from 0 to 404 days) after termination of the high dose fuiosemide and 
hydrochlorothiazide treatment Five patients were still alive aftei a 1 year follow up period 
DISCUSSION 
In the past 20 years the synergism between loop diuretics and thiazides has been descri­
bed in several studies (4-13]. However, administration of loop diuretics in these studies 
were in relatively low doses (i.e. oral furosemide dosages lower than 500 mg. 24h ') and to 
our knowledge this is the first study describing this synergism in patients with severe 
congestive heart failure and advanced renal failure showing diuretic resistance to high 
dose furosemide. 
Table 2. Effects of combined administration of high dose furosemide and hydrochlorothiazide 
BW(kg) 
BW reduction (kg day1) 
UV(ml.24h') 
U
s o d m
m
( m m o l - 2 4 h ' ) 
Upoiassium ( m m o 1 2 4 n ') 
Uchiondelnimol 24h ' ) 
FeNa (%) 
S
sodmm( m m o 1 I') 
Spoussium (mmol. Γ1) 
s
chionde (mmol 1') 
Varbonate (mmol l') 
S«™.™.!» (Mmol. Γ) 
Surea (mmol.1') 
ECC.(ml m i n ' . l 73m') 
Salbumm (S 1 ) 
S
u n c
 acid (mmol. Г) 
Before 
Treatment 
73 7 
01 
1899 
es 
65 
100 
3.5 
136 
4.1 
94 
28 
148 
17 
32 7 
33.0 
0 67 
±13.9 
±0 3 " 
±958 
±58 
±33 
±67 
± 3 2 
±5 
±0.5 
±5 
±2 
±69 
±6 
±22 5 
± 5 2 
±0 26 
During 
Treatment 
13 
3065 
206 
115 
243 
11.5 
3.3 
±0.8# 
±925# 
±84# 
±55# 
±94# 
±9 0# 
±0 5# 
After 
Treatment 
670 
2000 
84 
83 
116 
2.9 
134 
4 2 
86 
33 
177 
26 
276 
35.6 
0.79 
±13 3 
±666 
±58 
±33 ' 
±65 
± 1 9 
±8 
±0.7 
±8# 
± 4 ' 
±78' 
±10# 
±22 5 
±3.9" 
± 0.27t 
Abbreviations1 BW= body weight; 1П/= urine volume; UMwm, etc= urine electrolyte excretion; 
FeNa=fractional sodium excretion; ECC= endogenous creatinine clearance; 
SSlldmm, etr= serum concentrations 
Results are mean ± standard deviation 
* = ρ < 0.05, t = p< 0.01, # =p<0 001, compaired to before treatment with the Wi!coxon-test 
*' = n= Π 
The value of serum potassium during treatment represents the nadir of serum potassium during treat­
ment. Administration of potassium supplements was started at a serum potassium value of 2 5 mmol I ' 
Under physiological conditions, approximately 25% of the filtered NaCl is reabsorbed in 
the loop of Henle, while 5% to 10% of the filtered NaCl load is reabsorbed in the distal 
tubule. However, the distal tubules have the ability to increase NaCl transport capacity 
when the delivered load of NaCl in this segment of the nephron increases (18-20]. 
Furosemide acts from the tubular lumen on the thick ascending limb of the loop of 
Henle and blocks the major part of the sodium reabsorbing capacity in this part of the 
nephron. As a result, more sodium is delivered to the distal parts of the nephron. In rats 
a chronic increment of the sodium delivery to the distal tubules appeared to induce 
hyperplasia of the cells and an increase of the sodium transport capacity in this segment 
[18,21,22]. It was shown that the sodium retaining capacity of the distal convoluted 
tubule was increased substantially after chronic use of loop diuretics and this seems to 
be an important cause of diuretic resistance [18,19,21,22]. 
Administration of high dose furosemide, preferably given as a continuous intravenous 
pump infusion, has been demonstrated to be a safe, efficient and controllable method of 
overcoming diuretic resistance to usually recommended doses (40 to 250 mg daily dosage) 
in chronic heart failure [2,3] The patients presented here all used high doses of furose 
mide (at least 250 mg daily), administered either orally or by continuous intravenous 
pump infusion, for at least 2 weeks, prior to combined use of high dose furosemide and 
hydrochlorothiazide During this phase, fractional sodium excretion was low in all 
patients, reflecting diuretic resistance It is also possible that diuretic resistance to high 
dose furosemide was the result of a decreased tubular excretion of furosemide, because 
we did not measure renal furosemide excretion In an animal experimental study it was 
shown that triamterene (and not amilonde or spironolactone) inhibits the tubular secre­
tion of furosemide in a non-competetive manner [23] However, in the lattei study, as well 
as many of the studies on the coadministration of furosemide and tnamteiene in hu 51 
mans, this coadministration resulted in increased natnuiesis [24,25] Therefore, it is 
unlikely that administration of triamterene together with high dose furosemide (n=7) Ξ 
will attribute to the diuretic resistance to high dose furosemide, as observed in the = 
patients in this study Another possible cause for this diuretic resistance to high dose ·< 
furosemide could be a reduced response in the loop of Henle However, the striking na- ¡| 
tnuretic response during combined use of high dosages of fuiosemide and hydio- 3 
chlorothiazide in the patients presented here suggests that these furosemide doses are 
really able to reduce sodium reabsorption in the loop, even after prolonged use 
In most of the studies describing the synergism between loop diuretics and thiazides, 
the former was combined with metolazone, a diuretic agent which is registered in only a 
few countries in Europe Metolazone is structurally related to the benzothiadiazines, 
with pharmacologic effects similar to hydrochlorothiazide [14,26] The major action of 
hydrochlorothiazide, like other thiazides, is from the luminar surface on the distal con-
voluted tubule Used as monotherapy, hydrochlorothiazide has no significant diuretic 
effect in patients with a considerably impaired renal function (endogenous creatinine 
clearance lower than 30 ml min 1 73m') [15,26] One patient was subsequently treated 
with high dose furosemide alone, hydrochlorothiazide alone and a combination of high 
dose furosemide and hydrochlorothiazide (data not shown) Only the lattei treatment 
resulted in an increased natnuresis 
For these reasons, it seems unlikely that hydrochlorothiazide could by itself account for 
the natnuresis during the period of combined use of furosemide and hydrochlorothiazide 
in the patients presented Therefore, it is most probably the increased sodium reabsorb-
ing capacity of the distal tubules and the collecting ducts in these patients that causes a 
diminished natriuretic response to high dose furosemide Evidence for the presence of 
this mechanism in humans was found in a previous study [27] Animal studies showed 
that even the increased sodium reabsoibing capacity of the distal tubule after chronic 
furosemide treatment could be almost completely blocked by thiazides [19,28] 
Thus, the simultaneous administration of high dose furosemide and hydrochlorothiazide 
leads to a decreased sodium reabsorbtion in the loop of Henle and to a block of the 
increased sodium transport capacity in the distal tubule resulting in a significantly 
increase in fractional sodium excretion 
The addition of hydrochlorothiazide in patients after chronic administration of loop 
diuretics (all patients in this study used high dose furosemide for at least 2 weeks) instead 
of simultaneous introduction of the two diuretic drugs might be even more powei ful 
because of the increased sodium reabsorbing capacity of the distal tubule in these 
patients This increased reabsorbing capacity could also explain why hydrochlorothiazide 
is still effective in those patients with a reduction of the renal function below the level 
where thiazides as monotherapy are reported to become ineffective This observation is 
confnmed by the results of a recent study, showing that coadministration of thiazides 
increased efficacy of loop diuretics in patients with advanced renal failure [16] 
In this study we did not analyze the effects of addition of a diuretic acting specifically on 
the proximal tubule to furosemide and hydrochloiothiazide on natnuresis In some of 
our patients we observed that the natriuretic effect of the combination of diuretics 
descubed persisted some days after administiation of hydrochlorothiazide was stopped 
Three patients showed signs of dehydiation some days after withdrawal of hydrochlo-
rothiazide and required intravenous ïehydration The reason for this prolonged effect 
might be the leduced renal clearance of hydrochlorothiazide in these patients (who all 
used 50 mg 01 100 mg hydrochlorothiazide) with an impaiied renal function resulting in 
a longer half life and accumulation of hydrochlorothiazide [26] Abetter caidiac output 
after amelioration of the hydration state or a stronger osmotic diuretic effect of the higher 
serum urea are other possible explanations for the impioved natnuicsis after the com-
bined tieatment 
It should be emphasized that the combination of high dose furosemide and hydrochloro-
thiazide should only be used under carefully controlled circumstances Besides side-ef fects 
like hyponatremia alkalosis dehydration and loss of renal function hypokalemia shoud be 
avoided most of all Daily clinical and laboratory examination should be performed until a 
new equilibrium has been achieved The (not significant) ι eduction in renal function can be 
caused by slight dehydration or by a dnect effect of hydrochlorothiazide [29] 
Since the appearance of ototoxic side effects is positively related to the plasma 
furosemide concentration, patients treated with mtiavenously administered high dose 
furosemide and a reduced ìenal function (and thus a ι educed renal clearance of 
furosemide are at risk foi ototoxicity [30] On the other hand in an eai hei study on the 
use of high dose fuiosemide in chronic hemodialysis patients there weie no audiometuc 
signs of ototoxicity |31] To avoid ototoxic plasma concentrations the patients in this 
study were mainly treated orally and in all of those receiving fuiosemide intravenously 
fuiosemide was administered as a continuous infusion None of the patients in this 
study complained of healing loss or tinnitus However, this study did not comprise an 
audiometrie evaluation 
Left ventricle peiformance was significantly reduced in all patients studied They all had 
end stage congestive heart faihuewith a very shoit life expectancy Whethei survival 
was piolonged by combined use of high dose fuiosemide and hydrochlorothiazide 
which is merely a symptomatic therapy could not be pioven because of the absence of a 
matched control group The quality of life was definitely improved by ìeducing peripheral 
oedema and avoiding symptoms of lung oedema as demonstrated by the reduction in 
NYHA class On the othei hand this therapy may worsen the prognosis Although chron 
ie diuietic therapy may lead to a decrease in the hyperactivity of the sympathetic ner-
vous system |32], diuretic treatment will cause further stimulation of the renin 
angitensinogen system, causing negative hemodynamic effects [33 35] To reduce these 
effects angiotensin converting enzyme inhibitors and diuretics should be used simulta 
neously whenever possible Furtheimore diuretic theiapy can be associated with car-
diac arrest [36| 
A further benefit of this combination therapy is that an overhydrated state could be 
treated without the use of invasive techniques such as hemofiltration hemodialysis or 
continuous ambulatory peritoneal dialysis for example to bridge a period to a heart 
transplantation as in one of the patients included in this study 
In conclusion, we observed that high dose furosemide (500 to 4000 mg daily dosage) and 
hydrochlorothiazide have a powerful synergistic diuretic effect in patients with severe conges­
tive heart failure showing diuretic resistance to high dose furosemide despite a significantly 
reduced renal function (mean endogenous creatinine clearance 32.7 ±22.5 ml. min. '1.73m;). 
Because of its side effects this combination therapy should only be used in a carefully con­
trolled setting and should be reserved for a selected group of patients not responsive to other 
diuretic regimes. 
ACKNOWLEDGMENT 
We thank professor Ρ Smits from the Department of Pharmacology, university of 
Nijmegen, for his constructive comments and criticism. 
REFERENCES 
1 Guidelines loi thi evaluation jnd management of heail lailuie a u p o n of ihe Ann n e i n He.nl Associai ion l.isk I uice on 
Pi.ictiu Guidelines emulat ion VJ45 92 2764 2784 
2 Gerlag PG \ j n Mi i|el ]| High dost Іигоммпкк in the treatment ol it fradoiy congestive heai l falline 
ArchlnieinMed 19H8 M8 2H6 291 
3 WiTcrci G Donaldson M High-dose fruscimele loi tardiac ladine lantel 1995 346 254 
-1 Olesen KU Duponi Π Hensted Jensen 1 1 he combined dnirelR action ol qunie t ha/one and furosemide in congesme 
heart f.uluu A pel mutation trial lesi Acta Med Seand 1970 187 33 40 
5 GunstoneRI Winy AJ Sham HG Mjemo D Sabuka Ι Μ Í linit.il expeliente л ітіі nielolazone in fill\ two \lnt.in patienis 
svnergy withliusemide Postgiad Med J 1971 47 789 79 i 
6 Smurd 11 Olesen KU Wenne\old \ The supra addilne n.ii run eric tilecr addii ion ol bendi oll umethiazidc and hume tannic in 
cungeslivc henn failure Permutation inai rests in patienis in long leun ι real meni with bumetanidc 
\mlleart j 1975 89 16J 170 
7 GhuseRR.GupraSk Synergism adion ol mclol.i7one with "loop diuielics Πι Med | Clin Res RI 1981 282 1432 14 Η 
8 r-psleniMR I epp ΒΛ llolfman A I tunson R Potentiation of furosemide b\ metola7onc iniel iacton eiltnij 
Clin Ther Res 1977 21 656 6f>7 
9 Bi.ilerDC Presslc\ RH Anderson SA Medianísimo! the synergisric combination ofmclolazone and bnmeianide 
(Phaimacol I xp Ihei 1985 213 70 74 
10 Wollam GL Tara7i RC Biavo 11 Dustan IIP Diurcni poiencv ol combined tydiochlorothiazide and furosemide thcrapv m 
patients wnh azotemia Am J Med 1982 72 929 938 
11 Kiungi \ Held MJ Pawsey CC Yi.innikas | 1 jurent с JK Allei WJ Mctolazone in ireatmt nr ol severe rcfi.icroi y congestive 
caidiac l.nluie lantet 1990 335 29-31 
12 Osier ]R hpslein M Smollerà Combined theijp> with tlnazide-tvpe and loopdiuulic agents loi icsislant sodium ι eleni ion 
Ann Intel η Med 1983 99 405-406 
13 Channel KS McLean КЛ I awson Mailhew Ρ Kithaidson M Coinbnialion diuulic lieainienr in seveie hearr falline aiantlomised 
conlrolhdriial Di Henil | 1994 71 146 150 
14 Pust hell JB Clinic al pharmacologic implications m diuretic selection Am ] Cai dm) 1986 57 6Λ 13Λ 
15 Cud\ RJ Kuho SH Pickworrh KK Diurelit rrcaimenl lor ihe sodium lelenhon of congesliw ht utfai luit 
Aichlnl t rnMtd 1994 154 1905-1914 
16 Hisei D Schrntci M Nevibeck M Ritz E Condministiation of thiazides increases tin. efhcjc\ ofloopdiuieiics ι ven ni patients 
wnh advanced ìciial failure Kidnevlnl 1994,46 482 488 
17 BoiblJGG MolhuvscnJA Гхас t dctci initiation of the centi al \t nous pressure b\ a simph clinic .il mtthotl Lanier 1952 2 304 306 
18 Fllbon DU Velazquez ll Wright PS Acljpiaiion of I he disiai convoluted tubule of the rat Strutturai and lunclional effetti ol 
dietarv salt intake and chiome dun ene infusion | Clin Imesl 1989 83 113 126 
19 HhsonDll Diuretic drugs and the heaiiiieiu of edema l ionithnit to be neh and b.ick again AmJKidnevDis 1994 23 623 643 
20 Pllison DM Tht phvsiologic basis of dnuelic synergism Hi role in treating diuretic resistane«. Ann In tei η Med 1991 114 .486-894 
21 Kaissliim В Stanton HA Adaptation of distal tubule and collecting el ист lo mei eased sodium dehveiv 1 Ultiasliuciure 
Am|Ph\siol 1988 ¿55 Η 256 Π 268 
22 Si.inTon HA K.usshngH Adaptation of distal lubuleand collecting duct loinaeased Na dehveiv II Na+ and K+ lianspori 
AmJPh\siol 1988 255 1 Ι269Γ1275 
23 Uropot M boi gel Γ Muist hlei Γ Pharmacodynamics and phainiacokinelics ol luioscmide combinations with potassium 
leiainingand thiazide likediuietits cicalante and ткторипсіиіе studies 
Naunvn SchniicdebergsAich Phaimacol 1986 333 157 461 
24 vanMc\el|J km Y Smits Ρ Rüssel ГС \an Ginneken CA Crihnaii 1"W Cumpai ison ol the diuretic elicci and absorption 
ol a single dose ol lurosi mide and Ireeand the hxed combinations of furosemide and Uiamtcicne in healih\ male adults 
huí J Clin Phaimacol 1990 39 595 597 
25 blinke Kuppel AJ lintelmanH HuigeMC Kooien)) Lie in Kl lusreiinans ГА ( ross over comparison ol the fixed combination nf 
h\ihochlorothiazide and ma m tei ene and the fice combination of lurosumdeand ui j inierenein the maintenance π calment of 
congestive heait failuie Гиг) Clin Phaimacol 1986 30 341 341 
26 Niemevei С HascnlussG Wais U Knaul 11 Schafci Koning M Mutsthlei Г Pharmacokinetics of h>diothlorolhiazide m leljiion 
to lenal lunction 1 ui J Clin Phaimacol 1983 24 661-665 
27 1 non NR Wilt ox CS Unwin R) Mechanism of impaiied natriuretic ι espouse io furosemide dui ing prolonged iherapv 
Kidnevlnl 1989 36 682 689 
28 Hhson Dil Velazquez I] Wright IS Thiazide si nsm ve sodium с hloi ide coliaiisport in eaily distal lubule 
Am J Plnsiol 1987 253 Г546Г554 
29 KnanfH Mulst hier I |Diuielit theiap> in iena! insufficiency! Disc h Med Woehensthr 1987 112 1785 1789 
30 R\bakIP Otoloxicm ol loop diuretics Otolar\ngol Clin North Am 1993 26 829-844 
31 \an Oidi η RVV \ an Me\el Ц (.erlag PC \cuio.ind long term effetti, of rherapv w it h high dose fmoscmide in chrome 
пепюіІілКччраііеіт A m | \ i p l u o l 1992 12 351356 
M Bavliss) NorellM Canepn \nsonК Surron G Poole Wilson Ρ Untreated heart failure clmital and neuioendomneelfeits 
ol introducing dlllK tics Hrlleail | 1947 57 1722 
3 J Iki.im H Chan W I spine r J A NIL hoi Is MG Ilaeiundvn.imu. and hormone lesponscs io acuti and d u o m i fnisemidi thcr,ip\ ш 
contesine he τι г failure Clin bu 1980 59 443 449 
34 Pm ki г M Trenment оШпишс heart lailuu Ілпсеі 1992 340 92 95 
35 Ta\lor SII Refocus on diuiui i s in the l ieatnuntof heati lailurc hui Ileait J 1995 16 [Suppl (17 15 
36 SiscovickDS Knghunathan IT l'saiy ßM et al Diuretu thernpv for hypeitension and the riskol рппіагч cardiat arresi 
N I nglj Med 1994 330 1852 1857 
54 
CHAPTER SIX 
T H E N A T R I U R E T I C E F F E C T O F F U R O S E M I D E I S N O T 
PRESERVED BY COADMINISTRATION OF 
HYDROCHLOROTHIAZIDE IN HEALTHY VOLUNTEERS 
Tom P.J. Dormans, Paul G.G. Gerlag, Frans G.M. Rüssel, Yuen Tan and Paul Smits 
Submitted for publication 
ABSTRACT 
56 
Aims: The study was designed to evaluate whether the decline in njtnuresis during 
chronic administration of furosemide, can be avoided by coadministration of a thiazide 
drug 
Methods: Unnary sodium excretion (mean ±SD) during 5 h after an inti avenous injection of 
furosemide 40 mg was measured on three separate occasions without pretreatment, and, - in 
a double-blind randomized crossover fashion,- after a two-week pretreatment period with a 
combination of furosemide 20 mg b 1 d taken orally and a single daily oral dose of placebo, 
and after a two-week pretreatment penod with furosemide 20 mg b 1 d taken oially in addi­
tion to a single daily oral dose of hydrochlorothiazide 25 mg 
Results: Pretreatment with furosemide reduced the mean natriuretic response to this 
drug (267 mmol (95% CI 252-282 mmol) without pretreatment vs 218 mmol (95% Cl 194-
242 mmol) after рге-tieatment with furosemide and placebo (p<0,05) 
This reduction could not be prevented by coadmimstiation of hydiochlorothiazide 
(233 mmol (95% CI 217-249 mmol), p<0,05) 
Conclusion: Coadministration of hydrochlorothiazide does not preserve the natriuretic 
effect of furosemide in healthy male volunteers 
INTRODUCTION 
It is well established that after chronic administration of fuiosemide, the natriuretic 
response diminishes [1-3] This decrease is often referred to as biaking phenomenon |4] 
Adaptations in both the proximal tubule and the distal convoluted tubule contribute to 
the decline in natriuretic effect of furosemide Both animal and human studies indicate 
that the sodium reabsorbing capacity of the distal convoluted tubules increases dui ing 
chronic fuiosemide administration |5-7j This increased sodium absorption may com­
pletely offset the natriuretic effect of loop dunetics, causing diuretic resistance 
In animal studies it was shown that thiazide diuretics can block sodium transport capaci 
ty of the distal convoluted tubules completely, even after chronic fuiosemide administra-
tion Moreover, use of thiazides may inhibit the increase in sodium leabsoibing capacity 57 
of the distal convoluted tubules dui ing chronic furosemide administration |8] This ^ 
means that the development of diuietic iesistance to loop dunetics may be pi evented or 5 
postponed by concomitant administration of a thiazide Whether thiazides can actually < 
limit the increase in sodium reabsoibing capacity of the distal convoluted tubules during | 
chronic treatment with furosemide in humans is still uncleai ° 
о 
Therefore we hypothesized that, if adaptations in the distal convoluted tubules con- S 
tribute importantly to the decline of natnuresis during chiome administration of g. 
furosemide, the natnuietic response can be pieserved by coadministration of a thiazide Ξ 
drug S 
Q. 
= 1 
CU 
METHODS I 
Subjects 
Seven healthy male volunteers ranging in age from 22 to 40 years (mean 29) participated 
in the study after appi oval of the hthics Committee of Univeisity Hospital Nijmegen A 
routine biochemical assessment (including serum minerals, BUN, creatinine and uric 
acid) was performed at the start of each of the three parts of the study Results were with­
in normal limits in all participants and no significant diffei enees were observed 
between the determinations on each of the three study days Weight and blood pressure, 
also determined on each of the three study days, did not change either 
Table 1 Body weight, serum electrolytes, serum une acid, BUN, creatinine clearance, and cumula­
tive unnary excretion of sodium and jurosemide (F) ina5h and 24 h urine sample, 
following intravenous administration of 40 mgfurosemide without pretreatment, 
after a 14 day oral pretreatment with furosemide (20 mgb id) and placebo, and after 
a 14 day oral preti eatment with furosemide (20mgbid) and hydrochlorothiazide (25 mg) 
Values are presented as mean ±SD 
Body weight (kg) 
Serum Sodium (mmol l1) 
Serum Potassium (mmol l') 
Serum Chloride (mmol l') 
Serum Calcium (mmol l') 
Serum Magnesium (mmol l') 
Serum uric acid (mmol l') 
Serum phosphate (mmol l') 
Serum urea (mmol Γ) 
Creatinine clearance (ml mm ') 
U-N, 5 h (mmol) 
U-N, 24 h (mmol) 
U-Furotemidf 5 h ( m g ) 
U F u r o S 1 m i d i
2 4 h ( m g ) 
nopretreatment 
SO 
141 
4 0 
105 
2 27 
0 81 
0 34 
104 
5 9 
126 
267 
304 
28 5 
28 0 
±10 
±1 
±0 2 
±2 
±0 07 
±0 05 
±0 04 
±0 09 
±0 9 
±18 
±20 
±44 
±15 
±2 0 
pretreatment 
F + P 
79 
139 
4 0 
105 
2 27 
0 80 
0 38 
101 
6 0 
124 
218 
301 
28 6 
301 
±10 
±2 
±0 2 
±3 
±0 07 
±0 05 
±0 07 
±0 09 
±12 
±14 
±33" 
±52 
±10 
±13 
pretreatmeiit 
F + HCrz 
81 
140 
3 9 
107 
2 24 
0 84 
0 40 
0 95 
6 8 
129 
233 
312 
28 0 
29 8 
±10 
±2 
±02 
±3 
±0 06 
±0 03 
±011 
±0 18 
±0 8 
±20 
±22' 
±33 
±0 4 
±0 7 
'p<0 05 vs no pretreatment 
During the study volunteers were not placed on a standard diet Volunteers were not 
allowed to drink coffee, tea or alcohol thioughout the study days 
Study protocol 
The study was performed in a double-blind randomized placebo-controlled crossover fashion 
The study consisted of two treatment periods Subjects were randomized to receive either two 
oral doses of 20 mg furosemide (8 a m and 5 p m ) and one single oral dose of placebo (8 am), 
or two oral doses of 20 mg furosemide (8 a m and 5 p m ) and one single oral dose of 
hydrochlorothiazide (25 mg) ( 8 a m ) Medication was used for 14 days in each of the two 
arms of the study On day 15 no medication was used On day 16 after an initial bladder voiding 
40 mg furosemide was injected intravenously as a bolus Unne was sampled by asking volun­
teers to void at 30,60,90.120,180, 240 and 300 minutes after administration of furosemide 
Urine losses of each period were replaced volume for volume by a combination of intra­
venous saline solution and tap water during the subsequent period After 5 h the subjects 
went home and collected urine from 5 to 24 h Sodium and furosemide concentrations 
were determined in each of the urine samples To prevent photochemical degradation of 
furosemide, urine samples were protected against light After a washout period of at 
least two weeks the crossover mode of treatment was performed in an identical way 
Adherence to the described regimen was checked by collection of urine samples over 
24 h on day 2 and day 14 for measurement of furosemide and hydrochlorothiazide 
Hydrochlorothiazide concentrations were also determined m the urine samples over 24 h 
on day 16 
In order to visualize the decline in the natriuretic response to furosemide after chronic 
treatment with this drug, we also investigated the natriuretic response to furosemide 
without pretreatment To this end. the natriuretic response to a single intravenous injec­
tion of furosemide 40 mg was investigated This test was separated from the treatment 
periods by at least two weeks 
Urine furosemide concentrations and urine hydrochlorothiazide concentrations were 
measured according to previously described methods [9,10] 
For the statistical evaluation, Student's t tests foi paired data were used at the 5% signifi­
cance level 
RESULTS 
Body weight, serum electrolytes (sodium, potassium, magnesium, calcium, phosphate), 
serum uric acid, creatinine clearance and urine furosemide recovery (both 5 h and 24 h) 
after intravenous bolus injection of furosemide on day 16 of the two treatment periods did 
not differ significantly from the baseline measurements (see also Table 1) The recovery of 
furosemide and hydrochlorothiazide in the 24 h ui inary output confirmed compliance 
with the medication intake No traces of hydrochloiothiazide were detected in the unnaiy 
output on two treatment days 
Figure 1 Mean (±SD) cumulative urinary sodium excretion after intravenous injection 
of 40 mg furosemide m seven healthy volunteers Cumulative sodium excretion was 
measured at three separate occasions without pretreatment (Control), after oral pre 
treatment during two weeks with furosemide 20 mgbid and one single daily dose of 
placebo (Furosemide + Placebo), and after oral pi etreatment diinng two weeks with 
furosemide 20 mg b ι d and one single daily dose ofhydi ochlorothiazide 
25 mg (Fui osemide + HCTZ) 
Cumulative sodium excretion (mmol) 
300
 T 
0 -I 1 1 1 1 1 1 1 
0 30 60 90 120 180 240 300 
Time (min) 
Figure 1 presents the cumulative natnuresis (mean +SD ) during 5 h after intravenous 
administration of furosemide The mean urine sodium excretion decreased significantly 
after both treatment periods when compared with baseline measurements 267 mmol 
(95% CI 252-282 mmol) versus 218 mmol (95% CI 194-242 mmol, p<0,05) after pretreat­
ment with furosemide and placebo and 233 mmol (95% CI 217-249 mmol, p<0 05) after 
pretreatment with furosemide and hydrochloiothiazide Urine sodium excretion after 
intravenous bolus injection of furosemide did not differ significantly, when comparing 
the two pretreatment schedules 
DISCUSSION 
This study convincingly shows that chiome treatment with furosemide reduces the natn 
uretit response to this di ug Tins reduction in natriuretic effect could not be prevented by 
cotreatment with a thiazide diuretic There are a number of possible explanations why in 
oui study hydrochlorothiazide exerted no preservative effect on the natnuietic effect of 
fuiosemide Firstly, two weeks of fuiosemide administration may indeed induce adapta-
tion of the distal convoluted tubules in healthy subjects, leading toa decreased natnuietic 
response to fuiosemide However, 25 mg of hydrochlorothiazide dosed once daily may be 
insufficient to pievent adaptation of the distal convoluted tubulai cells in healthy volun-
teers In clinical studies with patients, suffeung from heart failure and treated chronical-
ly with furosemide, addition of 25 mg of hydiochlorothiazide caused a dramatic 
increase in nati uiresis, consistent with the ability of hydrochlorothiazide to block the 
sodium reabsoiption in the hypertrophied distal convoluted tubules of these patients 
[11-14] However, neithei these studies, noi any other human study proves that addition 
of hydrochlorothiazide may prevent adaptation of the distal convoluted tubules 
Moreover, the dose-response îelationship remains unknown 
Secondly, in our subjects alteiations in sodium reabsorbing capacity of the distal convo-
luted tubules may not have occurred and the differences in natriuretic effects between 
the baseline measurements and the measurements following chronic administration 
may have been caused by mechanisms that are not influenced by the addition of 
hydrochloiothiazide e g adaptations in the proximal tubule or in the cortical collecting 
tubule 
In animal studies examining the adaptation of the distal convoluted tubules during con-
tinuous infusion of fuiosemide, dramatic hypertrophy of cells of the distal convoluted 
tubules and increased sodium îeabsorbing capacity was observed after one week of 
furosemide infusion [5,6) In humans it is unknown how long and at which dose furo-
semide should be administered before these structural and functional changes in the 
distal convoluted tubules aie induced In one human study indirect data indicated the 
presence of functional adaptation of the distal convoluted tubules after one month of 
furosemide administration [7] So it is possible that two weeks of furosemide administra-
tion maybe too shoit to induce functional adaptation of the distal convoluted tubules 
Another explanation could be that the chosen dose schedule of furosemide maybe 
inadequate In animal studies furosemide was administered as a continuous infusion [6] 
By giving furosemide as two single oral dosages the drug-free interval may become too 
long to induce an adaptation of the distal convoluted tubules However, in the human 
study by Loo?! et al furosemide, administered as two separate oral doses (40 mg b i d ) obvi-
ously resulted in an increase of sodium reabsorbtion at a thiazide sensitive segment of 
the nephron such as the distal convoluted tubules [7] 
Finally, adaptation of the distal convoluted tubules may have been missed if the process 
of adaptation is rapidly reversible Because of the elimination half life of hydrochloro-
thiazide, natriuretic effects of furosemide could only be analyzed approximately 40 hr 
after the last administration of hydrochlorothiazide 
We conclude that in healthy volunteers the natriuretic effect of furosemide decreases 
after chronic administration However, in this study coadministration of hydrochloio-
thiazide with furosemide did not prevent the decrease in the natriuretic response to 
furosemide 
This study was suppoi ted by a grant of Hoechst-Roussel, The Netherlands 
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CHAPTER SEVEN 
COMBINATION DIURETIC THERAPY 
IN SEVERE CONGESTIVE HEART FAILURE 
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SUMMARY 
Severe congestive heart failure is often characterized by fluid ïetention A (chronic) state 
of overhydration influences has a negative influence on both the quality of life and the 
prognosis of these patients Therefoie, the use of diuretics remains a cornerstone in the 
treatment of heart failure However, diuretic resistance, a failure to correct the hydra 
tion state adequately with the use of conventional dosages of loop diuretics, is a fre-
quently occurring complication in the treatment of advanced stages of congestive heart 
failure 
Several intia- and extrarenal mechanisms may be involved m the development of diuretic 
resistance An important pathophysiological mechanism leading to diuretic resistance 
seen after chronic use of loop diuretics is the functional adaptation of the distal tubule 
Studies in animals demonstrate that the sodium reabsorption capacity of this nephron 
segment increases significantly when the sodium delivery to this segment is augmented, 
as is the case during administration of loop diuretics 
The use of combinations of diuretics acting on different segments of the nephron 
appears to be an effective option in the treatment of diuretic resistance Several combi-
nations have been used, however, the combination of a loop diuretic and a thiazide drug 
acting on the distal tubule appears to be the most effective Howevei, since the use of 
this combination may lead to serious adverse effects such as hypokalemia, metabolic 
alkalosis and dehydration, caieful momtoiingof the patient on combination diuretic 
therapy is necessary 
INTRODUCTION 
Heart failure is a majoi health problem [1,2], and its incidence is expected to further 
increase in the next decade [3] Since no cuiative therapy is currently available for the 
majority of patients, the goals of treatment are to improve quality of life and to postpone 
progression of the disease [4] Although important advances in the pharmacological treat-
ment of heart failure have recently been achieved, it is still inevitable that a considerable 
number of patients will piogress to the advanced stages of this disease 
The clinical picture of advanced stages of heart failure is often dominated by the pres-
ence of oedema and congestion, causing symptoms of dyspnoea, fatigue, nausea and dis-
comfort Moreover, chronic congestion contributes to further progression of the disease 
|5,6] Foi these 2 reasons, maintenance of an adequate state of hydration is very impor-
tant Tins is usually achieved by use of loop diuretics in combination with a salt restric-
tion and a limitation of physical activity Howevei, as the disease progresses, oedema 
may îeoccur despite these measures In some of these cases, the decrease in efficacy of 
diuretic therapy appears to be caused by diuretic resistance, a phenomenon that can be 
defined as the failure to create a negative sodium balance despite the use of conventional 
dosages of furosemide (frusemide) (250 mg per day or an equivalent amount of anothei 
loop diuietic), a sodium restricted diet (60 to 80 mmol sodium per day) and restriction of 
physical activity The mechanisms responsible for diuretic resistance are very diverse 
(Table 1) In decompensated heart failuie, intestinal absorption of orally administered 
furosemide may be altered, causing inadequate concentrations of loop diuretic on the 
site of action [7] Decrease of renal perfusion due to various causes ìesults in a decrease 
of the capacity of the pioximal tubule to secrete furosemide and/οι bumetanide into the 
urine [8] Endogenous acids and non-steroidal anti-inflammatory di ugs compete with 
loop diuietics for secretion into the tubule by the óigame acid pump in the proximal 
tubule [9] 
In clinical practise the use of combinations of diuretics acting on different segments of 
the nephron, often referred to as sequential nephron blockade, has shown to be highly 
effective in the tieatment of diuretic resistance in congestive heart failure [10] Recent 
studies give insight in to some of the pathophysiological mechanisms involved in diuretic 
resistance In this article, we focus on the mechanisms that explain the synergism of com-
binations of diuretic drugs in severe heait failure, indications for their use and adveise 
effects 
MECHANISMS OF DIURETIC RESISTANCE 
Under physiological conditions sodium reabsorption takes place in all segments of the 
nephron In the proximal tubule, 60 to 70% of the filtered sodium is reabsorbed, in the 
loop of Henle, the distal tubule and in collecting tubule 20 to 25%, 5 to 10% and only 3% 
of the filtered sodium, îespectively, This means that more than 99% of the filtered sodi-
um is usually reabsorbed m the tubular system [ 111 However, in heait failure, with or 
without diuretic therapy, these numbers are diffeient Several mechanisms account for 
the vai ying contributions of the nephron segments to the sodium reabsorption 
Sodium reabsorption in heart failure 
In heart failure, the absolute amount of sodium that is filtered may be decreased due to 
reduced renal perfusion in a state of low cardiac output Secondly, heart failure is char-
acterized by activation of both the renin-angiotensin system and the sympathetic stimu-
lation In heait failure the filtration fraction is increased, which is mediated by vasocon-
striction of the efferent arteriole 
This vasoconstriction is mainly induced by an inci eased intrarenal production of 
angiotensin II [12] As a result, transcapillary hydrostatic pressure and oncotic pressure is 
decreased, causing increased sodium and water reabsorption in the proximal tubule 
Moreover, Angiotensin II may exert a direct sodium-retaining effect on the proximal 
renal tubule [13,14], and it increases sodium reabsorption indirectly in the collecting 
ducts by an upregulation of aldosterone secretion Although the use of angiotensin-con-
verting enzyme (ACE) inhibitors in heart failure is advocated angiotensin II levels are 
often insufficiently decreased in patients with severe heart failure due to intolerance of 
adequate dosages of ACE-mhibitors 
Catecholamines directly induce an increase of sodium reabsorption by several mecha­
nisms they stimulate sodium reabsorption in the proximal tubules, indirectly stimulate 
this reabsorption by stimulation of renin release, and reduce renal perfusion as a result 
of their vasoconstrictive effects on the afferent arterial system [15-17] Other mecha­
nisms that play a role in the development of volume overload are the stimulation of the 
cerebral thirst centre by angiotensin and the enhanced release of antidiuretic hormone 
in end stage heart failure [5] 
Table 1 Causes of treatment failures with conventional dosages of loop diuretics in patients 
with decompensated heaitfailure 
I noncompliance with medical regimen: 
Nonadherence to sodium restriction 
Nonadherence to drug regimen 
Π True diuretic resistance 
IIA Pharmacokinetic causes 
Altered intestinal absorption of the loop diuretic 
Decreased renal perfusion due to 
• low cardiac output 
• atherosclerosis, renal artery stenosis, cholesterol emboli 
• hypovolemia 
• decreased filtration fraction (e g due to use of ACE inhibitors or NSAIDs) 
Reduced tubular secretion 
• nefrologic pathology 
• hypovolemia 
• competitive inhibition by NSAIDs, probenecid, endogeneous acids 
(renal insufficiency, gout) 
I/S Pharmacodynamic causes 
Adaptation of distal convoluted tubule to chronic use of loop diuretics 
Abbreviations ACE=angiotensm-convertmg enzyme, NSAlD=non-sterotdal anti inflammatory drug 
In addition to activation of sodium retaining mechanisms, the natriuretic effects of atri­
al natriuretic peptide are attenuated in heart failure [5] 
These mechanisms may all contribute to the sodium îetaining state (and thus the devel-
opment of oedema) that characterizes the advanced stages of congestive heart failure 
Due to activation of the sodium retaining mechanisms in severe heart failure, loop 
diuretics are less effective, and so dose-response curves of loop diuretics are shifted 
downward and to the right in patients with congestive heart failure [18] In a number of 
these patients, an extreme activation of the described sodium retaining mechanisms 
may thus cause diuretic resistance 
Pharmacodynamic effects of diuretics 
The administration of loop diuretics has a number of effects 
• Loop diuretics inhibit the Na К -2C1 cotransporter from the luminal site of the thick 
ascending limb of the loop of Henle, thereby blocking the sodium reabsorption in 
this segment of the nephron almost completely Usually an increased urinary sodium 
excretion will follow 
• When the commonly used inteimittent dosing schedules of loop diuretics are used, 
no diuretic diug is available at the site of action during a consideiable part of the 
dosing interval In this so called 'post-diuretic phase' sodium is avidly reabsorbed, 
resulting in a rebound sodium retention in the nephron Moreover, the natriuretic 
effect of loop diuretic is attenuated after repeated dosages while the patient is on a 
salt restricted diet ¡19| Both these observations can not completely be explained by 
enhancement of sympathetic stimulation and further increase of the activity of the 
renin-angiotensin-aldosterone axis (20| However to pi event activation of the latter 
in heart failure, diuretics are combined with ACE-inhibitors, whenevei possible 
• By blocking the sodium reabsorption in the loop segment, loop diuretics cause an 
increase in tubular sodium concentration at the level of the distal convoluted tubule [11] 
In studies in rats, it was shown that high rates of sodium delivery to the distal convo-
luted tubule, induced by chronic furosemide infusion caused a hypertrophy of this 
segment of the nephron that was associated with an increased capacity to reabsorb 
sodium [18-20] These morphological and functional changes weie observed aftei one 
week of fuiosemide infusion Although the exact mechanisms involved in these 
structural and functional adaptations are unknown, it was hypothesised that cellu-
lar sodium concentrations regulate tubular cell growth directly [24] Data obtained 
from a human study indicate that these adaptations to chronic furosemide adminis-
tration also occur in humans [25] This mechanism may explain why the diuretic 
efficacy of loop diuretics after chiome administration attenuates in heart failure 
Thiazides are able to block essentially all sodium reabsoibtion in the distal convoluted 
tubule, even after hypertrophy has occuried |26] This means that thiazides aie highly 
effective when both the sodium reabsorbing capacity of the distal tubule and the sodium 
delivery to the distal tubule are increased as is the case after chronic administration of a 
loop diuretic It explains the synergistic natriuretic effect of loop diuretics and thiazides 
On the other hand, chronic administration of thiazides induces a ìeduction of the sodi 
um reabsorption capacity in this paît of the nephron [23] This observa tion indicates that 
functional adaptations due to increased sodium delivery in the distal tubule may be 
avoided or corrected by administration of thiazides 
W H A T DIURETIC COMBINATIONS ARE USEFUL? 
Many different combinations of diuretic drugs have been described in the past three 
decades In nearly all of the described combinations loop diuretics form the basis of com 
bination therarapy Although the two most widely used loop diuretics, furosemide and 
bumetanide, differ with respect to pharmacokinetic properties, the difference in overall 
response to equipotent amounts of these drugs is subtle and piobably of no clinical rele-
vance in patients with congestive heart failure[27] In the following we discuss most of 
the possible combinations of drugs Diuretic drugs currently available and their site of 
action in the nephron include 
• acetazolamide, theophylline and mannitol (pioximal tubule), 
• ethacrynic acid, furosemide, bumetanide, torasemide and piretanide (loop of Henle), 
• hydrochlorothiazide, chlorothiazide, bendroflumethiazide, chlorthalidone and 
metolazone (distal convoluted tubule), 
• amilonde, triamterene and spironolactone (collecting duct) 
As a general rule, combinations of two diuretic drugs acting on the same segment of the 
nephron will not result in a synergistic effect and therefore should not be combined 
Loop and proximal diuretics 
Few studies have been done examining the combination of a loop diuretic with a drug 
acting on the proximal tubule Siguí dand Oleson established that the proximally acting 
phosphodiesterase inhibitor aminophylhne (theophylline ethylenediamine) in combina-
tion with long term treatment with bumetanide 2mg 3times daily in patients with con 
gestive heart failure, produced a synergistic effect Addition of the proximally acting 
diuretic drug appeared to be superior to monotherapy with bumetanide given in a daily 
dosage of up to 6 mg |28] It should be noted that theophylline has not only diuretic prop 
erties, but also inotropic and chronotropic effects, which may contribute to the improve-
ment of natnuresis in congestive heart failure However, the use of theophylline as a 
diuretic drug in heart failure may be limited by its chronotropic effects 
In a recent study, it was established that coadministration of the carbonic anhydrase 
inhibitor acetazolamide, to heart failure patients with an inadequate nati ìuretic 
response to furosemide, was very effective [29| 
These studies clearly show that the combination of a loop diuretic and a diuretic acting 
on the proximal tubule has synergistic diuretic effects in the acute phase However, no 
information is currently available on the efficacy of this combination when applied on a 
long term basis Moreover, It has not been established whether treatment with diuretics 
acting on the proximal tubule induces structural and functional changes in the down 
stream segments of the nephron 
Loop diuretic and diuretic acting on the distal convoluted tubule 
Many clinical studies report the synergistic effect of loop diuretics and thiazides or thiazide-
like drugs in congestive heart failure [30-42] The guidelines of the American College of 
Cardiology /American Heart Association and the European Society of Cardiology on the 
treatment of heart failure recommend the use of this combination in case of diuretic 
resistance to a loop diuretic |1,43] As described above, the mechanism behind this syner 
gism consists of the functional adaptations in the distal tubule following chronic admini-
stration of a loop diuretic [21,23,44] Many different thiazide and thiazide-hke drugs have 
been used in combination with a loop diuretic Most of the published data relates to meto-
lazone However, comparisons of thiazides with respect to their efficacy when used in 
combination therapy are sparse [45] On the basis of the available literature, thiazide drugs 
are equally effective 
Used as monotherapy, thiazides are ineffective at glomerular filtration rates <30 ml mm ' 
However, coadministration of thiazides increases the efficacy of a loop diuretic in patients 
both with and without renal failure [35,41,42] 
Loop diuretic and collecting duct tubule 
Addition of triamterene or amilonde to a loop diuretic appears to have a limited effect on 
natnuiesis, probably because the sodium reabsorbing capacity of the collecting duct 
tubule of the nephron is small [ 11J On the other hand, coadministration of spironolac­
tone (100 mg once a day) in congestive heart failure refractory to high dose bumetanide 
(10 mg per day), impioved natnuresis significantly [46] 
INDICATIONS FOR COMBINATIONS OF DIURETICS IN HEART FAILURE 
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In case of an inadequate lesponse to diuretics in a patient suffering from heai t failure a
 o 
stepwise evaluation may help to find the cause of it § 
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ω 
• Is the patient leally overhydrated? A careful physical examination usually will δ 
answer this question During long term follow-up of a patient body weight is a very о 
important parameter §• 
ñ 
• Ensure that there are no causes for oedema other than heart failure Hypoalbumi- -
nemia and other causes of heart failure, that need to be treated by other means (eg =f 
valvular disease or (constrictive) pericarditis) need to be excluded ä 
çT 
E" 
• How is patient compliance to the medical regimen'' It should be emphasized that 5 
adherence to a sodium-restricted diet is essential for the success of diuretic treat-
ment This can be evaluated by determination of urinary sodium excretion If the uri-
nary sodium excretion exceeds 100 mmol per day, without any concurrent body 
weight change, poor compliance with dietary therapy (and not diuretic resistance) is 
the cause of persistent oedema When poor compliance with drug intake is suspec-
ted,urinary drug excretion may be evaluated 
• When noncompliance with the medical regimen is excluded, diuietic resistance is 
identified as the cause of therapy-resistant oedema 
When diuretic resistance is present, improvement of the efficacy of the loop diuretic 
prescribed could be the next step 
• Increase the dosage of the loop diuretic Large doses of loop diuretics (daily oral 
dosage up to 2000 mg) have shown to overcome diuretic resistance [47] Many clini-
cians feel reluctant to use such high dosages of diuretics, because of the potential for 
ototoxicity [48] In our experience, however, irreversible ototoxic side effects only 
occurred after coadministration of aminoglycosides In addition, audiometrie evalua-
tions have revealed that short term completely reversible ototoxic side effects 
occurred significantly more frequent after administration of intravenous bolus injec-
tions of furosemide than after administration of an equal dosage as a continuos 
intravenous infusion (Dormans et al, unpublished data) 
• Administer the loop diuretic two or three times a day This strategy reduces the drug-
free intervals, and thus the post-diuretic sodium retention [49,50] However, incon-
venience due to frequent nocturnal voiding should be avoided 
When the effect of these steps is insufficient several therapeutic strategies are to be 
considered 
• Intravenous administration of a loop diuretic increases its bioavailability The 
amount of drug delivered to the site of action will be increased Because the time 
course of delivery is an important determinant of the efficacy, a continuous intra-
venous infusion is more efficacious than intravenous bolus injections [51 53] In a 
recent study it was reported that administration of bumetanide as a continuos infu-
sion triggered less braking than an equal dosage administered as a seperate intra-
venous bolus injection [54] In other words, the diuretic efficacy is better preserved 
when using a continuous intravenous infusion However, intravenous administration 
usually makes admission to a hospital necessary 
• Combinations of diuretics are highly effective, but may cause severe metabolic dis-
turbances Hypokalemia must be avoided Other important adverse drug effects are 
hyponatremia, dehydration and metabolic alkalosis This makes frequent control 
and monitoring of serum electrolytes necessary, especially in the first weeks after 
addition of the thiazide to the loop diuretic In addition, it should be remembered 
that use of combination diuretic therapy may cause too rapid a loss of fluid 
ïesultingin hypotension and dehydiation A too vigorous dehydration may result in 
a temporary decrease of the effective circulatory volume This may cause hypotension 
and deterioration of renal function Therefore, in addition to serum electrolytes and 
body weight, renal function and blood pressure also should be monitored Finally, 
noninvasive assessment of the central venous pressure is of value as a valid indicator 
of the state of hydration 
• It is necessary to tailor the treatment to each individual patient to achieve a gradual 
reduction of oedema For these reasons, hospital admission of the patient is pre 
ferred when adding a thiazide drug to a loop diuretic 
Although it is generally advocated to increase the dosage of the loop diuretic to the max 
ímum recommended dosage (240 mg fuiosemide per day or an equivalent dosage of 
another loop diuretic), other strategies have been proven to be succesful, firstly, the addi-
tion of a thiazide to a low dosage of a loop diuretic in case of an inadequate response to 
the latter [55] The theoretical advantage of early introduction of a thiazide in the course 
of development of diuretic resistance is that the thiazide may avoid functional and struc-
tural adaptations in the distal convoluted tubule or reverse them at an early stage |23| A 
variation on this treatment schedule is the intermittent addition of thiazides, e g twice 
a week Titration can be achieved using body weight changes as the most important 
parameter [10] Secondly, monotherapy with high dose furosemide (daily dosages varying 
from 250^000 mg) has been shown to be safe and effective [47,56] Addition of a thiazide 
to these high dosages furosemide has been shown to be a powerful diuietic tool in 
patients with severe congestive heart failure |42] 
In cases where even the combined use of a loop diuretic and a thiazide fails to reduce 
the extracellular volume to the desired level, there are still some alternatives By addi-
tion of a inotropic drug, e g dobutamine or milrinone, improvement of cardiac output 
can be achieved This may lead to an increase of the amount of filtered sodium Secondly, 
extracorporal techniques (hemofiltration, hemodialysis, peritoneal dialysis) may lead to 
short term improvement and restoration of diuretic responsiveness [57-59] However, in 
our opinion the results of the chronic intermittent use of hemofiltration and hemodialy-
sis were disappointing, and therefore should be reserved for remediable cases of heart fail-
ure or as a bridge to heart transplantation [60| 
CONCLUSIONS 
The combined use of a loop diuretic and a diuretic acting on the distal convoluted tubule 
has been shown to be a very powerful tool in the treatment of diuretic resistance to con-
ventional therapy in congestive heart failure. However, adverse effects, especially hypo-
kalemia, necessitate frequent control and monitoring of serum electrolytes and the clini-
cal condition of the patient after initiation of this therapy. An important mechanism 
behind this diuretic synergism is the functional adaptation of the distal convoluted 
tubule after chronic administration of loop diuretics. 
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CHAPTER EIGHT 
VASCULAR EFFECTS OF LOOP DIURETICS 
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ABSTRACT 
Although it is generally believed that the beneficial effect of loop diuretics is the result of 
a rapid increase in diuresis, substantial evidence, from a large number of in vitro and in 
vivo experiments, has accumulated, showing that administration of furosemide causes 
direct vascular effects, which probably contribute to its acute clinical effects 
Several mechanisms are involved in the vascular response to loop diuretics The role of 
the renin-angiotensin-aldosterone axis, prostaglandins and the direct vasculai effects of 
loop diuretics on both the arterial and venous parts of the vasculature aie discussed 
¡INTRODUCTION 
Diuretic theiapy has proved to be effective in the treatment of acute and chronic heart 
failure The potent loop diuretics furosemide and bumetanide are frequently used in 
the treatment of disease states characterized by fluid and sodium retention After intra-
venous administration of furosemide, clinical relief of symptoms often precedes the 
increase in diuresis in patients with acute heart failure suggesting the presence of an 
extrarenal effect Although it is generally believed that the beneficial effect of loop 
diuretics is the result of a rapid increase in diuresis, substantial evidence, fiom a large 
number of in vivo and in vitro experiments, has accumulated showing that administra-
tion of furosemide causes vascular effects, which probably contribute to its acute clinical 
effects 
At first sight the reports on the vascular non-diuretic effects of fuiosemide seem conflicting 
However a great deal of the disparity in the results seem to be due to differences in the 
vascular bed studied (arterial or venous, renal or pulmonal y, etc) the species studied, the 
timing (acute vs chronic effects), systemic vs local effects, direct vs indirect effects and dif-
ferences in disease states In this paper the literature on vascular effects of loop diuretics 
(with emphasis on furosemide) is reviewed with refeience to the differences in expen 
mental protocols Finally some general conclusions are drawn and suggestions for fu tui e 
investigations aie given 
IN VITRO STUDIES 
The direct vascular effects of furosemide are difficult to study in vivo because of interfer-
ing counteracting mechanisms which may even completely mask dnect effects In a 
number of in vitro studies the piesence of Na К 2C1 -cotransport activity has been 
demonstrated in endothelial as well as in vascular smooth muscle cells |1 3], and this 
observation represents a primary focus of interest with regard to the vascular effects of 
furosemide Howevei, inhibition of Na К 2C1 -cotransport activity occurs only at high 
furosemide concentrations These concentrations are reached in the renal tubule, but 
not in the caidiovascular system [4] It should be emphasized that in all in vitro studies 
much highei concentrations were needed to induce vascular responses than in the 
human in vivo situation An additional difference causing much higher concentrations 
of free furosemide is the absence of protein binding in the media used 
Table 1. in vitro experiments on the vascular effects of furosemide 
Vasculature Species Drug- Main effects 
concentration 
Reference 
Artenai 
Aorta 
Mes 
Ear and renal 
Ear 
Pul, mes. tib 
Tail 
Venous 
Rabbit 
Rat 
Rabbit 
Rabbit 
Dog 
Rat 
330Mg ml' 
1-81 Mg ml' 
20 Mg ml' 
20-330 Mg ml ' 
32-960 Mg. ml 
5 mg kg" 
Portal Rat 
Portal Rabbit 
Pulmonary Dog 
Hyperpolarisation and relaxanon of smooth muscle cells [6] 
Dose-dependent inhibition of response to norepinephrine [7] 
Inhibition of response to norepinephrine, attenuated by albumin [8] 
Direct endothelium independent relaxing effect [9] 
No relaxation of precontracted arteries [10] 
Endothelium-dependent reduction of electrical snmulatcd contraction [111 
1-100 Mg. ml ' Reducnon of response to norepinephrine and angiotensin II [5| 
20 Mg ml' Inhibition of response to norepinephrine, attenuated by albumin [8] 
32-960 Mg ml' Endothehum-mdependent relaxation 
of norepinephnn-induced contraction [10] 
Abbreviations· Ear = central ear artery; Mes = mesenterial, Pu! = pulmonary; 
Tib = anterior tibial artery 
'Administered dose m stead of furosemide concentration 
The in vitro studies focussing on the vascular effects of furosemide are summarized in 
Table 1. In the early 1970's an inhibitory effect of furosemide on the vasoconstrictor 
response to norepinephrine and angiotensin II was observed in the rat portal vein [5]. It 
was demonstrated that incubation with furosemide causes a membrane hyperpolarisa-
tion of 5.5 mVin the relaxed rabbit pulmonary artery [6]. Many vasodilatory agents act 
by hyperpolarisation of the plasma membrane and subsequent closure of voltage 
dependent calcium channels, so this observation is consistent with, and possibly 
explains the direct vasodilatory action of furosemide. 
Furosemide appeared to have a direct vascular effect in the perfused mesenteric vascular 
bed of the rat [7]. In an in vitro study with arterial vascular smooth muscle in segments of 
rabbit blood vessels, furosemide (20 mg. ml') induced a small decrease in resting tension |8]. 
In the isolated rabbit central ear artery a direct relaxing effect of furosemide on isolated 
vessel segments was concentration-dependent (0.1-1.0 mM furosemide) [9]. It was demon-
strated that inhibition of Na'K'2Cl cotransport activity or hyperpolanzation of the mem-
brane was unlikely to be the sole mechanism responsible for the vasorelaxant effect of 
furosemide. 
In an in vitro study using dogs it was demonstrated that furosemide did not have a direct 
effect on arterial smooth muscle, but exhibits selective venorelaxant activity [10]. The 
magnitude of this effect was most pronounced in the pulmonary vascular bed. Moreover, 
the vasorelaxant activity of furosemide was independent of endothelium, nitric oxide, 
cyclic GMP and prostanoids. 
The role of the endothelium in the direct vascular effects of furosemide is still unclear. 
Whereas one report on an ex vivo experiment showed that the effect of furosemide on 
the response to sympathetic stimulation was endothelium-dependent [11], others did 
not find an important role for the endothelium in mediating the relaxation caused by 
furosemide in vitro [9]. The discrepancy between these results with respect to the 
endothelium-dependency may be caused by the different concentrations of furosemide 
studied and by the use of albumin-containing solutions [8]. 
Table 2 in vivo experiments on the acute hemodynamic effects offuwsemide 
Spedes Dose Маш effects Reference 
(Diseases state| 
Human (AHF) 0 5-1 0 mg kg· lv Decrease PWP increase VC MAP and CO unchanged [12| 
Dog (hgated ureters) 2 mg kg Decrease PWP PAP increase VC SVR MAP unchanged |13] 
Human (hypertension) 120-4000 mg day' po Decrease MAP blood volume unchanged [14| 
Human (hypertension) 120-200 mg day' po Decrease MAP and SVR increase VC blood volume unchanged [15J 
Human (hypertension) 80 mg lv Decrease PAP and PWP and blood volume VC Forearm unchanged [16| 
Human (CHF) 1 mg kg Decrease PAP and CO |17| 
Human (CHF) 1 3 ± 0 6 m g k g ' i v Decrease SVI increase MAP and SVR [18] 
Rat (hypertension) 3 m g k g lV Decrease CO and SVI increase SVR |19| 
Human (salt depleted) 5-80 mg lv Increase VC |20| 
Abbreviations AHF = acute heai t failure, CHF = chronic heart failure, CO = cardiac output, iv = 
intravenously, MA1'= mean arterial pressure, PAP = pulmonary artenal pi essure,po = orally, PWP = 
pulmonary wedgepressuie, SVI = stroke volume index, SVR = systemic vascular ιesistance, 
SVI - stroke volume index, VC = venous capacitance 
IN VIVO STUDIES AFTER SYSTEMIC ADMINISTRATION 
During the 1970's inteiest increased in the vascular effects of diuretics With the devel­
opment of tools to monitor changes in hemodynamic parameters, these effects could be 
described more appropriately In most of these studies, as discussed in the next para­
graph and summarized in Table 2 loop diuretics were administered systemically 
However, it should be noted that changes in hemodynamic parameters observed directly 
after administration of the loop diuretic, do not necessarily imply direct vasoactivity of 
the loop diuretic 
A study by Dikshit elcil is one of the first reports that focussed on the vascular effects of 
loop diuretics [12] In 20 patients with left ventricular failure, intravenous administra­
tion of furosemide caused a prompt fall in left ventricular filling pressure, which was 
accompanied by an increase in venous compliance, the latter being a marker for venodi-
latation These phenomena preceded an increase in u n n e and electrolyte output In 
dogs, furosemide pioduced a rapid reduction in pulmonary wedge pressuie and an 
increase in venous compliance even though the ureters were hgated [13] These observa­
tions indicate that this venous effect may not have been the result of a decrease in plas­
ma volume The dissociation of diuretic and vascular effects was confirmed in a study 
with hypertensive patients despite a fall m blood pressure, plasma volume did not 
change after administration of furosemide in combination with a high salt intake [ 14] 
In patients with peripheral oedema and mild hypertension the use of furosemide resulted 
in a decrease in mean arterial pressure, cardiac output and total peripheral lesistance, 
whereas the venous capacitance increased without change in plasma and blood volume [15] 
However, the dissociation between venodilation and plasma volume is not always obvious 
In patients with mild heart disease or hypertension, 80 mg ι ν furosemide caused a 
decrease in right atnal pressure, pulmonary arterial pressure and pulmonary artery 
wedge pressure (signifying increased venous compliance), together with a decrease in 
cardiac index within 20 mm |16] In this study, a hemoconcentration was observed as 
well, suggesting that the hemodynamic effects were secondary to intravenous volume 
reduction through diuresis The relationship between hemodynamic and hormonal 
changes after furosemide injection and during chronic furosemide treatment was stud­
ied m patients with congestive heart failure [17] 
Cardiac output decreased significantly after furosemide injection (1 mg kg' body weight), 
leached its nadir after 90 mm and returned to baseline withm 4 h The mean pulmonary 
aitenal pressure decreased steadily throughout the 4 h observation period These changes 
were not accompanied or preceded by changes in plasma renin activity, angiotensin II or 
aldosterone In this study patients were on a fixed diet, urine losses were not replaced 
isovolumetrically After continuous oral furosemide therapy during 8-10 days reciprocal 
changes between hemodynamic and hormone indices were observed As the diuretic 
response diminished, cardiac output and pulmonary arterial pressure declined, whereas 
the renin-angiotensin system was activated This suggests that during chronic therapy 
plasma renin activity and angiotensin II might counteiact the vasodilatory effects of 
furosemide However, there are some reports that aie in disagreement with this hypoth­
esis [18,19] In patients with severe congestive heart failure, intravenously administered 
fuiosemide caused an early fall in stroke volume index and a quick transient increase in 
the systemic vascular resistance, a rise in mean arterial blood pressure (within 20 mm 
after injection), associated with an increase in plasma renin activity, norepinephrine 
and plasma arginine vasopiessin levels (18] These results were strengthened by the out­
come of a study in spontaneously hypertensive rats [19], in which furosemide (3 mg kg1) 
caused an early fall in sti оке volume and cardiac index A decrease in mean arterial 
blood pressure was observed after a delay of 2 to 4 h, which sustained for 6 to 8 h after 
injection Total peripheral vascular resistance increased substantially and returned to 
baseline range within 24 h The supposed mechanisms involved in the differences 
between the acute and chronic effects include an adaptation of baroreflex activity, a 
direct vasodilatory effect of diuretics, a deci eased ìeactivity of the vascular system to 
piessor stimuli, a reduction of extracellular body fluid volume, and/or the production of 
endogeneous vasodilator substances mediated by furosemide 
The dose dependency of the vascular effects of furosemide was characterized in healthy 
volunteers by using dosages ranging from 5 to 80 mg [20] Increases in venous capacitance 
were observed 5 min aftei ι ν administration of 5 and 10 mg furosemide Ovei the dose 
range 20 80 mg, no significant increases were observed However, after 10 min venous 
responses showed significant increases in venous capacitance, equally for all dosages 
used An oral dosage of 80 mg furosemide produced a rise in venous capacitance, 15 mm 
after administration and a decrease in forearm bloodflow 15-60 min after administration 
A decrease in calf blood flow was observed within 15 mm following administration of 
furosemide, regardless of salt balance or use of indomethacin [20] This latter effect of 
hirosemide was associated with a rise in plasma renin activity and was not observed in 
anephnc patients [21 ] 
Table 3 Experiments on the role of the kidney m the vascular effects offuwsemide 
Species |Disease state) Dose Main effects Reference 
Human (Functionally anephnc) 3 mg kg'iv Increase FBI· unchanged SBP VC weight hematocrit PRA [21| 
Human (anephnc) 80mgiv VC and BP unchanged (22] 
Rat (acute nephrectomy) 5mgkg"'iv Complete inhibition of vasoconstrictor response to NE and AT [I [23] 
Dog (ligation uretersi 2 mg kg'iv Decrease PAP and PWP increase SVR and VC BP unchanged [13| 
Dog (acute nephrectomy) 2 m g k g ' i v no hemodynamic changes [13| 
Abbreviations ΛΤΠ = angiotensin 11, BP = blood pressure, FBF =jorearm blood flow iv = mti avenous-
ly, NE= noiepmepliiiii PAP = piilmonaiy ai tenal pi essine, PRA-plasma renin activity, PWP = pul­
monal ν wedge pi essili e, SBP = systolic blood pi essili e, SVK = systemic vascular resistance, 
VC= venous capacitance 
THE ROLE OF KIDNEYS 
In an attempt to elucidate the role of the kidneys in the hemodynamic effect of 
furosemide, vascular responses were studied m functionally anephnc hypertensive 
patients [21] In contrast to experiments in subjects with normal renal function, intra­
venously administered furosemide caused a significant increase in foieaim blood flow 
of 55% within 15 mm, whereas venous capacitance weight hematocrit and plasma renin 
activity were unchanged (see Table 3) Possibly, this represents a direct vascular effect of 
furosemide, which becomes unmasked m the absence of counteracting mechanisms, 
such as the renin-angiotensin system In another study, the effect of intravenously 
administered furosemide on venous capacitance and calf blood flow was compared in 
healthy volunteers and anephnc patients [22] Venous capacitance increased in healthy 
volunteers, but not in anephnc patients Moreover, this effect of furosemide required a 
salt retaining state and it could be blocked by the use of the cyclo-oxygenase blocker 
indomethacin, suggesting an important role for renal prostaglandins in the systemic 
vascular effects of fuiosemide 
Furosemide (5 mg kg') attenuated the vasoconstrictor responses of the mesenteric blood 
vessels in the rat to both exogeneous angiotensin II and norepinephnne [23] Acute bilateral 
nephrectomy or treatment with indomethacin (2 mg kg' ι ν ) completely prevented this 
ìnhibitoiy effect In a subsequent report the inhibitory effect of furosemide on the vaso-
constrictor response to sympathetic nerve stimulation was absent after chemical renal 
medullectomy [24] The authors explained this effect by postulating that in the renal 
medulla non-piostanoid vasodilatoiy lipids are produced which mediate the vasodilato-
ry effect of fuiosemide [25] Intrarenal prostaglandins piobably are involved in the 
release of such a lipid Although substantial evidence of a direct vascular effect of 
furosemide is available from several m vitro experiments (see foregoing and Table 1), a 
coincidence of hormonal changes with the observed vascular effects was not considered 
THE RENIN-ANGIOTENSIN-ALDESTERONE SYSTEM 
The release of renin is controlled by three mechanisms the intrarenal baroreceptor, the 
sympathetic nervous system and the macula densa receptor [26] Results of some studies 
show a participation of prostaglandins in the renin release [27-29] It was demonstrated 
that prostaglandins mediate renin ìelease in response to intrarenal baroreceptor stimu-
lation [30] On the other hand, renin ι elease due to symthathetic nerve stimulation is 
prostaglandin-independent [31] 
Micropuncture experiments in rats indicate that renin release resulting from macula 
densa ìeceptor stimulation during sodium deprivation is prostaglandin-dependent [29], 
wheieas in dogs the macula densa mechanism of renin release could be blocked by inhi-
bition of prostaglandin synthesis [32] It is known nom ex vivo expenments that 
furosemide exerts a direct stimulating effect on renin secretion [33] In the isolated per-
fused rat kidney, furosemide-stimulated renin secretion did not require intact PGI syn-
thesis [34] The authors proposed that increased prostaglandin production and increase 
of renin release after furosemide administration is not causally related, but may be 
based on a common response to changes in sodium balance In fact, prostaglandin syn-
thesis could even be a counteracting mechanism participating in the vasoconstnctoi 
action of angiotensin II [35] 
8o The importance of angiotensin II in the vascular effects of 5 mg intravenously administered 
fuiosemide was studied in healthy volunteers [36] Captopril 50 mg abolished the acute 
Î increases in venous capacitance and attenuated the increase in forearm vasculai resistance 
s The mechanism suggested is that angiotensin II is formed secondarily to furosemide-
£ stimulated renin release, and that the decrease in forearm blood now is the result of the 
Е. vasoconstrictive effect of angiotensin II Angiotensin II receptors are virtually absent in 
Ζ veins, so the net effect appears to be venodilation due to the angiotensin induced release 
°- of vasodilatory prostaglandins from the kidney [36] This view may not be entirely cor-
S rect, as it has been demonstrated that angiotensin II has a direct venoconsti ictive effect 
s on the human dorsal hand vein [37] 
i? 
~ To determine whether the vascular effects of furosemide are shared by bumetanide, 
° another frequently used loop diuretic, the vascular and renal effects of equipotent 
л dosages of fuiosemide and bumetanide were compared in healthy volunteers with mod 
g- erate |38| and severe salt depletion [39] In the case of moderate salt depletion, both 
2, furosemide (10 and 100 mg) and bumetanide (250 Mg and 250 mg) caused an increase in 
o renal blood flow in both dosages Changes in peripheral vascular responses did not differ 
| from placebo Both treatments led to an acute increase in urinary prostaglandin metabo 
η lite excretion (which maybe a reflection of an increased lenal blood now) and plasma 
renin activity (the latter not increased by bumetanide 250 pg) Angiotensin II was 
incieased significantly 30 min after 100 mg furosemide and 2 5 mg bumetanide Plasma 
noiepinephnne was not influenced by any of the treatments [38] In conti ast with these 
observations was the vascular response on furosemide (10 and 20 mg) and bumetanide 
(250 and 500 Mg) in marked salt depletion [39] Significant reductions in forearm blood 
now were observed after both furosemide dosages, but not after either of the bumeta­
nide dosages Both drugs had no significant influence on venous capacitance 
Furosemide induced an increase in plasma renin activity, whereas bumetanide did not 
The differences between furosemide and bumetanide with regard to acute arterial vaso 
constrictive activity may be attnbuted to the ability of furosemide (and the disability of 
bumetanide) to stimulate acute renin release from the kidney 
The disciepancy between the results of this study [39] and the study by Johnston eta! [38] 
with respect to vascular effects maybe caused by differences in the degree of salt deple­
tion This is emphasized by others [17,40| There are no in vitro studies that compare the 
vascular effects of furosemide and bumetanide As lllustiated in the foregoing para­
graphs, the total body sodium content is an important factor in the modulation of the 
indirect vascular response to furosemide Administration of a loop diuretic to a salt-
depleted subject may furthei activate the renin-angiotensin system, causing a more pro­
nounced arterial vasoconstriction 
PROSTAGLANDINS 
In 1975 it was shown in dogs that pretreatment with the cyclo-oxygenase inhibitor 
indomethacin blocked the increase in renal blood flow caused by furosemide [411 Since 
then several studies explored the role of prostaglandins in the natriuretic and vasculai 
réponses to furosemide [30,34,40,42-52] It is of importance to distinguish the effects of 
circulating prostaglandins of renal origin from prostaglandins produced in the local 
(extrarenal) vascular bed, since the furosemide-induced vascular effects may well be 
dependent on prostaglandins locally produced in the vessel wall However, in in-vivo 
experiments it is difficult to study these two sources of prostaglandins separately 
The kidney releases PGI , PGE , PGF, and tromboxane A, [42] PG1, and PGE2 possess 
important vasodilatory properties under conditions of prior vasoconstriction 
Prostaglandin-induced vasodilatation plays an important role in the maintainance of 
glomerular filtration and perfusion by dilatation of the afferent arteriole in a salt 
deplete state, when the renin-angiotensin system is activated |53] Furosemide has been 
shown to increase the urinary excretion of prostaglandin |38,50,52] Whether this is 
caused by increased renal blood flow or by increased production of prostaglandins is 
unclear On the other hand, the reports on the effects of inhibition of prostaglandin syn-
thesis on furosemide-induced natnuresis aie conflicting, probably due to varying salt 
balances during the experiments [42] 
In healthy volunteers PGI, induced renin release and furosemide-induced renin release 
was associated with renal PGI2 formation [54] In a study performed in normotensive 
volunteers, îndomethacm (75 mg) decreased both the peak urine flow rate and total sodi-
um excretion within 1 h of a 30 mg ι ν furosemide dose, while an increase in renal plas 
ma flow and glomerular filtration rate after furosemide was inhibited [48| The increase 
of unnary excretion of PGE, was abolished by indomethacin The urinary excretion of a 
metabolite of systemic PGI2 was unaltered after furosemide injection The authors stated 
that the early hemodynamic effects of furosemide depend on an increased synthesis of 
prostaglandins, particularly PGE, and probably also PGI However, it is questionable 
whether the non-renal effects are a result of increased circulating prostaglandin levels 
[24,43] Arguments that underscore these doubts are prostaglandins are very labile, are 
rapidly metabolized and increased plasma levels of prostaglandins have never been 
measured after furosemide administration 
Although the studies mentioned above suggest that furosemide induces an increment in 
renal prostaglandin production, they do not clarify whether systemic prostaglandin syn­
thesis - the local production in the extrarenal vasculature - is increased by furosemide 
Mediation of the cardiovascular effects of furosemide by vascular products of the aiachi-
donate metabolism were studied in ex vivo experiments, using an isolated perfused 
canine lung lobe |47] Furosemide decreased the mean pulmonary artery pressure This 
direct arterial vasodilatory activity of furosemide was similar to that of PGI and could 
be inhibited with indomethacin, suggesting that furosemide induces a local production 
of PGI, in resistance and/or capacitance vessels Recently, an in vitro study was published 
showing that furosemide in primary cultured bovine aortic endothelial cells stimulated 
the formation of endothelium derived kmin, a potent stimulator of endothelial nitric 
oxide and PGI formation [43| These experiments suggest that hemodynamic effects of 
furosemide are mediated by prostaglandins released from the local vasculature 
Figure 1. Diagrammatic scheme illustrating the possible mecanisms offurosimide-induced vascoac-
tivity on artery and vein. The upper part of the figure represents direct vascular 
effects, whereas the lower part represents the vascular effects mediated by hormonal 
changes 
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CONCLUSIONS 
Although in the past 25 years much research has been done, the exact mechanism by 
which furosemide induces its vascular effects remains unclear. In Figure 1 the mecha­
nisms involved in the vascular effects are shown. It seems clear that both direct and indi­
rect mechanisms play a role. The venous vascular response to furosemide appears to be a 
direct effect, while the arterial response in vitro only occurs at supratherapeutic concen­
trations, and probably is mediated and modified by other factors like the degree of salt 
depletion, renin, angiotensin II and prostaglandins in vivo. The prostaglandins are either 
produced by the kidneys or by the endothelium, whereas the precise role of the endothe­
lium has not yet been completely clarified. 
Much attention has been paid to the arterial response, while the effects on the venous 
component have only been roughly monitored due to a lack of sensitive techniques to 
monitor local venous effects. However, especially in patients suffering from cardiac 
failure, the venous vasodilation might be of importance in the observed acute beneficial 
effects. 
There are two methods available to study direct vascular effects in vivo. First, direct 
effects on resistance arteries in the human forearm can be studied with the perfused 
forearm technique. Using this method direct vasoconstrictive or vasodilator effects on 
resistance arteries in the human forearm can be examined by drug administration into 
the brachial artery and venous occlusion Plethysmographie recordings [55]. Second, with 
a linear variable differential transducer it is possible to measure direct venous vascular 
effects on a selected dorsal hand vein [56,57]. With these methods it is possible to examine 
local vascular effects without provoking systemic counterregulatory effects. In a quest to 
explore the genuine direct vascular effects of loop diuretics in vivo, these methods pro­
vide the best options for future studies. 
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ABSTRACT 
Background: In humans, hemodynamic changes observed within minutes after systemic 
administration of furosemide are often referred to as dnect vasoactivity However, these 
immediate changes do not per se imply a direct vascular effect We examined the genuine 
direct vascular effects of furosemide on the human forearm vascular bed and dorsal hand 
Methods and Results: Forearm blood flow in response to infusion of increasing dosages of 
furosemide into the brachial artery was recorded by venous occlusion plethysmography 
Local plasma concentrations of furosemide reached a maximum of 234 ±40 pg ml during 
the highest infused dose, but did not significantly affect the ratio of flow in the infused/ 
86 non-infused arms Venous distensibihty of a dorsal hand vein was measured using a linear 
variable differential transformer During precontraction with norepinephrine, five 
1 increasing dosages of furosemide (1 to 100 pg min ) were administered locally Additional 
η experiments using local administration of indomethacin or Nf- monomethyl-L-arginine 
S (L-NMMA), were earned out to determine whether effects were dependent on local prostag-
E. landin or nitric oxide synthesis, respectively Also, the effects of systemic administration of 
ш furosemide were examined Local administration of furosemide led to a dose-dependent 
°- venorelaxation of 18 ±6% at the first to 72 ±16% at the last dose Indomethacin almost com-
о 
S pletely abolished furosemide-induced venorelaxation, whereas L-NMMA had no effect 
£ Systemic administration of furosemide resulted in a time-dependent increase of hand vein 
3s distensibihty, reaching 45 ±11 % aftei 8 minutes. 
η 
1/1 
° Conclusions: Furosemide does not exert any direct arterial vasoactivity in the human 
й forearm, even at supratherapeutic concentrations In contrast, at concentrations esti-
o mated to be in the therapeutic range, we observed a dose-dependent direct venodilator 
Z, effect on the dorsal hand vein to be mediated by local vascular prostaglandin synthesis 
INTRODUCTION 
The loop-active diuretic furosemide has been the standard treatment for heart failure for 
several decades Apart from its pnmary diuretic action, furosemide is also thought to 
have effects on the cardiovasculai system In heart failure, systemic administration of a 
loop-active diuretic has been reported to relieve the symptoms of pulmonary oedema 
immediately, even before diuresis sets in [1,2] Although these effects are referred to as 
"direct" vascular effects, systemic administration of a drug does not permit distinction 
between a direct action on the vascular wall versus changes induced by caidiovascular 
reflexes or regulatory systems 
It is well established that furosemide itself stimulates the îelease of renin, thereby 
increasing levels of angiotensin II [3-5] as well as of prostaglandins from the kidney [6[ 
The effects on these two vasoactive hormonal systems have been associated with ai tenal 
vasoconstriction and venous vasodilation observed after systemic administration of the 
drug [3,4] Conversely, vai ìous in vitro experiments indicate that furosemide, sometimes 
at rather high concentrations, does exert a direct vasodilator effect on isolated ai tenal 
and venous vessels [7.8,9] In the in vivo situation, this furosemide-induced direct artei lai 
vasodilation could be blunted by the vasoconstrictive effects of angiotensin II after sys-
temic administration, and it is not clear whether the previously reported in vivo venodi-
lation is the ìesult of a direct or indirect effect of furosemide on venous smooth muscle 
cells [1,3,10] Thus, up to now it is unknown whether furosemide-induced effects on sys-
temic hemodynamics are the result of a direct or indirect action of the drug on the vas-
culature in vivo 
In the present study, we thoroughly investigated the genuine direct vasculai effects of 
furosemide on resistance arteries in the forearm and on the dorsal hand vein of healthy 
subjects To this end, we used the perfused forearm technique and the linear vai ìable dif-
ferential transformer (LVDT) technique, respectively With these methods interpretation 
of the results will not be confounded by dnect effects on kidney or reflex effects secondary 
to changes in blood pressure or total plasma volume 
METHODS 
Subjects 
Seveial protocols using two techniques were conducted for this study, all approved by 
the local ethics committee Before pai ticipation, written informed consent was obtained 
from a total of 60 healthy volunteers Participants were asked to refrain from drinking 
alcohol oi caffeine containing beverages for at least 24 hours before their studies Salt 
intake was not restricted None of the participants smoked or used any medication 
(including analgesics) All experiments were performed in a single-blind fashion in a 
temperature-controlled laboratory (23"C to 24"C for the perfused forearm experiments 
and 28"C to 29"C for the venous distensibihty measurements) with the subject in supine 
position 
Demographic characteristics of the participants are summarized in Table 1 
88 
Table 1 Demographic charactet istics of the study groups 
Arterial Vasoactivity Venous Vasoactivity 
n(M/F) 22 (21/1) 38 (33/5) 
Age (years) 25 9 ±1 2 470 ±191 
Weight (kg) 773 ±14 75 0 ±6 8 
Height (cm) 183 ±2 182 ±6 
Body mass index (kg m ') 23 0 ±0 4 22 7 ±2 0 
Syst blood pressure (mm Hg) 128 ±3 134 ±22 
Diast blood pressure (mm Hg) 73 ±1 80 ±9 
Data are mean ±SD 
Arterial vascular activity measurements 
Two protocols were conducted in a total of 22 subjects to assess the direct arterial vasoac­
tivity of loop-active diuretics First, we examined the direct arterial vasoactivity of 
furosemide and bumetanide and second, the effect of locally administered furosemide 
on norepinephnne-induced vasoconstriction The perfused forearm technique was used 
for both protocols Foi this technique, the left brachial artery was cannulated with a 20-
gauge catheter (Angiocath, Deseret Medical, Becton Dickinson) after induction of local 
anesthesia (hdocaine 2%) This catheter was used foi drug infusion (automatic synnge 
infusion pump, type STC-521, Terumo) and blood pressure monitoring (Hewlett Packard 
GmbH) At least 30 minutes after mtra-artenal cannulation, baseline values of FBF were 
measured in both arms three times per minute by ECG-tnggered venous occlusion plethys 
mography with mercury-in-Silastic strain gauges (Hokanson EC4, DE Hokanson) [11] 
To ensure that forearm bloodf low (FBF) recordings referred predominantly to the fore­
arm skeletal muscle resistance arteries, the hand circulation was occluded during all 
FBF recordings by a wrist cuff inflated 100 mmHg above the systolic pressure |12] The 
upper arm collecting cuffs were simultaneously inflated to 45 to 50 mmHg with a 
rapid cuff inflator (Hokanson E-20) In all experiments, we also inserted a catheter into 
a deep ipsilateral foiearm vein During the last minute of each drug infusion period of 
10 minutes a venous blood sample was taken and drug concentrations were measured 
by high-performance liquid chromatography assay as previously described [13] 
Direct arterial vasoactivity of loop-active diuretics 
Dosages of furosemide were normalized to forearm volume (water displacement method) 
Total infusion rate was kept constant at 100 μΐ min ' 100 ml of forearm volume' 
Furosemide was infused at 1-3-10-30-100 \ig min' dl ' in 8 subjects In another 6 subjects, 
fuiosemide was infused at 1000 pg min' dl'for 6 minutes In 4 subjects, we administered 
bumetanide (0 025-0 075-0 25-0 75-2 5 Mg min ' d l ' ) instead of furosemide to perceive pos­
sible differences in vasoactivity between these two loop-active diuretics 
Effect of furosemide on norepinephrine-induced vasoconstriction 
Animal data suggest that furosemide may exert an anti vasoconstrictor effect, because 
the drug did not directly dilate mesenteric resistance vessels but rather inhibited the 
vasoconstrictor effect of norepinephrine and angiotensin II [14] To study this possible 
mechanism in humans, we measured the reduction of FBF in response to cumulative 
intra-arterial norepinephrine infusions in the absence and presence of local furosemide 
administration 
In 4 subjects, norepinephrine was infused at 10, 30, and 100 ng min ' dl ' before and after 
local administration of furosemide (10 pg min' dl' for 20 minutes, preceded by a 30-
minute interval aftei the first noi epinephrine dose-iesponse curve) Previous experi­
ments revealed that intrabrachial infusion of this dose of furosemide led to clinically 
ι élevant concentrations m the infused forearm 
Venous vascular activity measurements 
Four piotocols were earned out to determine the venous vasoactivity of furosemide The 
direct venous effect of locally administered furosemide was examined, after which 
involvement of vascular prostaglandin and nitric oxide (NO) synthesis was assessed Also, 
the venous effect of systemic administration of furosemide was examined All piotocols 
were conducted by the LVDT technique, in which venous distensibihty of a dorsal hand 
vein was measured with LVDT as described by Aellig [15] and evaluated by Alradi and 
Cai ruthers [16] A total of 51 experiments were performed in 28 young and 10 elderly sub-
jects Regression analysis established that there was no significant correlation between 
age and percentage venodilation (J=0 18,p=NS), after which all data wei e pooled 
With the subject in the supine position in a temperature controlled laboratory (28°C to 
29°C), the arm under investigation was placed on a rigid suppoit at an angle of 30" from 
the horizontal to allow complete emptying of the superficial hand veins A sphygmo-
manometer cuff placed on the upper ai m was then inflated to 45 mmHg A suitable 
large superficial vein with no apparent tributaries in the immediate area of examina-
tion was chosen, and a 23-gauge butterfly needle was inserted into the vein The light-
weight (0 2-g) probe of the LVDT was placed over the summit of the chosen vein 10 mm 
downstream from the tip of the needle Under these conditions, dorsal hand vein disten-
sibihty is maximal during venous occlusion When the venous pressure remains constant 
at 45 mmHg, changes in venous diameter are proportional to changes in venous tone 
Owing to the low venous tone present under these conditions [17], venodilatoi effects 
can only be quantified on veins that have been preconstneted To examine furosemide-
lnduced venodilation, we used continuous infusion of inci easing concentrations of nor-
epinephrine to precontract the veins Infusion of the norepinephrine concentration that 
achieved a precontraction of=30% of maximal vein diameter was sustained throughout 
the experiment Previous experiments fiom our laboratoi y showed that this method has 
a good îeproducibility' In 15 subjects the coefficient of variation of the maximal vaso-
constnctor îesponse to noi epinephrine (before and after an interval of 2 hours) was 9% 
In addition, norepinephrine dose-response curves on different days did not significantly 
differ from each other Sustained infusion of norepinephrine alone resulted in a stable 
vasoconstrictor response (70 ±7% contraction after 10 min and 73 ±6% contraction after 
60 min, n=10), indicating the absence of tachyphylaxis to norepinephrine During the 
experiment blood pressure and heart rate were monitoied every 5 minutes by a Dinamap 
1846 SX attached to the contralateral arm 
Direct venous vasoactivity of furosemide 
In a total of 20 subjects, NaCl 0 9% (0 1 ml mm ) was replaced by five increasing doses of 
furosemide (1, 3,10, 30, and 100 pg mm') at the same infusion rate for 10 minutes each 
The cuff was deflated for 30 seconds every 5 minutes At the end of the experiment, 
saline was infused again, still with concomitant norepinephrine infusion 
Involvement of vascular prostaglandin synthesis 
in the direct venous vasoactivity of furosemide 
In vivo, an increase in the venous capacitance induced by sybtemically administered 
furosemide has been reported to be inhibitable by îndomethacin |3| This observation 
suggests a role for prostaglandins as a mediator of vasoactive effects of fuiosemide The 
source of the piostaglandins involved in this mechanism maybe the kidneys, because 
they may release prostaglandins into the systemic circulation |3], alternatively, local pro-
duction in the peiipheral vasculature could be involved [18] To determine the role of the 
nonrenal prostaglandins in the venous vasoactive effects of furosemide, we examined 
the effect of locally administered indomethacin (12 5 pg min , 10 minutes) on the 
furosemide-mduced venous vasoactivity In 8 subjects furosemide (100 Mg min ) 
together with a placebo (NaCl 0 9%, 0 1 ml mm ) was locally infused into a preconstric-
ted vein for 10 minutes Venodilation was assessed, after which placebo was replaced by 
indome-thacin for 10 minutes and venodilation was assessed again To exclude a possible 
constrictor response by indomethacin alone, control experiments were performed in 4 
subjects to determine the effect of indomethacin (12 5 and 125 Mg min ) on baseline 
venous tone 
Involvement of vascular NO synthesis in the direct venous vasoactivity of furosemide 
NO is a potent vasodilator released by vascular endothelial cells Although the 
fuiosemide-induced vascular effects in vitio appear to be independent of the endotheli 
urn, a recent study showed that furosemide augmented the NO production of isolated 
cultured endothelial cells [7,18] To study the role of NO in the furosemide induced venous 
vasoactivity, we repeated the protocol as described above, now using N' -monomethyl-L-
arginine (L-NMMA) (60 pg mm ) instead of indomethacin to inhibit NO production 
Extensive studies have shown that this dose of L-NMMA has no effect on basal venous tone 
and is able to block the venodilation caused by acetylcholine [19,20] 
Effect of systemic administration of furosemide on dorsal hand vein distensibility 
All previous reports concerning the effects of furosemide on human vein capacitance 
used systemic administration [1,3,4,10] To examine whethei fuiosemide administered 
systemically in therapeutic dosages exerts a vasodilatoi activity comparable to that of 
locally administered fuiosemide, we administered furosemide (40 mg) intiavenously in 
thecontialateial arm in 15 subjects Venous distensibility of the precontracted hand vein 
was lecoided during the following 8 minutes 
Drugs 
Furosemide solutions were freshly prepared from 2-ml ampoules containing 10 mg ml 
furosemide as a disodium salt (Lasix, Hoechst Manon Roussel) and were further diluted 
in physiological salme immediately before each experiment Norepinephrine (1-mg ml 
ampoules), indomethacin (Indocid PDA, Merck Sharp and Dome, 1-mg ml ') and L-NMMA 
acetate (Chnalfd) were dissolved in physiological saline immediately before use 
Data analysis 
Data are expressed as mean ±SEM unless noted otherwise and were analyzed by 
Student's t test or repeated measures ANOVA for paired data if appiopiate If ANOVA 
showed that a significant difference existed between conditions, it was followed by post 
hoc t tests (including Bonferroni coi rection) to determine dose dependency or time 
dependency Linear regression analysis was performed on the relation between age and 
percentage furosemide-induced venodilation (correlation coefficient according to 
Pearson) A value of p<0 05 was considered to indicate significance 
Direct arterial vasoactivìty 
Το i educe the variability of blood flow data and to correct for systemic changes, the ratio of 
the FBF measurements in the infused and noninfused arm was calculated foi each time 
point with the noninfused arm used as a contemporaneous control for the infused arm [21 ] 
The FBb values of the last 3 minutes of each drug infusion were averaged to one value 
Direct venous vasoactivìty 
The response of norepinephnne-induced constriction was measured and furosemide-
mduced effects were expressed as the percentage attenuation of the average control con 
striction All results are expressed as a percentage of baseline vein size The furosemide-
índuced venodilation was determined during the last 3 minutes of each furosemide 
infusion 
RESULTS 
Systemic effects 
Foieai m volume averaged 984 ±32 ml During the arterial vasoactivìty experiments, blood 
piessure, heart rate, and FBF in the noninfused arm did not change significantly after intra 
brachial infusion of furosemide During local administration of furosemide in the venous 
vasoactivìty experiments, blood piessure increased over =1 hour from 113 ±2/62 ±1 to 116 ±2/66 
±2 mm Hg (for systolic and diastolic blood pressure p=0 03 and 0 003, respectively, ANOVA 
with repeated measures) There was no change in heart rate (61 ±2 to 61 ±2 bpm, p=NS) 
More relevantly, blood pressure increased within 5 minutes after systemic administiation 
of 40 mg of furosemide from 118 ±1/68 ±2 to 121 ±2/71 ±2mmHg(p=0 01 and p< 0 0001, 
respectively, Student t test) Heart rate remained unchanged (63 ±2 to 65 ±1 bpm) 
Direct effects on FBF 
Ratios of infused to control FBF and ipsilateial venous plasma concentiations of 
furosemide are shown in Figure l(top) Dui ing five increasing dosages of finosemide, 
there was no significant effect on FBF compared with the placebo infusion In 6 subjects, 
we infused furosemide 1000 Mg min dl for 6 minutes, leading to local furosemide plas-
ma concentrations of 234 ±40 pg ml In these subjects, furosemide increased FBF in the 
infused arm slightly, by 23 ±9 7% (p<0 05), but without a significant effect on the FBF 
ratio of the infused and noninfused arms (p=0 08) 
Intra arterial bumetanide infusions led to local plasma concentrations ranging from 39 
±11 to 1748 ±327 ng ml and also failed to alter FBF (data not shown) 
Effect of furosemide on norepinephrine induced vasoconstriction 
As shown in Figure 1, local infusion of norepinephrine into the brachial artery led to a 
dose dependent decrease in FBF (p<0 001), with no significant effect on systemic blood 
pressure This vasoconstriction was not inhibited by local infusion of furosemide (p=NS) 
Direct effects on dorsal hand vein distensibility 
Vein diameter of the participants was 0 74 ±0 05 mm On average, infusion of norepi 
nephnne constricted the vein of investigation to 31 ±2% of the control size 
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Figure 1. Direct arterial vasoactivity offurosemide 
Top, bars represent mean ±SEM measured local venous plasma concentrations of 
furosemide (right axis). Line graph shows the mean ±SEM FBF ratio (infused/noninfused 
arm) during intrabrachial infusions offurosemide (left axis) as measured by venous occlu-
sion plethysmography. There was no significant change in forearm blood flow ratio. Values 
are presented as mean ±SEM of 8 and 6 experiments 
Bottom, ratio of FBF during intrabrachial norepinephrine administration, both in the 
presence of placebo (solid circles/solid line) and after and during concomitant infusion of 
furosemide (10 \jg. min', dl', open circles/dashed line). Constrictor response to norepine-
phrine (p<0.00í) was not inhibited by local furosemide administration (p=NS). Values are 
presented as mean ±SEM of 4 experiments. Ρ values refer to statistical differences between 
conditions for these dose-responses as analyzed by ANOVA with repeated measures over the 
complete dose-response curves 
Figure 2 demonstrates that continuous local infusion of furosemide results in a dose-
dependent attenuation of the constrictor effect of norepinephrine (p<0.001). Post hoc t tests 
(with Bonferroni correction) revealed a dose-dependent venodilation between doses of 0, 
1,10, and 100 Mg. min '. This direct venodilating effect of furosemide was rapid in onset. 
After the last furosemide infusion was replaced with NaCl 0.9% infusion, venodilation 
waned within a few minutes. 
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Figure 2. Direct venous vasoactivity of furosemide 
Left, percentage increase in venous distensibihty of a norepinephrine-constricted dorsal 
hand vein before and during increasing doses of local furosemide infusions. Values are pre­
sented as mean +SEM of 20 experiments. Horizontal axis indicates dose infused per 
minute, not final concentration 
Right, percentage increase in venous extensibility of a norepinephrine-constricted dorsal 
hand vein following contralateral systemic administration of furosemide (40 mg) at 2,4 
and 8 minutes after bolus injection. Values are mean +SEM of 15 experiments. Ρ values refer 
to the statistical differences between conditions for these dose- or time-dependent responses 
as analyzed by AN0VA with repeated measures over complete dose-response curves 
Involvement of vascular prostaglandin synthesis in the direct venous vasoactivity of furosemide 
In 8 subjects, furosemide-induced venorelaxation was assessed in the absence and presence 
of local indomethacin administration. Figure 3 (left) shows that indomethacin inhibits 
furosemide-induced venodilation, because in this sub-group furosemide dilated the vein by 
54 ±17% and furosemide in combination with indomethacin, by 14 ±17% (p=0.025). 
Control experiments showed that indomethacin itself had no constrictor effect on basal 
vein tone. When baseline vein distensibility is taken as 100%, indomethacin 12.5 and 125 pg. 
min' led to vein distensibilties of 101.4 ±0.5% and 100.2 ±1.2%, respectively (n=4, p=NS). 
Involvement of vascular NO synthesis in the airea venous vasoactivity offurosemide 
Figure 3 (right) shows that furosemide-induced venorelaxation was not inhibited by local L-
NMMA administration. In this subgroup, venorelaxation was 60 ±11% before and 53 ±14% 
after placebo was replaced by L-NMMA (n=8, p=NS). 
Effect of systemic administration offurosemide on dorsal hand vein distensibility 
As shown in Figure 2 (right), parenteral administration (contralateral antecubital vein) of 
40 mg furosemide led to increases in vein diameter of 18 ±8%, 26 ±11% and 45 ±11% at 2,4 
and 8 minutes, respectively (p<0.01). Post hoc tests (Bonferroni) revealed that venodila-
tion was significant from baseline at t=4 minutes (p=0.028) and 8 minutes (p=0.001 ). 
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Figure 3. Percentage increase in venous distensibility of a norepinephrine-constricted dorsal hand 
vein induced by local administration offurosemide (100 \ig. min') both in the presence of 
placebo and after and during concomitant infusion of indomethacin (12.5 mg. min', left; 
p<0.025) or L-NMMA (60 mg. min', right; p=NS). Values are mean ±SEM of 8+8 experiments. 
Ρ values refer to statistica! differences between conditions as analyzed by Student's t test 
for paired data 
DISCUSSION 
It is generally accepted that the reduction in venous return as a result of a nondiuretic 
vascular effect by furosemide is therapeutically important in achieving rapid sympto­
matic relief for patients with left ventricular heart failure. The mechanism of this action 
is unclear. Because of the absence of data on the direct vasoactivity offurosemide in 
vivo, we examined the vascular effects of local furosemide administration on arterial 
and venous vessels in humans. Our data strongly suggest that furosemide does not exert 
any direct arterial vasodilator or antivasoconstrictor activity in the human forearm but 
does have a direct venodilator effect, which is associated with vascular prostaglandin 
synthesis. 
Direct effects on FBF 
Our results demonstrate the absence of a direct effect of loop-active diuretics on FBF during 
intra-arterial infusions, which result in clinically relevant plasma concentrations in the 
infused forearm. The absence of vasoactivity in this concentration range is consistent 
with most previous experiments on isolated arteries [7,8]. In these in vitro experiments, 
direct vasodilator properties offurosemide were observed only at concentrations >10" mol.l ', 
whereas in our first series of experiments, the furosemide concentration at the highest 
infusion rate reached 47 ±10 mg. ml1, equivalent to 1.4*10" mol. Г. 
To examine the direct arterial effects of furosemide at very high concentrations in vivo, 
we infused furosemide 1000 mg min' dl into the brachial artery, leading to a local con­
centrations of 234 ±40 Mg ml' (0 7 1 Ί 0 ' mol 1') Even at these supratherapeutic concentra­
tions, only a negligible met ease in FBF was observed 
In the rat, furosemide did not change baseline mesenteric blood flow, but systemic 
administration did inhibit the decrease in blood now produced by angiotensin II and 
norepinephrine [14] In contrast, we observed no effect of local furosemide on norepi-
nephnne-induced attenuation of FBF From our studies, we conclude that furosemide 
does not exert any direct arterial vasodilator or antivasoconstnctor activity in the 
human forearm As such, the previously reported decrease in forearm blood flow after 
systemic administration of furosemide is probably due to an indirect effect of the drug, 
in particular a stimulation of the renin-angiotensin system [3,4,22,5| Of course, our 95 
experiments do not allow us to exclude direct arterial vasoactivity of furosemide in 
other vascular beds, eg, the lung or kidney s 
< 
Direct effects on dorsal hand vein distensibility s 
The present investigation shows that furosemide exerts a direct vasodilator effect on pre- 5 
constricted dorsal hand veins Time-control experiments demonstrated that this effect of -t 
fuiosemide cannot be explained by a spontaneous reduction in noiepinephiine-induced ^ 
constriction ovei time The local concentration of furosemide cannot be estimated pie- 3 
cisely because the venous flow was not measured in these studies However, if the flow in | 
the dorsal hand vein is assumed tobe 1 ml mm'(5% of arterial FBF) fuiosemide plasma ™ 
concentrations can be estimated to lange from 0 2 to 20 pg ml ' during our dose-response .^ 
studies [23] Systemic administration of 40 mg furosemide leads to a plasma concentra- I 
tionof 3 8+0 3 Mg ml' in the first 15 mm in normal subjects, which is within the range 5 
of the estimated plasma concentrations [24| This, as well as the observation of a similar 
venodilator effect after systemic administration of 40 mg of furosemide, suggests that 
the increase of venous compliance observed aftei systemic administration of furosemide 
maybe the result of direct effects on the venous cuculation Compared toother sub­
stances such as nitroprusside and substance P, which exert venodilatory properties at an 
infusion rate of nanograms per minute, furosemide is much less potent |25,26| However, 
its effect does have clinical relevance, especially in the first few minutes after parenteral 
administration 
Mechanism of action 
Two hypotheses concerning the direct vascular effects of furosemide emerge from the 
literature The first hypothesis focuses on furosemide-induced inhibition of vascular 
Na -K -2C1 cotransport, whereas the second is directed to the role of prostaglandins in the 
vascular activity of furosemide 
Na К -2 Cl Cotransport Inhibition 
The presence of Na -K -2C1 cotransport in endothelial and vascular smooth muscle cells 
has been established, but its role in regulation of vascular tone is unclear [27-29] In a 
iccent report, furosemide relaxed canine venous but not arterial vessels taken from a 
vai ìety of vascular beds [9] In the same vessels Na -K -2C1 cotransport disti ìbution was 
determined and the magnitude of the vasodilator effect was found to con elate with Na-
K-2C1 cotransport distribution The correlation between Na-K-2C1 cotransport distribu-
tion and vascular activity suggests a role for this cotransporter in the vascular action of 
furosemide Howevei, inhibition of renal Na -K-2C1 cotransport occurs at 10"403 mol 1' 
furosemide [30], concentiations 10 to 50 times the local concentration in the hand vein, 
and the importance of this action of furosemide to its venodilator properties remains 
uncertain 
Augmented prostaglandin synthesis 
The effect of systemic administration of furosemide on venous capacitance has been 
compared between healthy subjects and anephnc patients Venous capacitance 
increased in healthy volunteers but not in anephnc patients |3] This effect could be 
blocked by pretreatment of the cyclooxygenase inhibitor indomethaciii, suggesting a 
role for renal prostaglandin release in the vascular effects of furosemide Our ïesults 
indicate that ìenal piostaglandin synthesis is not necessarily important for the direct 
venous vasodilation, because the release of renal prostaglandins cannot have been stim-
ulated after the local furosemide infusions This does not rule out the possibility that 
furosemide-induced vasodilation is mediated by activation of vascular PGI synthesis 
Lundergan et αϊ, using an isolated canine lung lobe perfused with autologous blood at 
constant flow, demonstrated that furosemide-induced decreases in pulmonary artery 
96 perfusion pressure were mediated by prostaglandins because they were abolished by 
treatment of the lung with indomethacin [31] Recently, it was shown in cultiucd bovine 
Щ aortic endothelial cells that fuiosemide stimulated the production of piostacychn and 
η NO at clinically relevant concentrations [18] 
< 
Ш 
i. In our study, the direct venodilator effect of furosemide on veins was almost totally abo-
Z lished by local administration of indomethacin, indicating that this direct vascular 
£• effect is dependent on local vascular prostaglandin synthesis It is unclear whether the 
S endothelial or the vascular smooth muscle cell is the source of the prostaglandin pro-
ï duction augmented by furosemide In vivo endothelial stripping with distilled water [32] 
3¡ seems a possibility to address this question, but these experiments are quite invasive and 
~ NSA1D treatment will be necessary to prevent blood clotting [32], which will obscure the 
° interpretation of the furosemide induced venodilation It is unknown whether the 
<§. furosemide-enhanced vascular PGb production [18] is the consequence of a nonspecific 
0 action of furosemide or due to inhibition of the vascular Na К -2C1 cotranspoitei 
Z, Furthermore, the effect of systemic treatment with indomethacin 01 othei NSAID's on 
3 the iurosemide-mduced venorelaxation and its clinical implications aie unknown 
1 The venoielaxation persisted after addition of L-NMMA, so it appeal s that the effect is 
η not mediated by endothelial nitric oxide release 
Conclusions 
The present study provides the first evidence that furosemide at therapeutic concentra­
tions exerts no direct vasodilator or antivasoconstnctor effect on arterial resistance ves­
sels in the human forearm but directly dilates veins in human The direct venodilation 
was inhibited by local indomethacin administration but not by blockade of NO synthe­
sis, indicating that the direct vascular venodilation is dependent on local prostaglandin 
but not on NO production Hemodynamic changes observed directly after systemic 
administration of furosemide are probably due to a direct venodilator effect of the drug 
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CHAPTER TEN 
THE INFLUENCE OF THE MODE OF ADMINISTRATION 
O F H I G H D O S E F U R O S E M I D E O N T H E O C C U R R E N C E 
OF OTOTOXIC SIDE EFFECTS 
Tom P.J. Dormans, Paul G.G. Gerlag, Harm Kahman, Yuen Tan, Frans G.M. Rüssel 
and Paul Smits 
Submitted for publication 
ABSTRACT 
Aim: To assess the influence of the mode of administration of high dose furosemide on 
the occurrence of furosemide induced ototoxicity (FIO) 
Background: Ototoxity is reported to be a majoi side effect of furosemide and appears to 
be related to the serum furosemide concentiation and piobably to the unbound fraction 
High fiequency audiometry (HFA) has been shown to be a very sensitive technique for the 
detection of ototoxicity 
Methods: In 10 patients (2 female 8 male) with heart failure (n~2) chronic renal insuffi 
ciency (n-7) and nephrotic syndrome (n=l) high dose furosemide (mean (±SD) dosage 
488 (±163 mg) was administeied on three separate occasions oially as an intravenous 
bolus injection and as a continuous intravenous infusion lespectively Serum furose 
mide as well as unbound furosemide concentrations were measured and audiometrie 
evaluation included a questionnaire and HFA 
Results: After oral ingestion no ototoxic side effects were reported or detected by HFA 
Short term (less than 15 minutes) side effects weie reported after bolus injection (n=10) 
and aftei continuous infusion (n=3) One patient reported tinnitus after bolus injection 
while no one ìeported hearing loss HFA ìevealed a decrease in thiesholds at t=5 min 
aftei bolus injection (n=8) and continuous infusion (n=3) while conventional speech 
and puie tone audiometry were unchanged At t=60 min aftei bolus injection MO was 
still detectable in 6 patients while at t-240 min HFA was ìetuined compared to base 
line levels in all patients Serum fuiosemide concentiations weie significantly highei 
in patients with deciease of thiesholds at high-frequency audiometry at t=5 min (FIO 
81 ±49pg ml no FIO 25 ±24 Mg ml p<0 01) The mean unbound furosemide fraction 
was 2 2 ±1 0% and was independent of the total serum concentration or mode of admin 
istration 
Conclusion: HFA appears to be more sensitive than both interview and conventional 
audiometnc techniques for the detection of fuiosemide induced ototoxicity FIO occurs 
moie fiequently after intravenous bolus injection than during continuous intiavenous 
infusion ПО was a short term completely reversible side effect in all patients in this 
study 
INTRODUCTION 
Loop diuretics are commonly applied in the management of pathological fluid îetention 
in heart, liver and renal disease The efficacy of these drugs is beyond doubt Well-recog-
nized side effects of loop diuretics are gastrointestinal symptoms (panel eatitis and mild 
nausea, vomiting and diarrhoea), dermatologie side effects (skin eruptions), metabolic 
disturbances (hypokalemia, hyponatremia, metabolic alkalosis, hyperuricemia, hyper-
glycemia), cai diovascular complications due to dehydration, and direct and indirect vas-
cular effects, and - most frequently reported - ototoxic side effects [1] 
Although the first large studies describing the intiavenous administration of furose-
mide, a widely used loop diuretic, did not mention ototoxicity as a side effect, in the 
early 1970's reports of reversible furosemide-mduced ototoxicity (FIO) appeared in litera-
ture |l-5) Not only reversible, but even sporadic cases of irreversible hearing loss due to 
the use of furosemide were observed [5-7] Especially patients with a decreased renal 
function, and thus a reduced clearance of the drug, who were treated with intravenous 
bolus injections of furosemide appeared to be at risk It was concluded that the maxi 
mum plasma furosemide concentration was an important determinant of the develop-
ment of FIO importantly [8] Later, animal studies suggested that the unbound fraction of 
the drug was the major determinant of FIO [9,10] As a result clinicians became ìeluctant 
to use high dosages of furosemide, despite its excellent efficacy 
In a previous study we showed that in patients with severe heart failure high dose 
furosemide administered as a continuous intravenous infusion was more efficacious 
than an equal dosage administered as an intravenous bolus injection [11| Moreover less 
ototoxic side effects seemed to occur when applying continuous intravenous infusion 
However, this study did not include a careful audiometrie evaluation to assess the inci-
dence and characteristics of FIO In the current study we used high-frequency audiome-
try (HFA), a sensitive tool for the early detection of ototoxicity, to evaluate the influence 
of the mode of furosemide administiation on the occurrence of FIO We performed this 
study in a group of patients at risk foi FIO patients suffering from heait failure or renal 
insufficiency, in need for high dose fuiosemide 
Table 1 Characteristics of the subjects 
Patient Sex Age Weight Cause of ECC Renal Serum Furosemide 
no 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
Mean 
SD 
Range 
mff 
m 
m 
m 
m 
m 
m 
f 
f 
m 
m 
|years| 
62 
39 
63 
76 
66 
72 
23 
51 
60 
41 
55 
16 
23 76 
(kgl 
75 
81 
92 
81 
75 
74 
61 
73 
76 
107 
80 
12 
61 107 
Illness 
CRI 
CRI 
CHF 
CRI 
CHF 
CRI 
NS 
CRI 
CRI 
CRI 
(mLmin'l 
4 
3 
40 
2 
26 
15 
97 
4 
22 
29 
24 
27 
2 97 
replacement 
HD 
HD 
HD 
CAPD 
-
-
albumin (g. l'I 
42 
49 
42 
41 
41 
45 
27 
37 
42 
40 
40 
6 
27^9 
1 dosage) 
250 
500 
500 
500 
750 
750 
375 
500 
250 
500 
488 
163 
250 750 
Abbreviations are CAPD= continuous ambulant peritoneal dialysis, CHF= congestive heart failuie, 
CR[= chronic renai insufficiency, f= female, HD= chrome intermittent hemodialysis, m= male, 
NS= nephrotic syndrome 
We hypothesized that the use of high dose furosemide administered as a continuous 
intiavenous administration causes less FIO as compaied with administration of the same 
dose as an intravenous bolus injection To get more insight into the relationship between 
the mode of administration and the development of HO, a pharmacokinetic evaluation 
was included in this study and total as well as unbound furosemide concentrations were 
measured 
P A T I E N T S A N D M E T H O D S 
Patients 
This study was approved by the Medical Ethical Committee of St Joseph Hospital 
Veldhoven, and informed consent was obtained from all patients that weie included The 
characteristics of these 10 patients are shown in Table 1 Mean (±SD) age was 55 ±16 years, 
mean body weight at the start of the study was 80 ±12 kg The mean endogenous creati­
nine clearance was 24 ±27 ml min Two patients suffered from chronic heart failure, one 
patient used high dose furosemide as a treatment for oedema caused by nephrotic syn­
drome, while seven patients were treated because of chronic renal insufficiency Of the 
latter group, four were dependent on renal replacement therapy Three of them under­
went chronic intermittent hemodialysis, while one was treated with continuous ambu­
lant pentoneal dialysis (CAPD) All patients were on high dose furosemide (ι e daily 
dosage of at least 250 mg) for an average period of 433 ±577 days (range 20-1957 days) 
The mean daily dosage used in the study was 488 ±163 mg (range 250-750 mg) 
Before patients were included, they underwent an otological evaluation consisting of a 
questionnaire about prior ear diseases, ototoxic drug usage, and noise exposure, an oto­
logic examination, and a baseline audiometrie assessment including detei mination of 
pure tone thresholds from 250-8 000 Hz, pure-tone thresholds from 8 - 20 kHz (HFA) and a 
base-line speech audiogiam 
Study protocol 
The study consisted of three parts, separated by time intervals of one week On each 
study day body weight was determined, blood samples were taken to determine serum 
sodium, potassium, chloride, albumin, creatinine, urea, uric acid and hemoglobin In 
addition 24-h urine was collected for determination of creatinine excretion All fluids 
containing fuiosemide (blood samples, syringes containing furosemide) were protected 
from light to avoid photochemical degradation On the fust study day after an overnight 
fast each patient received his daily furosemide dosage as a single oral dosage Since an 
earlier study showed that in patients with heart failure peak plasma furosemide concen­
trations occurred 150 min after oral administration of the drug, blood samples were 
drawn at t=0 and t=150 min for determination of serum furosemide concentration (total 
and unbound concentration) Simultaneously HFA was performed 
On the second study day an equal dosage was administered as an intiavenous bolus injec­
tion The dosage was injected within two minutes Blood samples were drawn at t=0, 5,10, 
150 mm and 240 min HFA of both ears wasperfoimed at t=5,60, 240 and 480 min On the 
third study day furosemide was administered as a continuous intravenous infusion A loa­
ding dose, consisting of 20% of the total dosage was administered as an intravenous bolus 
injection within two minutes, followed by a continuous intravenous infusion of 8 hours, at 
a rate of 10% of the dose per hour The schedule for blood sampling and audiometrie evalua­
tion was identical to the one used on the second study day In addition HFA and blood sam­
pling was also repeated on t=480 min In the patients on hemodialysis the dialysis schedule 
was kept constant during the entire study penod and the time interval to the last hemodia­
lysis treatment was equal on all the three study days for each patient The patient on CAPD 
changed the dialysate light before the administration of furosemide on each study day 
Audiometrie evaluation 
Auditory function was monitored during the treatment by means of a questionnaire, 
pure-tone threshold audiometry and HFA During each study day patients were repeated-
ly asked to answer a standard questionnaire on sensations (hearing loss, tinnitus, nausea, 
flushes, fear) occurring after ingestion or injection of furosemide HFA (Demlar extended 
high frequency audiometer, Model 20K, ELB&associates, Hillsborough, USA, earphones 
HV/1A Plus) was performed according to the time schedule mentioned above at 8,10,12, 
14,16 and 18 kHz Any disturbing noises were avoided within the room, when audiome-
try was earned out All patients were alert and cooperative Change of auditory function 
during therapy was determined as a difference between the initial and final assessment 
of the auditory thresholds FIO determined by using the HFA was defined as an increase 
of äl5 dB at one frequency oi >10 dB at two frequencies in auditory threshold at least 
unilaterally If the entena foi FIO were reached οι if tinnitus or hearing loss was repon­
ed, pure-tone thresholds from 250 to 8 000 Hz weie additionally determined 
Analytical methods 
Serum furosemide concentrations were measured by high-perfoi mance liquid chro­
matography [13] Unbound furosemide concentrations were detei mined after equilibrium 
dialysis during 5 5 hour at 37°C against isotonic phosphate buffered saline with pH 74 
The dialysis cell contained 1 ml serum and 1 ml buffer, separated by a cellulose dialysis 
membrane (Cuprophan 150M) [14) 
Data analysis 
Plasma protein binding of furosemide was best modeled assuming one class of binding 
sites The data were analyzed with the aid of the nonlinear regression program 
WmNonlin (Scientific Consulting, Ine , Apex NC, USA) according to the following equa­
tion, derived from the mass-action law 
C-Ç+n· P 
K„+C„ 
where С is the total serum furosemide concentration, C
u
 the unbound furosemide con­
centration in serum, η the number of protein binding sites, Ρ the serum protein concen­
tration, and Kd the dissociation constant of the drug-protein complex Since furosemide 
binds nearly exclusively to albumin, for Ρ the individual serum albumin concentrations 
of the patients were taken The molecular weight of albumin was assumed to be 65,000 
Statistical analysis 
Serum furosemide concentrations measured after intravenous bolus injection and con­
tinuous infusion, respectively were compared by using the two-tailed t test for paired 
data Differences in serum furosemide concentrations between patients with and with­
out FIO were analyzed by the two-tailed t test for unpaired data 
RESULTS 
Ototoxic evaluation 
None of the patients reported any ototoxic or related side effect after oral ingestion of 
furosemide Immediately after administration of the intiavenous bolus injection all 
(n~10) reported sensations that were directly related to the administration of 
fuiosemide, while only three patients experienced side effects (flushes in all three cases) 
after administration of the loading dose preceding the continuous intravenous infusion 
(see Table 2) Flushes were reported by all patients who experienced side effects Tinnitus 
was reported by one patient aftei bolus injection, while other reported side effects after 
intravenous bolus injection were nausea (n=2), vomiting (n=l), fear (n=l), dyspnoea (n=2) 
and urge for defaecation (n=l ) However, in all patients side effects were short-lasting and 
disappeared within 15 minutes Remarkably, none of the patients experienced hearing 
loss at any moment during the three study days. 
HFA evaluation revealed that after oral ingestion of furosemide none of the patients 
reached the criteria for FIO at t=150 mm Five minutes after intravenous bolus injection 
FIO was detected in 8 patients The repeat of HFA at t=60 min showed that the threshold 
elevation in 6 patients persisted At t=240 min HFA in all patients resulted in audiograms 
identical to baseline measurements During administration of furosemide as a continuous 
intravenous infusion three patients reached the HFA criteria for FIO at t=5 min Two of 
these patients experienced flushes at this moment At t=60 min HFA thresholds returned 
to baseline levels in all thiee patients At t=240 min, t=360 min and t=480 min no 
changes were observed When FIO was observed, additionally puie-tone thresholds at 
250-8 000 Hz were determined However, comparison with baseline measurements did 
not reveal any changes within this frequency range in any of the patients 
Serum furosemide concentration ^g ml ') 
140 τ 
·•.. Infusion 
Bolus 
Time (min) 
Figure 1 Mean serum (±SD) furosemide concentrations after admimsti ation of furosemide as an 
intravenous bolus injection or as a continuous intravenous infusion 
(dosage 488 ±163 mg, range 250-750 mg) 
Pharmacokinetic evaluation 
Mean serum electrolytes, hemoglobin, uric acid, urea, and creatinine did not differ sig­
nificantly between the three study days. Neither did the mean serum albumin concen­
tration (40 ±6 g. 1 ', range 27-49 g. 1 '). Figure 1 shows the mean serum furosemide concen­
trations after intravenous bolus injection and continuous intravenous infusion, respec­
tively. At t=5 min and t=10 min mean serum furosemide concentrations were significant­
ly higher after bolus injection than after continuous infusion. At t=150 min mean serum 
furosemide concentration was significantly higher after bolus injection compared with 
both oral and continuous infusion administration. Comparison of the mean furosemide 
concentration of the latter two at t=150 min showed no significant difference. The rela­
tionship between the serum furosemide concentration and the unbound furosemide 
concentration is shown in Figure 2. The estimated values for η and K¿ were 1.14 ±0.11 and 
3.8 ±0.6 Mg. ml ' (11.4 ±1.8 μΜ), respectively. The mean unbound fraction of furosemide did 
not differ significantly when the two modes of administration were compared (infusion: 
2.2 ±1.1%, range 1.4 - 5.4%; bolus: 2.2 ±1.0%; range 1.5 - 5.4%). The variable time after injec­
tion did not influence the unbound fraction. 
10-
Unbound furosemide (Mg. ml1) Figure 2. Relationship between total and 
unbound serum furosemide con­
centrations. Concentrations were 
measured att=5 min, t=15 min 
and t=150 min after intravenous 
bolus injection or continuous 
intravenous infusion 
0 < : - ' ' - — ι ι 
0 50 100 150 200 
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Table 2 Furosemide-mduced ototoxicity as determined by subjective experiences of the patients 
and high frequency audiometry 150 minutes after oral admmistiation and 5 minutes 
after intravenous administration as bolus injection and a continuous infusion 
Sensations experienced after administration of furosemide Increases of threshold at HFA 
Oral Bolus Continuous 
t=°150 min t-5 min t-5 min 
Patient 
no 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
Oral 
t=150mln 
-
-
-
Bolus 
t=5 min 
Hush 
Flush, Fear 
Flush Nausea 
Flush 
Flush, Dyspnoea Defaecation urge 
Flush, Dyspnoea 
Flush, Tinnitus 
Flush, Nausea Vomiting 
Flush 
Flush 
Continuous 
t=5min 
-
-
-
Flush 
Flush 
Flush 
-
Abbreviations HFA= high-frequency audiometry, t= time 
Relationship between pharmacokinetics and high-frequency audiometry 
The mean plasma furosemide concentration at t=5 min of the patients who reached the 
criteria for FIO, was significantly higher as compared with the group of patients without 
signs of FIO (81 ±49 [ig ml ' (FIO) versus 25 ±24 pg ml ' (without FIO), ρ < 0 01 ) (see Figure 2) 
At t= 60 mm the mean serum furosemide concentration appears to be significantly high 
er after bolus injection compared with continuous infusion At t=60 min HFA ci ltei ia 
were reached in 6 patients after intravenous bolus injection and in none of the patients 
after continuous intravenous infusion As shown in Figure 1 the mean serum furose­
mide concentration remained on a steady level throughout the infusion time during 
continuous infusion However, high frequency audiometiy in the three patients that 
showed FIO after continuous intravenous infusion, retui ned to baseline levels at t=60 mm 
and no signs of FIO occurred throughout the rest of the infusion time 
DISCUSSION 
This study shows that FIO occurs less frequently when furosemide is administered as a con­
tinuous intravenous infusion as compared to administration of an equal dose as an lntia-
venous bolus injection In this study we used HFA for the detection of FIO To our knowledge 
this is the fust study analyzing FIO with HFA HFA has shown to be a sensitive tool that can 
be used for the detection of ototoxic damage induced by diugs like aminoglycosides, and 
platinum dérivâtes [15,16] Both human and animal studies ievealed that ototoxic damage 
is primarily present at the basal end of the cochlea, associated with a reduced hearing sen-
sitivity in the higher-frequency region[17] This study establishes that HFA is more sensitive 
than history taking and the standard audiometrie techniques, which confirms the results 
of other studies analyzing the ototoxic effects of other drugs [15,16] 
Few studies have evaluated FIO by use of standard audiometrie tools [3,18,19] Heidland 
and Wigand studied 35 patients with end stage renal failure [18] In 15 patients 1000 mg 
furosemide was administered intravenously within 40 min 
Nine patients experienced transient hearing loss, which was confirmed by audiometry 
In 10 patients 600 mg of fuiosemide was infused within 40 min, causing minimal tian-
sient hearing loss in four of them In 10 patients the effect of chronic use (11-56 days) of 
orally administered high dose furosemide (daily dosage 500-1000 mg) was studied 
Serum furosemide concentration (pg ml') 
Yes No 
Furosermde-mduced ototoxity 
Figure 3 Serum furosemide concentrations at t=5 mm after administration of furosemide as an 
intravenous bolus injection oras a continuous intravenous infusion, piecedcd by a loa-
ding dose, in patients with and withoutfurosemide-mduced ototoxicity as determined 
with high frequency audiometry 
None of the patients developed hearing loss during this treatment and the audiometrie 
findings did not change importantly during this treatment Van Olden et al reported on 
the acute and long-term effects of the use of high dose furosemide (daily oral dosage 250-
2000 mg) in chronic hemodialysis patients [19] The serum furosemide concentrations 
ranged from 11 2 to 35 8 pg ml' Three monthly audiometry during chronic treatment 
did not show any ototoxicity In a large meta-analysis comparing the adverse reactions to 
bumetamde and furosemide in patients with heart failure, renal or hepatic disease, the 
overall incidence of drug-related audiometrie determined hearing loss was 1 1% in the 
bumetamde gioup and 6 4% m the furosemide group [20] 
In this study the clinically recognized FIO appeared to be a short-term and completely 
ìeversible effect lasting no longer than 15 minutes However, only one patient reported 
tinnitus and none of the patients repoi ted hearing loss, while all patients reported "non-
ototoxic" side effects like eg flushes, fear or dyspnoea after intravenous bolus injection 
Three patients reported flushes during continuous intravenous infusion of furosemide 
On the other hand, HFA revealed an increase in thresholds in the high frequency range 
in 8 patients after intravenous bolus injection and in 3 patients after continuous intra 
venous infusion, respectively Moreover, alterations in HFA lasted shorter than one hour 
in 5 patients, but persisted for at least 60 minutes in 6 patients, the latter in all cases 
after intravenous bolus injection Pure-tone audiometry and speech audiograms per-
formed when HFA indicated FIO revealed no changes at all 
In animal studies, using endocochlear potentials to establish ototoxicity, FIO occurred 5 
to 15 minutes after the intravenous dose and corresponded with the time of maximum 
perilymph fui osemide concentrations |21,22| It was also shown that endocochleai 
potentials remained depressed as long as perilymph fuiosemide concentrations exceed­
ed a threshold value of 1 3 pg ml In chinchillas the elimination of fuiosemide fiom the 
perilymph appeared to be mono-exponential [22] Furosemide perilymph concentiation 
parallelled the serum concentration within a wide range [22] With a perilymph serum 
gradient of 1 65 and a threshold perilymph furosemide concentration of 1 3 μg ml ' this 
means that FIO did not occur as long as the serum furosemide concentration remained 
below approximately 80 Mg ml ' 
In the group of patients that developed FIO the plasma furosemide concentration was 
significantly higher than in the group that developed no FIO (Figure 2) Since administra­
tion of furosemide as an intravenous loading dose followed by a continuous infusion 
results in lower serum furosemide concentiations, it seems obvious that this mode of 
administration less frequently causes FIO On the othei hand, FIO was detected in some 
patients after continuous infusion, despite the relatively low serum fuiosemide concen 
trations In other words, we were not able to define a threshold plasma fuiosemide concen 
tration Intenndividual differences and the relatively small number of patients studied 
may be responsible for this 
When FIO appeared during continuous intravenous infusion of furosemide, it was only 
present for a short time, although the serum furosemide concentration remained stable 
throughout the infusion period This suggests that the serum furosemide concentration 
is not the only determinant m the development of FIO, but also the rate of change in 
serum (and probably endolymph) furosemide concenti ation Tins hypothesis is support­
ed by the observation that after oral administration plasma furosemide concentrations 
were in the same range as the concentrations after continuous intravenous infusion 
while no clinical recognizable FIO occurred following the former mode of administia-
tion Another explanation could be that, when the serum furosemide concentration ι ìses 
above a certain threshold value an ototoxic effect is induced that is transient irrespective 
of the serum furosemide concentration Since in animal studies continuous intravenous 
infusion never has been applied, this hypothesis is yet to be confirmed However, in chin-
chillas the recovery time was shown to be positively correlated with the administered 
furosemide dosage [22] In one study in cats repeated intravenous doses of furosemide 
administered with an interval of one hour resulted in increasing depression of cochlear 
action potentials Howevei, complete recovery in all cases occurred within one hour, 
even after repeated doses [23] 
All patients had been using high dose furosemide for a longer period of time preceding 
the study This means that irreversible heanngloss alieady might have occurred before 
the start of the study On the other hand, the audiometnc evaluation performed before 
the start of this study was within normal age-corrected limits in all patients[17] 
Moreover, review of the literature shows that most of the cases of FIO reported concern 
reversible instead of irreversible FIO [5-7] This means that, regarding the frequent use of 
furosemide in clinical practice, irreversible ototoxicity solely attributable to furosemide 
is an extremely rare side effect Finally, in animals receiving furosemide chronically, no 
change was observed in baseline endocochlear potential, fall in endocochlear potential 
or time to complete recovery of endocochlear potential after intravenous furosemide 
injection, respectively, as compared to animals that were not pretreated [22] 
The exact mechanism of FIO is not known The most consistent finding in histopathologic 
studies is formed by reversible structural changes in the stria vascularis (24-27] The time 
course of these changes parallelled the alterations in endocochlear potentials 
It was shown that changes in endocochlear potential corresponded better with the 
furosemide perilymph concentration than the alterations of inner ear fluid electrolyte 
concentrations induced by furosemide [21,22] Moreover, changes in endocochlear poten-
tials could be attenuated by coadminstration of organic acids like salicylates, probenicid 
and penicillin, suggesting that FIO is mediated by an organic acid uptake mechanism in 
the cochlea [28] Probenecid reduced penetration of furosemide into perilymph [29] Two 
studies show that the FIO is determined by the quantity of unbound furosemide and by 
reducing this the absolute amount of unbound serum furosemide FIO was alleviated 
[9,10] We determined both unbound and total serum furosemide concentration 
However, oui results do not allow to draw a conclusion as to whether FIO is mainly deter-
mined by the unbound furosemide concentration, because total furosemide concentra-
tion and unbound furosemide concentration were strongly correlated (Figure 3) 
However, our in vivo observations suggest that the binding of furosemide to serum albu-
min is saturable, which means that the risk at FIO increases exponentially when patients 
receive very high dosages of furosemide when administered as an intravenous bolus 
injection It should be noted that in the patients studied, the mean unbound furosemide 
fraction was approximately 2 2% while in healthy volunteers on conventional dosages 
this is reported to be in the range of 1-4% [30] In patients with heart failure and renal 
failure using conventional dosages of furosemide the unbound fraction of furosemide 
was reported to be higher [31,32] 
In conclusion HFA appears to be a sensitive tool for the detection of FIO FIO occurs less fre-
quently, when furosemide is given as a continuous intravenous infusion compared with 
intravenous bolus injection Foi this reason and because of its greater diuretic efficacy the 
continuous intravenous infusion of furosemide is the mode of administration that is to 
be preferred in the clinical treatment of congestive heart failure, especially when high 
dosages of fuiosemide aie needed FIO appeared to be a short-term completely reversible 
phenomenon in all patients in this study 
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CHAPTER ELEVEN 
SUMMARY 
SUMMARY 
This thesis deals with various aspects of high dose Furosemide Furosemide is a loop 
diuretic applied in several disease states, characterized by oedema Standard dosing 
schedules of furosemide range between 40 and 240 mg per day We defined high dose 
furosemide as a daily dosage of 250^1000 mg Although it has been established more 
than twenty years ago that high dose furosemide is effective in some patients that do not 
respond to conventional dosages of furosemide seveial important questions still ìemain 
unanswered The studies described in this thesis were performed to obtain more insight 
in both the effects and side effects of the use of high dose furosemide Three major 
aspects are studied 
•The diuretic efficacy of high dose furosemide and the management of diuietic resis-
tance to high dose furosemide in chronic heart failure 
•The vascular effects of furosemide 
•The ototoxic side effects of high dose furosemide and its relationship to the mode of 
administration 
CHAPTER 2 
In earliei studies it has been shown that high dose furosemide (1 e a daily dosage larger 
than 240 mg) effectively corrects the hydration status in patients with congestive heart 
failure unresponsive to conventional dosages furosemide We conducted a study to obtain 
insight in the efficacy and safety of continuous intravenous administration of high dose 
furosemide in the treatment of patients with severe congestive heart failure unresponsive 
to conventional dosages of furosemide The theoretical advantage of this manner of 
administration is an increased efficacy, combined with less ototoxic side effects In this 
open uncontrolled study continuous intravenous infusion appeared to be a safe, control-
lable and efficacious tool in the treatment of chronic congestive heart failure 
CHAPTER 3 
Heie we compared the efficacy of high dose furosemide administered asa continuous 
intiavenous infusion with the administration as an equivalent intravenous bolus injec 
tion in patients with severe heait failure Continuous intiavenous administiation of 
high dose furosemide appeared to be more efficacious than intravenous bolus injection 
Ototoxic side effects were recorded more fiequently after intravenous bolus injection 
However, this study did not include a valid audiometrie evaluation 
CHAPTER 4 
It appears that a small group of patients suffering from severe heart failure with progres-
sion of the disease, finally become unresponsive to high dose furosemide These patients 
often are severely symptomatic We asked ourselves whether this group of patients might 
benefit from dehydiation by means of chronic intermittent hemofiltration and/or 
hemodialysis The results of this treatment were disappointing in terms of both survival 
time and quality of life On the basis of these results we concluded that in patients with 
severe congestive heart failure with diuretic resistance to high dose fuiosemide, chronic 
intermittent hemofiltration and hemodialysis is only of limited value and should only be 
used in case of a remediable cause of heart failure or as a bridge to heait transplantation 
CHAPTER 5 
We treated patients with severe heart failure unresponsive to a pharmacological legi-
men including high dose furosemide by adding hydrochlorothiazide to high dose 
furosemide Since the early 1970's it is known from several clinical studies that loop 
diuretics and thiazide drugs acting on the distal convoluted tubule act synergistically 
However, it is unknown whether this synergism is still piesent in patients unresponsive 
to high dose furosemide In this study addition of hydrochlorothiazide to high dose 
furosemide appeared to be a very powerful diuretic combination, causing a reduction of 
the extracellular fluid compaitment in all treated patients Hypokalemia and dehydia-
tion were the most serious side effects of this therapy 
CHAPTER 6 " 3 
Animal studies have suggested that chronic treatment with loop diuietics induces an I 
increased sodium reabsorbing capacity of the distal convoluted tubule, limiting the » 
natriuretic effect of the administration of a loop diuretic drug 
Moreover, it was shown that thiazides could block this increase in sodium reabsoibing 
capacity of the distal convoluted tubule This means that the natriuretic response to 
loop diuretics may be preserved, when a thiazide is added to the loop diuretic drug To 
study whether these mechanisms are present in humans and whether this may be of 
clinical relevance we performed an experiment in healthy volunteers Although we 
could prove that the natnuiet ic effect of furosemide was blunted aftei chronic use of 
this drug, we did not find a pieservative effect of coadministration of hydrochloro-
thiazide on the natriuretic effect of furosemide in the studied population 
CHAPTER 7 
An overview of the approach to diuretic resistance in severe heart failure is described 
Emphasis is put on the value of the use of combination diuretic therapy 
CHAPTER8 
We review the literatuieon the vascular effects of loop diurectics On basis of the hteia-
tuie available it can be concluded that several factors may be involved in the arterial vas-
cular response to loop diuretics, including the degree of salt depletion, renin, 
angiotensin II and prostaglandins while the venous vascular response appeal ed to be a 
genuine direct effect However, literature is not conclusive as to whether furosemide 
exerts direct vasoactivity in vivo 
CHAPTER g 
To further elucidate the direct vascular effects of furosemide we performed a numbei of 
experiments in healthy human volunteers The effects on the arterial vascular wall were 
examined using the perfused forearm technique, while the venous effects of furosemide 
were evaluated by means of a linear variable differential tiansducer measuring the dis-
tensibihty of a dorsal hand vein A direct effect of furosemide on the arteries in the fore-
arm could not be detected, while a dose-dependent direct venodilator effect on the dor-
sal hand vein existed, which appeared to be mediated by local vascular prostaglandins 
C H A P T E R I O 
In the last part a study on the ototoxic effects of furosemide is described Soon after the 
introduction of furosemide, reports on otoxic side effects of this drug appeared in litera-
ture While only a very small number of cases of irreversible ototoxicity directly related 
to the use of furosemide were descnbed, many clinicians feai this complication of the 
treatment with diuretics Most of the studies on fuiosemide-induced ototoxicity are per-
formed in animals, and few human data are available In chapter 10 the results of an 
audiometrie evaluation of the effect of different modes of administiation of high dose 
furosemide in patients with severe heart failure end stage ienal failure, or nephrotic 
syndrome are presented It is shown that furosemide-induced ototoxicity, though often 
without otologic symptoms (deafness, tinnitus, vertigo) and always completely 
reversible, often occurs after administiation of high dose furosemide By administration 
of furosemide as a continuous intravenous infusion instead of an intravenous bolus 
injection, the incidence of furosemide-induced ototoxicity can be substantially leduced 
There appeared to be a cleai relationship between the peak serum furosemide concen-
tration and the presence of ototoxicity, as determined by high-frequency audiometry 
CHAPTER TWELVE 
SAMENVATTING 
SAMENVATTING 
In dit proefschrift staat een aantal aspecten van de effecten van hoge doseringen furosemide 
centraal Furosemide is een hsdiureticum dat toegepast wordt bij de behandeling van een 
aantal ziektebeelden, die als gemeenschappelijk kenmerk de retentie van vocht oftewel de 
ontwikkeling van oedeem- heeft Cebi uikelijke orale dosenngen furosemide kunnen vaneren 
van 40 mg tot 240 mg per dag Met de term "hoge doseringen" furosemide wordt in dit proef-
schrift bedoeld dagdosenngen, variërend van 250 mg tot 4000 mg Het is ruim twintig jaar 
bekend dat het gebruik van hoge doseringen furosemide effectief kan zijn, wanneer er na 
toediening van gebruikelijke doseringen furosemide een onvoldoende diuretische respons 
wordt gezien De kennis omtrent de toepassing van hoge doseringen furosemide is echter 
nog steeds onvolledig. De studies, beschreven in dit proefschrift, werden uitgevoerd om 
meer inzicht te verwerven in de effecten en bijwerkingen van de toepassing van hoge 
doseringen furosemide in de klinische praktijk 
Drie onderdelen werden bestudeerd en beschreven 
• De diuretische effectiviteit van hoge doseringen furosemide en de behandeling van 
diureticaresistentie bij patiënten met chronisch hartfalen 
• De vasculaire effecten van furosemide 
• De ototoxische bijwerking van het gebruik van hoge doseringen furosemide en de 
invloed hierop van de wijze van toediening 
HOOFDSTUK 2 
Eerdere studies hebben aangetoond dat de toediening van hoge doseringen furosemide 
resulteerde in een correctie van de hydratietoestand van patiënten met chronisch hart-
falen, die na het gebruik van conventionele doseringen furosemide onvoldoende 
diuretische respons vertoonden Deze studie werd uitgevoerd om meer inzicht te krijgen 
in de effectiviteit en de veiligheid van de toediening van hoge doseringen furosemide als 
continu toegediende intraveneuze infusie bij de behandeling van bovengenoemde 
patiëntengroep De theoretische voordelen van deze toedieningswijze, in vergelijking 
met toediening als intraveneuze bolusinjecties, zijn een toename in effectiviteit en een 
kleinere kans op ototoxische bijwerkingen In deze ongecontroleerde studie bleek con-
tinue intiaveneuze infusie van hoge doseringen furosemide een veilige, stuurbare en 
effectieve behandehngsoptie voor patiënten met chronisch congestief hartfalen 
HOOFDSTUK 3 
De effectiviteit van twee manieren van toediening van equivalente hoge dosei ingen 
furosemide werd vergeleken bij patiënten met ernstig chronisch hartfalen continue intra-
veneuze infusie versus intraveneuze bolusinjectie Toegediend als continue intraveneuze 
infusie bleken hoge doseringen furosemide effectiever te zijn Ototoxische bijwerkingen 
werden door de patiënten vaker gemeld na intraveneuze bolusinjectie Daarbij dient 
aangetekend te worden dat in deze studie ototoxiciteit niet geëvalueerd werd met 
behulp van een valide audiometrisch onderzoek 
HOOFDSTUK 4 
In de klinische praktijk blijkt dat sommige patiënten met ernstig chronisch hartfalen, 
uiteindelijk niet meer of onvoldoende reageren op de behandeling met hoge dosenngen 
furosemide Dit gaat vaak gepaard met ernstige Symptomatologie 
De vraag was of deze groep patiënten baat heeft bij de correctie van de hydratietoestand 
met behulp van chronisch intermitterende hemofiltratie en/of hemodialyse De resulta-
ten van deze behandelingsvorm waren teleurstellend, zowel wat betreft de invloed op de 
kwaliteit van leven als op de overleving Op grond van deze resultaten luidde de conclusie 
dan ook dat de waarde van chronisch intermitterende hemofiltratie en/of hemodialyse 
beperkt is bij de behandeling van patiënten met chronisch gedecompenseerd hartfalen, 
met onvoldoende respons op de behandeling met hoge doseringen Furosemide Naar 
onze mening dient deze behandehngsoptie voor deze patiëntengroep dan ook alleen 
toegepast te worden, wanneer er sprake is van een reversibele vorm van hartfalen of m 
een overbruggingsfase naar een harttransplantatie 
HOOFDSTUK 5 
Op zoek naar een effectieve behandeling voor patiënten met ernstig chronisch hartfalen, 
bij wie toepassing van hoge doses furosemide onvoldoende effect sorteert, behandelden 
we deze groep patiënten door het thiazidediureticum hydrochloorthiazide toe te voe-
gen aan de hoge doses fuiosemide In de afgelopen drie decennia hebben diverse studies 
aangetoond dat hsdiuretica en thiazidediuretica (werkzaam in de distale tubulus) syner-
gistisch zijn Het was echter onduidelijk of deze synergie nog steeds aanwezig is wanneer 
de diuretische respons op hoge doseringen furosemide insufficient is In deze studie 
bleek de combinatie van hoge doseringen furosemide en hydrochloorthiazide ook in 
deze patiëntengroep een zeer krachtige diuretische behandelmethode, resulterend in 
een afname van oedeem bij alle behandelde patiënten Hypokaliemie en dehydratie vorm-
den de belangrijkste bijwerkingen 
HOOFDSTUK 6 
In dierexperimenteel onderzoek is aangetoond dat chronische behandeling met hsdiure-
tica leidt tot een toename van de natnumreabsorberende capaciteit van de distale tubu-
lus Deze functionele adaptatie van dit segment van het nefron leidt tot een reductie van 
het natriuretische effect van furosemide Bovendien bleek dat de gelijktijdige toediening 
van een thiazidediureticum de toename in natnumreabsorberende capaciteit kon voor-
komen Dit betekent dat de natriuretische respons op toediening van een hsdiureticum 
behouden zou kunnen worden door gelijktijdige toediening van een thiazidediureticum 
Het is onduidelijk of dit mechanisme ook aanwezig is bij de mens, en zo ja, of dit mecha-
nisme klinisch 1 élevant is Om hier meer inzicht in te krijgen voerden we de in dit hoofd-
stuk beschreven studie bij gezonde jonge vrijwilligers uit Hoewel we in deze studiepopu-
latie konden aantonen dat het natriuretisch effect van furosemide 'uitdooft' bij chro-
nisch gebruik van dit diureticum, bleek uit deze studie niet dat door gelijktijdige toedie-
ning van hydrochloorthiazide, het natriuretische effect van furosemide "gefixeerd" kon 
worden 
HOOFDSTUK 7 
In dit hoofdstuk wordt een overzicht gegeven van de behandeling van diureticaresisten 
tie bij patiënten met ernstig hartfalen, waarbij de nadruk ligt op de toepassing van com-
binaties van diuretica 
HOOFDSTUK 8 
In dit hoofdstuk wordt een literatuuroverzicht gegeven van de studies naar de vasculaire 
effecten van hsdiuretica Op basis hiervan kan vastgesteld worden dat waarschijnlijk 
diverse factoren een rol spelen bij de artenele vasculaire respons op hsdiuretica, onder 
andere de mate van zoutdepletie, de plasma renine activiteit, angiotensme II en 
Prostaglandines De veneuze vasculaire respons lijkt door een direct effect van het 
diureticum op de veneuze vaatwand bepaald te worden Wat betreft de aanwezigheid 
van direct vasculaire effecten van furosemide in vivo, is de literatuur is echter niet een 
duidig 
HOOFDSTUK 9 
Bij gezonde vrijwilligers weiden een aantal studies uitgevoeid, metals doel meer inzicht te 
verkrijgen in de direct vasculaire effecten van fuiosemide De effecten van furosemide op 
de artenele vaatwand werden bestudeerd met behulp van het onderarmsmodel, de effec-
ten op de veneuze vaatwand werden bestudeerd met behulp van de 'lineai variable diffe-
rential transducer', met deze techniek kunnen variaties in de diameter van een vene op de 
handrug bepaald worden Een direct effect van furosemide op de artenele vaatwand kon 
niet vastgesteld worden Wel bleek er een dosisafhankelijk dnect venodilaterend effect te 
bestaan, hetgeen leek te berusten op de lokale afgifte van Prostaglandines 
HOOFDSTUK 10 
In dit hoofdstuk wordt een studie beschreven, waai in de oto toxische effecten van 
furosemide geëvalueerd werden Ototoxische bijwerkingen werden al koit na de intro-
ductie van furosemide in de klinische praktijk beschreven Hoewel het merendeel van de 
beschreven casus reversibele ototoxiciteit vermeldde, is er echter ook een zeer beperkt 
aantal gevallen bekend, waarbij irreversibele ototoxiciteit het directe gevolg was van het 
gebruik van furosemide Het gevolg hiervan is dat veel klinici vanwege deze potentiële 
bijwerking huiverig zijn om furosemide, en met name hoge doseringen furosemide voor 
te schrijven Het merendeel van het onderzoek naar door furosemide geïnduceerde oto 
toxiciteit is verricht bij proefdieren In hoofdstuk 10 worden de resultaten weergegeven 
van een audiometrische evaluatie van de invloed van de wijze van toediening van hoge 
doseringen furosemide op de ototoxische bijwerking bij patiënten met chionisch hart-
falen, chronische niermsufficientie of nefrotisch syndroom Met behulp van hoge tonen 
audiometrie kon worden aangetoond dat het gebruik van hoge doseringen furosemide 
vaak gepaard gaat met ototoxiciteit, weliswaai meestal zonder otologische symptoma 
tologie (doofheid, tinnitus, vertigo) De waargenomen ototoxische schade bleek altijd 
volledig reversibel Door furosemide toe te dienen als continue intraveneuze infusie in 
plaats van intraveneuze bolusinjecties, kan de incidentie van door furosemide geïn-
duceerde ototoxiciteit in belangrijke mate worden beperkt Er bleek een duidelijk ver-
band te bestaan tussen de maximale serum furosemide concentratie en het optreden 
van ototoxiciteit 
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STELLINGEN 
Bij de behandeling van patiënten met ernstig chronisch hartfalen heeft een 
hoge dosis furosemide, toegediend als continue intraveneuze infusie, een gro-
ter natriuretisch effect dan een gelijke hoeveelheid furosemide, toegediend 
als een eenmalige intraveneuze bolusinjecoe. 
Dit proefschrift 
Chronisch intermitterende hemofiltraüe of hemodialyse is van beperkte 
waarde bij de behandeling van patiënten met ernstig gedecompenseerd chro-
nisch hartfalen, die onvoldoende reageren op het gebruik van hoge doseringen 
furosemide. 
Dtt proefschrift 
Toevoeging van een thiazidepreparaat aan een hoge dagdosis furosemide is 
een effectieve vorm van diuretische behandeling van patiënten met ernstig 
gedecompenseerd chronisch hartfalen, die onvoldoende reageren op het 
gebruik van hoge doseringen furosemide alleen. 
Dit proefschnft 
Furosemide heeft een dosisafhankelijke venodilaterende werking, die berust 
op lokale prostaglandineproductie 
Dtt proefschrift 
Door furosemide geïnduceerde, reversibele ototoxische effecten treden min-
der vaak op bij toediening van hoge doseringen furosemide in de vorm van 
een continue intraveneuze infusie dan bij toediening als intraveneuze bolus-
injectie 
Dtt proefschrift 
Geprotocolleerde poliklinische behandeling en begeleiding van patiënten met 
ernstig chronisch hartfalen door een gespecialiseerd team leidt niet alleen tot 
een verbetering van de functionele status en een reductie in ziekenhuisopna-
mes, maar kan ook kosteneffectief zijn. 
}Am Coll Cardiol 1997,30.725-732 
Circulation 1997;96.2842-2848 
De bepaling van de intra-abdominale druk bij patiënten, na een ernstig abdo-
minaal trauma of na een grote intra-abdominale ingreep, verschaft op een-
voudige wijze te verkrijgen objectiveerbare informatie, van belang voor het tijdig 
vaststellen van de indicatie voor een (re)laparotomie. 
Am] Surg 1997; 174:667-673 
De Limburgse stinkkaas is niet alleen een lokale delicatesse, maar mogelijk 
ook een effectief middel ter profylaxe van malaria-infectie. 
Lancet 1996; 348:1322 
Een belangrijk nadelig gevolg van de afschaffing van de militaire dienstplicht 
is dat dienstweigering op grond van gewetensbezwaren niet meer overwogen 
hoeft te worden. 
Een niet-rokengedeelte in een restaurant is net zoiets als een niet-urineren-
gedeelte in een zwembad. 
Anthony Kedley 
Voor de verzekeringstechnische consequenties van het overleven van kanker 
bestaat (nog) geen afdoende remedie. 
Het inlassen van een kort 'middagdutje' na de lunch komt tegemoet aan een 
fysiologische behoefte en leidt tot een hogere activiteit en productiviteit in 
het verdere verloop van de dag. 
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